Oxadiazol derivatives for use in the treatment of atrial fibrillation

The administration of an HDAC6 inhibitor compound of Formula (I) effectively reduces AF burden and maintains sinus rhythm by increasing acetylated alpha tubulin levels, addressing the inadequacies of current AF therapies.

WO2026234588A1PCT designated stage Publication Date: 2026-11-12NOVARTIS AG +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2026/054480
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current therapies for atrial fibrillation (AF) are inadequate, particularly in maintaining sinus rhythm and suppressing AF episodes, with a high demand for oral therapies targeting HDAC6 inhibitors.

Method used

Administering a compound of Formula (I) or its pharmaceutically acceptable salt, which is an HDAC6 inhibitor, at a dose of 100 to 600 mg per day, to treat cardiac arrhythmia such as AF, reducing AF burden and maintaining sinus rhythm.

Benefits of technology

The compound effectively reduces AF burden by 10-45% and prolongs sinus rhythm, increasing peripheral acetylated alpha tubulin levels, thereby addressing the limitations of existing AF treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000002_0001
    Figure IMGF000002_0001
  • Figure IMGF000002_0002
    Figure IMGF000002_0002
  • Figure IMGF000002_0003
    Figure IMGF000002_0003
Patent Text Reader

Abstract

The disclosure provides methods of treating atrial fibrillation of a subject (e.g., patient) in need thereof. The methods comprise administering to the subject (e.g., patient) an HDAC6 inhibitor compound of Formula (I) or a pharmaceutically acceptable salt thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Docket No. PAT059983-PCT-SEC01METHOD FOR TREATING ATRIAL FIBRILLATIONCROSS-REFERENCE TO RELATED APPLICATIONS

[0001] The present application claims priority and benefit to the U.S. Patent Application No.63 / 803,041 filed May 9, 2025 and U.S. Patent Application No. 64 / 015,657 filed March 24, 2026, the disclosure of each of which is incorporated herein by reference in its entirety.FIELD

[0002] The disclosure provides methods of treating cardiac arrhythmia, such as atrial fibrillation of a subject (e.g., patient) in need thereof. The methods comprise administering to the subject (e.g., patient) an HDAC6 inhibitor compound of Formula (I) or a pharmaceutically acceptable salt thereof.BACKGROUND

[0003] Atrial fibrillation (AF) is a common cardiac arrhythmia that becomes more prevalent with age. Globally, over 50 million people are estimated to have a diagnosis of AF. The lifetime risk of AF among middle-aged adults is around 30%, varying based on risk factors. AF symptoms include palpitations, chest discomfort, fatigue, and lightheadedness. AF can cause impaired quality of life and is associated with increased risks of stroke, heart failure, and mortality. In the United States, AF accounted for approximately 488,000 hospital discharges and 740,000 emergency department visits in 2019. Acetylation of a-tubulin is associated with stable, long-lived microtubule structures.

[0004] A low-molecular weight HDAC6 inhibitor, e.g., Tubastatin A, has been shown to increase the level of acetylated a-tubulin in atrial cardiomyocytes and ameliorated AF in a beagle dog model (Zhang et al 2013). For example, in animals subjected to rapid atrial pacing for seven days to induce an AF substrate, concurrent treatment with Tubastatin A reduced both AF inducibility and duration. Mechanistic studies suggested that this pharmacodynamic effect was mediated by preservation of cardiomyocyte Cav1.2 channel function that would otherwise have been downregulated by the rapid atrial pacing procedure. Downregulation of Cav1.2 activity has been demonstrated in atrial tissue from chronic AF patients.

[0005] Thus, further investigation into HDAC6 as a potential therapeutic target to treat AF and restore sinus rhythm in patients is necessary. In addition, there is a high demand for therapies (e.g., oral therapies) for AF, in particular, therapies to suppress AF and maintain sinus rhythm, and more specifically for HDAC6 inhibitor therapies for AF.Docket No. PAT059983-PCT-SEC01SUMMARY

[0006] In an aspect, the disclosure provides, inter alia, a method of treating cardiac arrhythmia such as atrial fibrillation (AF), e.g., method of reducing AF burden, in a patient in need thereof, the method comprising administering to the patient a compound of Formula (I)or a pharmaceutically acceptable salt thereof,wherein:Li, L2or L3are each independently a bond or -(C1-C2 alkylene)-;Ri is -CX2H or -CX3;-OH, -O(Ci-C4alkyl), -NRDRE, -(C1-C4 alkyl), -CF3, -CF2H, -CN, -aryl, -heteroaryl, -(C1- C4alkyl)-aryl or -(Ci-C4alkyl)-heteroaryl, wherein at least one H of the -aryl, - heteroaryl, -(C1-C4 alkyl)-aryl or -(Ci-C4alkyl)-heteroaryl may be substituted with -X, - OH, -CF3or -CF2H;R3is -H, -(C1-C4 alkyl), -(Ci-C4alkyl)-O-(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O-(Ci-C4alkyl), -(C3-C7 cycloalkyl), -(C2-C6 cycloheteroalkyl), -aryl, -heteroaryl, -adamantyl, / '•'S< 2«XJ or < 29XJ wherein:at least one H of -(C1-C4 alkyl) may be substituted with -X or -OH,at least one H of -aryl or -heteroaryl each independently may be substituted with -X, - OH, -O(Ci-C4alkyl), -OCF3, -O-aryl, -NRDRE, -(C1-C4 alkyl), -CF3, -CF2H, -C(=O)- (C1-C4 alkyl), -C(=O)-O(Ci-C4alkyl), -C(=O)-NRDRE, -S(=O)2-(Ci-C4alkyl), aryl,Docket No. PAT059983-PCT-SEC01least oneH of may be substituted with -X, -(C1-C4 alkyl), - NRDRE, -CF3or-CF2H, andat least one H of -(C3-C7cycloalkyl), -(C2-C6cycloheteroalkyl), adamantyl,7,. Z,<, x J A i^6 or ^9 may be each independently substituted with - X, -OH or -(Ci-C4alkyl);Y1, Y2and Y4are each independently -CH2-, -NRF-, -O-, -C(=O)- or -S(=O)2-;Y3is -CH- or -N-;Z1 to Z4are each independently N or CRZ, wherein at least three of Z1 to Z4may not be simultaneously N, and Rzis -H, -X or -O(Ci-C4 alkyl);Z5and Z6are each independently -CH2- or-O-;Z7and Z8are each independently =CH- or =N-;Zg is -NRG- or-S-;RAand RBare each independently -H, -(C1-C4 alkyl), -(C1-C4 alkyl)-OH, -(C1-C4 alkyl)- NRDRE, -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl, -(C1-C4 aryl)-heteroaryl, -(C3-C7>'"U< .\ / X >I Qcycloalkyl), -(C2-C6heterocycloalkyl) ors$ , wherein:at least one H of the -(C1-C4 alkyl), -(C1-C4 alkyl)-OH or -(Ci-C4alkyl)-NRDREmay be substituted with -X,at least one H of the -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl, -(C1-C4 alkyl)-heteroaryl, - (C3-C7cycloalkyl) or-(C2-C6heterocycloalkyl) may be substituted with -X, -OH, - O(Ci-C4alkyl), -(C1-C4 alkyl), -CF3, -CF2H or-CN, andv / H\ , ,b .at least oneH of 's may be substituted with n-X, -OH, -O(Cr C4alkyl), -(C1-C4 alkyl), -CF3, -CF2H, -CN, -(C2-C6heterocycloalkyl), -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or -heteroaryl-(Ci-C4alkyl);Rcis -(C1-C4 alkyl), -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or -(Ci-C4alkyl)-heteroaryl, wherein at least one H of -(C1-C4 alkyl) may be substituted with -X or -OH, at leastDocket No. PAT059983-PCT-SEC01 one H of -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or -(Ci-C4alkyl)-heteroaryl may be substituted with -X, -OH, -CF3or -CF2H;RDand REare each independently -H, -(C1-C4 alkyl), -aryl or -(Ci-C4alkyl)-aryl, wherein, at least one H of -(Ci-C4alkyl) may be substituted with -X or -OH, at least one H of - aryl or -(C1-C4 alkyl)-aryl may be substituted with -X, -OH, -CF3or -CF2H;RFis -H, -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(C1-C4 alkyl)-O-(Ci-C4alkyl), -C(=O)-(Ci-C4alkyl), -C(=O)-O-(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O-(Ci-C4alkyl), -(C1-C4 alkyl)- NRDRE, -S(=O)2-(Ci-C4alkyl), -aryl, -(Ci-C4alkyl)-aryl, -(C2-C4alkenyl)-aryl, - heteroaryl, -(C1-C4 alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -(C2-C6heterocycloalkyl) or -(C1-C4 alkyl)-C(=O)-(C2-C6heterocycloalkyl), wherein:at least one H of -(C1-C4 alkyl), -(C1-C4 alkyl)-OH, -(Ci-C4alkyl)-O-(Ci-C4 alkyl), -C(=O)-(Ci-C4alkyl), -C(=O)-O(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)- O(Ci-C4alkyl), -(Ci-C4alkyl)-NRDREor -S(=O)2-(Ci-C4alkyl) may be substituted with -X, andat least one H of -aryl, -(Ci-C4alkyl)-aryl, -(C2-C4alkenyl)-aryl, -heteroaryl, - (Ci-C4alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -C2-C6heterocycloalkyl or -(Ci-C4alkyl)-C(=0)-(C2-C6heterocycloalkyl) may be substituted with - X, -OH, -CF3or-CF2H;RGis -H or -(C1-C4 alkyl);Q is -O- or a bond;isasingle bond or double bond, provided that, “ “ ” is a double bond, Y1 is =CH-;a to e are each independently an integer of 0, 1 , 2, 3 or 4, provided that, a and b may not be simultaneously 0, and c and d may not be simultaneously 0; andX is each independently F, Cl, Br or I,wherein the compound of Formula (I) is administered at a dose of about 100 to about 600 mg per day (e.g., about 50 to about 100 mg twice per day, or 50 mg or 100 mg twice per day) or at the equivalent dose for a pharmaceutically acceptable salt thereof.

[0007] In some embodiments, the compound of Formula (I) is one selected from the compounds in Table A.

[0008] In some embodiments, the compound of Formula (I) is selected from the group consisting of:Docket No. PAT059983-PCT-SEC01

[0009] In some embodiments, the AF is paroxysmal atrial fibrillation, persistent atrial fibrillation, long-term persistent atrial fibrillation, valvularatrial fibrillation, non-valvularatrial fibrillation, or non-permanent atrial fibrillation.

[0010] In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), or a pharmaceutically acceptable salt thereof, is administered orally.

[0011] In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), or a pharmaceutically acceptable salt thereof, is administered in a form of tablet or capsule.

[0012] In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), or a pharmaceutically acceptable salt thereof, is administered twice daily.

[0013] In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is administered at a dose of about 50 mg to about 300 mg, about 50 mg to about 200 mg, about 100 mg to 300 mg, about 50 mg to about 100 mg, about 100 mg to about 200 mg, or about 200 mg to about 300 mg, or at an equivalent dose for a pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID).

[0014] In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is administered at a dose of about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, or about 300 mg, or at an equivalent dose for a pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID).Docket No. PAT059983-PCT-SEC01

[0015] In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is administered at a dose of 50 mg, or 100 mg, or at an equivalent dose for a pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID).

[0016] In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof is administered for at least 6 weeks, at least 12 weeks, at least 18 weeks, at least 24 weeks, at least 30 weeks, or at least 36 weeks.

[0017] In some embodiments, the patient is a human patient.

[0018] In some embodiments, the patient is male orfemale 18 years old or older.

[0019] In some embodiments, the patient has a history of at least two AF episodes. In some embodiments, the patient has a history of at least two episodes of atrial fibrillation and / or atrial flutter. In some embodiments, the patient has a history of at least two episodes of atrial fibrillation and / or atrial flutter, where at least one episode is atrial fibrillation.

[0020] In some embodiments, at least one of the AF episodes occur within the last 12 months prior to the treatment and documented by 12-lead ECG, Holter, or any other ECG recording method, as confirmed by patient’s medical record.

[0021] In some embodiments, the patient has one or more of the following conditions:i. atrial fibrillation burden (AFB) of 1 % or higher on a local ambulatory Holter, mobile cardiac telemetry, ECG patch monitor, or other ambulatory electrocardiographic monitor within the last 12 months prior to the treatment ii. CHA2DS2-VASc score of 2 or higher in males, 3 or higher in femalesHi. Stable heart failure or with New York Heart Association class I or II symptoms iv. NT-proBNP level of 300 pg / mL or higher on a local lab test within the last 12 months prior to the treatment

[0022] In some embodiments, the patient is on guideline-directed stroke prevention treatment, as confirmed by the patient’s medical record.

[0023] In some embodiments, the patient has a body mass index (BMI) about or greater than 18.

[0024] In some embodiments, the patient has sinus rhythm documented by 12-lead ECG before administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof. In some embodiments, if the patient has persistent AF, the patient is cardioverted before administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof.

[0025] In some embodiments, the patient does not have one or more of the following conditions:Docket No. PAT059983-PCT-SEC01 (i) Permanent AF;(ii) Ongoing reversible cause of AF selected from hyperthyroidism, myocarditis, alcohol use, sepsis- or infection-related AF, surgery-related AF, and pulmonary embolism;(iii) Ongoing use of antiarrhythmic therapy;(iv) History of an AF ablation procedure (for example, within the last 6 months) without a recurrence of AF at least 2 or more months after the ablation; (v) Implanted pacemaker, defibrillator, or cardiac monitor;(vi) Infiltrative or hypertrophic cardiomyopathy;(vii) Current decompensated heart failure or hospitalization for heart failure within 3 months prior to the treatment;(viii) Left ventricular ejection fraction (LVEF) of 40% or less documented within the last 12 months prior to the treatment, or during the treatment, for example, if multiple LVEF measurements are recorded within the last 12 months, the most recent LVEF measurement should be used;(ix) Severe valvular disease or planned valvular intervention during study;(x) Stroke within the last 6 months, or other neurologic or psychiatric conditions likely to affect study compliance;(xi) Cardiac surgery within the last 6 months;(xii) Unstable angina, myocardial infarction, coronary angioplasty within the last 6 months; and(xiii) Known allergic reactions to adhesives or hydrogels.

[0026] In some embodiments, the patient does not have known history of or current clinically significant ventricular arrhythmias, personal history of an inherited arrhythmia syndrome, long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, idiopathic ventricular fibrillation, or arrhythmogenic cardiomyopathy.

[0027] In some embodiments, the patient does not have:(i) history of or current significant ECG abnormalities that indicate a high safety risk for participants in the study, or(ii) HR < 50 bpm (or HR < 45 bpm if on a beta blocker or calcium channel blocker); and / or QTcF > 450 msec (males) or QTcF > 460 msec (females).

[0028] In some embodiments, the patient does not have a history of drug abuse or unhealthy alcohol use within 12 months prior to the treatment.

[0029] In some embodiments, the patient is not (a) pregnant, (b) a nursing or lactating woman, or (c) a woman having child-bearing potential unless she is using effective methods of contraception during the treatment.Docket No. PAT059983-PCT-SEC01

[0030] In some embodiments, the patient does not have Liver disease or liver injury indicated by abnormal liver function tests.

[0031] In some embodiments, the patient does not have a history or presence of impaired renal function.

[0032] In some embodiments, just prior to administering, the patient has not used other drugs or therapies within 5 half-lives of the other drugs or therapies on the day of administering, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer.

[0033] In some embodiments, the patient has not been treated with any Vaughan Williams class I or III anti-arrhythmic drug.

[0034] In some embodiments, the patient has not been treated with amiodarone.

[0035] In some embodiments, prior to administering, the patient has not been in ongoing treatment with a drug that is a CYP3A4 inhibitor (e.g., moderate or strong CYP3A4 inhibitor).

[0036] In some embodiments, prior to administering, the patient has not been in ongoing treatment with a drug that is a CYP3A4 inducer (e.g., strong CYP3A4 inducer).

[0037] In some embodiments, the patient has not been treated with one or more selected from boceprevir, ceritinib, clarithromycin, cobicistat, conivaptan, danoprevir / ritonavir, elvitegravir / ritonavir, grapefruit or grapefruit juice, idelalisib, indinavir, indinavir, ritonavir, itraconazole, josamycin, ketoconazole, lopinavir / ritonavir, mibefradil, mifepristone, nefazodone, nelfinavir, ombitasvir / paritaprevir / dasabuvir / ritonavir (Viekira Pak), posaconazole, ribociclib, ritonavir, saquinavir, saquinavir / ritonavir, telaprevir, telithromycin, tipranavir / ritonavir, troleandomycin, tucatinib, voriconazole, aprepitant, amprenavir, atazanavir, atazanavir / ritonavir, casopitant, cimetidine, ciprofloxacin, crizotinib, darunavir, darunavir / ritonavir, diltiazem, dronedarone, duvelisib, erythromycin, faldaprevir, fedratinib, fluconazole, imatinib, isavuconazole, istradefylline, lefamulin, letermovir, Magnolia vine (Schisandra sphenanthera), netupitant, nilotinib, ravuconazole, tofisopam, verapamil, voxelotor, apalutamide, avasimibe, carbamazepine, enzalutamide, ivosidenib, lumacaftor, mitotane, phenytoin, rifampicin, rifapentine, and St. John’s wort (Hypericum perforatum).

[0038] In some embodiments, the patient has not been treated with a drug known to prolong the QT interval.

[0039] In some embodiments, the patient does not have significant illness which has not resolved within two weeks prior to administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), or the pharmaceutically acceptable salt thereof.

[0040] In some embodiments, the method further comprises assessing the treatment by measuring AF burden, time to recurrent AF, presence or absence of AF recurrence, ventricular arrhythmias, or QTc duration using an ECG Patch, a 12-lead ECG, a mobile handheld ECG, or a photoplethysmography (PPG) wearable device.Docket No. PAT059983-PCT-SEC01

[0041] In some embodiments, the method further comprises assessing the treatment by measuring a level of a biomarker from a blood sample obtained from the patient.

[0042] In some embodiments, the biomarker is peripheral acetylated alpha tubulin (AAT), for example, a fold change of the peripheral AAT is measured compared to a baseline AAT level measured prior to the administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), or the pharmaceutically acceptable salt thereof. In some embodiments, the biomarker is NT-proBNP and / or cardiac troponin and a serum level of the NT-proBNP and / or cardiac troponin is measured.

[0043] In some embodiments, the biomarker is FGF23 and / or BMP10 and a serum level of the FGF23 and / or BMP10 is measured.

[0044] In some embodiments, the method of treating AF results in increases in the peripheral AAT in the patient (e.g., by about 1.1 to 15.0 fold) compared to a baseline AAT level measured prior to the administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), or the pharmaceutically acceptable salt thereof.

[0045] In some embodiments, AF burden in the patient measured by the ECG patch is reduced (e.g., by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 35%, at least about 40%, or by at least about 45 %) after administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), or the pharmaceutically acceptable salt thereof.

[0046] In some embodiments, AF recurrence in the patient is reduced (e.g., by at least about 10%, at least about 15%, at least about 20%, by at least about 25%, or by at least about 30%) after administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), or the pharmaceutically acceptable salt thereof wherein the AF recurrence is measured by a time (d) from the date of the treatment to the time of a first recurrent AF episode.

[0047] In an aspect, the disclosure provides a method of reducing AF burden in a patient measured by the ECG patch, the method comprising administering to the patient a compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), as described herein, or a pharmaceutically acceptable salt thereof, wherein the method results in reduction of AF burden by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 35%, at least about 40%, or by at least about 45 % after administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), or a pharmaceutically acceptable salt thereof.

[0048] In some embodiments, the patient in need thereof has atrial flutter or is diagnosed with atrial flutter.

[0049] In some embodiments, the method further comprises reducing atrial flutter in theDocket No. PAT059983-PCT-SEC01 patient in need thereof.

[0050] In an aspect, the disclosure provides a method of reducing AF recurrence in a patient as measured by time (d) from the treatment to first AF recurrence and presence (or absence) of AF recurrence, the method comprising administering to the patient a compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), as described herein, or a pharmaceutically acceptable salt thereof, wherein the method results in reduction of the AF recurrence (e.g., by at least about 10%, at least about 15%, at least about 20%, by at least about 25%, or by at least about 30%) after administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), or a pharmaceutically acceptable salt thereof.

[0051] In an aspect, the disclosure provides a method of inhibiting or reducing histone deacetylase 6 (HDAC6) activity in a patient in need thereof, the method comprising administering to the patient a compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), as described herein, ora pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is administered at a dose of about 100 to about 600 mg per day (e.g., about 50 to about 100 mg twice per day, or 50 mg or 100 mg twice per day) or at the equivalent dose for a pharmaceutically acceptable salt thereof.

[0052] In an aspect, the disclosure provides a method of reducing a risk of recurrent atrial fibrillation (AF) episode in a patient in need thereof, the method comprising administering to the patient a compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), as described herein, ora pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is administered at a dose of about 100 to about 600 mg per day (e.g., about 50 to about 100 mg twice per day, or 50 mg or 100 mg twice per day) or at the equivalent dose for a pharmaceutically acceptable salt thereof.

[0053] In an aspect, the disclosure provides a method of preventing atrial fibrillation (AF) in a patient in need thereof, the method comprising administering to the patient a compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), as described herein, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is administered at a dose of about 100 to about 600 mg per day (e.g., about 50 to about 100 mg twice per day, or 50 mg or 100 mg twice per day) or at the equivalent dose for a pharmaceutically acceptable salt thereof.

[0054] In an aspect, the disclosure provides a method of increasing circulating acetylated alpha tubulin (AAT) in a patient in need thereof, the method comprising administering to the patient a compound of Formula (I) (e.g., compound of Table A or Table B, such as CompoundDocket No. PAT059983-PCT-SEC01 40, 43, 239, 285, 295, or 296), as described herein, ora pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is administered at a dose of about 100 to about 600 mg per day (e.g., about 50 to about 100 mg twice per day, or 50 mg or 100 mg twice per day) or at the equivalent dose for a pharmaceutically acceptable salt thereof.

[0055] In some embodiments, for the methods as described herein, the methods comprises administering to the patient the compound ofQ . Xxxo , or a pharmaceutically acceptable salt thereof.

[0056] In some embodiments, for the methods as described herein, the methods comprises administering to the patient the compound ofC '■■■'i '.a ... T° , or a pharmaceutically acceptable salt thereof.

[0057] In some embodiments, for the methods as described herein, the methods comprises administering to the patient the compound ofXs. It NX- < or °$ , or a pharmaceutically acceptable salt thereof.

[0058] In some embodiments, for the methods as described herein, the methods comprises administering to the patient the compound of, or a pharmaceutically acceptable salt thereof.

[0059] In some embodiments, for the methods as described herein, the methods comprises administering to the patient the compound of0, or a pharmaceutically acceptable salt thereof.

[0060] In some embodiments, for the methods as described herein, the methods comprisesDocket No. PAT059983-PCT-SEC01 administering to the patient the compound of6, or a pharmaceutically acceptable salt thereof.

[0061] In an aspect, the disclosure provides a pharmaceutical composition comprising an HDAC6 inhibitor and a pharmaceutically acceptable excipient, for use in the treating atrial fibrillation (AF) in a patient in need thereof, wherein the HDAC6 inhibitor comprises a compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), as described herein, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is administered at a dose of about 100 to about 600 mg per day twice a day (e.g., about 50 to about 100 mg twice per day, or 50 mg or 100 mg twice per day) or at the equivalent dose for the pharmaceutically acceptable salt thereof.

[0062] Other aspects of the invention are disclosed infra.BRIEF DESCRIPTION OF THE DRAWINGS

[0063] FIG. 1 shows that Compound A prolonged APD90in tachypaced rabbitcard io myocytes. Data points are mean ± standard deviation from 3 to 5 separate experiments. APDgo was normalized as the percentage of the baseline value before tachypacing and addition of compound.

[0064] FIG. 2 shows that Compound A prevents loss of L-type calcium channel current in tachypaced cells. Data show normal levels of Ca2+current (control), loss of current due to tachypacing (pacing) and preservation of current during tachypacing by Compound A. Data are mean ± standard deviation from 5 separate experiments.

[0065] FIG. 3 shows that Compound A prolonged APD90in atrial tissue from AF patients. All APD90values expressed as mean ± SD for n = 3 to 7 patient samples.

[0066] FIG.4 shows that Compound A increased the level of acetylated tubulin in AF patient atrial tissue. Data are expressed as mean ± SD, from samples from n=5 AF patients.

[0067] FIG.5 shows that Compound A reduced AF duration in a dog AF model. Values for AF duration are expressed as mean ± SD for n=3 to 4 animals per group except for sham, which employed n=2. For reference, values for each individual animal data are also shown as dots. RAP is rapid atrial pacing, positive (control) is a marketed anti-arrhythmic drug, 50 mg / kg.

[0068] FIG. 6 shows PK / PD relationship for AF duration in the dog AF model. Relationship between plasma concentration measured two hours after dosing and AF duration in the dog model (each point represents an individual animal in the vehicle, 0.3, 1, and 3 mpk, BID cohorts).Docket No. PAT059983-PCT-SEC01

[0069] FIG. 7 shows that Compound A increased levels of acetylated and total tubulin in left atrial tissue from a dog AF model. Data are expressed as mean ± SEM for n=4 animals per group except for sham (n=2), vehicle (n=3) and positive control ( n=3). RAP is rapid atrial pacing, A.U. are absorbance units from Western blot band quantitation, normalized to GAPDH. Effects in compound treated groups did not differ from vehicle in a statistically significant fashion (one-way ANOVA with Tukey’s test for multiple comparisons).

[0070] FIG. 8 shows that Compound A increased the level of acetylated-tubulin in PBMCs from a dog AF model. Data are expressed as mean ± SD for n=2 animals (sham, vehicle, positive control), n=3 (0.3 mpk and 3 mpk) or n=4 (1 mpk). A.U. are absorbance units from Western blot band quantitation normalized to GAPDH.

[0071] FIG. 9 shows that Compound A prolonged APDgo in a dog AF model. Values for APDgo are expressed as mean ± SD for n=2 to 4 animals per group. *** denotes P<0.001 vs sham, #* denotes P<0.001 vs vehicle, respectively. RAP is rapid atrial pacing; positive control is a marketed anti-arrhythmic drug, 50 mg / kg.

[0072] FIG. 10 shows that Compound A effects on induced AF duration in a second dog AF study. Values for AF duration are expressed as mean ± SD for n=3 to 4 animals per group except for sham, which employed n=2. For reference, values for each individual animal data are also shown as dots. RAP is rapid atrial pacing.

[0073] FIG. 11 shows Compound A Mean (SD) multiple dose plasma concentration-time profiles on Day 1 and Day 14.

[0074] FIG. 12 shows fold increase in AAT overtime with Compound A single ascending dose (SAD).

[0075] FIG. 13 shows fold increase in AAT overtime with Compound A multiple ascending dose (MAD).

[0076] FIG. 14 shows Compound A concentration-QTcF Analysis (estimated AAQTcF with 90% Two-Sided Cl).

[0077] FIG. 15 shows a scheme of the clinical study in Example 5.DETAILED DESCRIPTIONDefinition

[0078] Terms not specifically defined herein should be given the meanings that would be given to them by one of skill in the art in light of the disclosure and the context. As used in the specification and appended claims, however, unless specified to the contrary, the following terms have the meaning indicated and the following conventions are adhered to.

[0079] In the groups, radicals, or moieties defined below, the number of carbon atoms is often specified preceding the group, for example, (Ci-Cw)alkyl means an alkyl group or radical having 1 to 10 carbon atoms. In general, for groups comprising two or more subgroups, the lastDocket No. PAT059983-PCT-SEC01 named group is the radical attachment point, for example, “alkylaryl” means a monovalent radical of the formula alkyl-aryl-, while “arylalkyl” means a monovalent radical of the formula aryl-alkyl-. Furthermore, the use of a term designating a monovalent radical where a divalent radical is appropriate shall be construed to designate the respective divalent radical and vice versa. Unless otherwise specified, conventional definitions of terms control and conventional stable atom valences are presumed and achieved in all formulas and groups.

[0080] The articles “a” and “an” referto one or more than one (e.g., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

[0081] The term “and / or” means either “and” or “or” unless indicated otherwise. This term "and / or" also means that each one or both or all the components or features of a list are possible variants, especially two or more thereof in an alternative or cumulative way.

[0082] Unless indicated otherwise, an “or” conjunction is intended to be used in its correct sense as a Boolean logical operator, encompassing both the selection of features in the alternative (A or B, where the selection of A is mutually exclusive from B) and the selection of features in conjunction (A or B, where both A and B are selected). In some places in the text, the term “and / or” is used for the same purpose, which shall not be construed to imply that “or” is used with reference to mutually exclusive alternatives.

[0083] The term “about” or “approximately” means within 20%, preferably within 15%, preferably within 10%, and more preferably within 5% of a given value or range. In some embodiments, the term “about” or “approximately” means within 20% of a given value or range. In some embodiments, the term “about” or “approximately” means within 15% of a given value or range. In some embodiments, the term “about” or “approximately” means within 10% of a given value or range. In some embodiments, the term “about” or “approximately” means within 5% of a given value or range.

[0084] The term “optionally substituted” as used herein means that a given chemical moiety (e.g., an alkyl group) can (but is not required to) be bonded other substituents (e.g., heteroatoms). For instance, an alkyl group that is optionally substituted can be a fully saturated alkyl chain (e.g., a pure hydrocarbon). Alternatively, the same optionally substituted alkyl group can have substituents different from hydrogen. For instance, it can, at any point along the chain be bounded to a halogen atom, a hydroxyl group, or any other substituent described herein. Thus, the term “optionally substituted” means that a given chemical moiety has the potential to contain other functional groups but does not necessarily have any further functional groups. Suitable substituents used in the optional substitution of the described groups include, without limitation, halogen, oxo, -OH, -CN, -COOH, -CH2CN, -O-(Ci-C6)alkyl, (Ci-C6)alkyl, (Cr C6)alkoxy, (Ci-C6)haloalkyl, (Ci-C6)haloalkoxy, -O-(C2-C6)alkenyl, -O-(C2-C6)alkynyl, (C2-C6)alkenyl, (C2-C6)alkynyl, -OH, -OP(O)(OH)2, -OC(O)(Ci-C6)alkyl, -C(O)(Ci-C6)alkyl, -Docket No. PAT059983-PCT-SEC01 OC(O)O(Ci-C6)alkyl, -NH2, -NH((Ci-C6)alkyl), -N((Ci-C6)alkyl)2, -NHC(O)(Ci-C6)alkyl, -C(O)NH(Ci-C6)alkyl, -S(O)2(Ci-C6)alkyl, -S(O)NH(Ci-C6)alkyl, and S(O)N((Ci-C6)alkyl)2. The substituents can themselves be optionally substituted. “Optionally substituted” as used herein also refers to substituted or unsubstituted whose meaning is described below.

[0085] The term “substituted” as used herein means that the specified group or moiety bears one or more suitable substituents wherein the substituents may connect to the specified group or moiety at one or more positions. For example, an aryl substituted with a cycloalkyl may indicate that the cycloalkyl connects to one atom of the aryl with a bond or by fusing with the aryl and sharing two or more common atoms.

[0086] The term “unsubstituted” as used herein means that the specified group bears no substituents.

[0087] Unless otherwise specifically defined, “aryl” means a cyclic, aromatic hydrocarbon group having 1 to 3 aromatic rings, including monocyclic or bicyclic groups such as phenyl, biphenyl, or naphthyl. When containing two aromatic rings (bicyclic, etc.), the aromatic rings of the aryl group are optionally joined at a single point (e.g., biphenyl), or fused (e.g., naphthyl). The aryl group is optionally substituted by one or more substituents, e.g., 1 to 5 substituents, at any point of attachment. Exemplary substituents include, but are not limited to, -H, -halogen, -CN, -O-(Ci-C6)alkyl, (Ci-C6)alkyl, -O-(C2-C6)alkenyl, -O-(C2-C6)alkynyl, (C2-C6)alkenyl, (C2-C6)alkynyl, -OH, -OP(O)(OH)2, -OC(O)(Ci-C6)alkyl, -C(O)(Ci-C6)alkyl, -OC(O)O(Ci-C6) alkyl, NH2, NH((Ci-C6)alkyl), N((Ci-C6)alkyl)2, -S(O)2-(Ci-C6)alkyl, -S(O)NH(Ci-C6)alkyl, and S(O)N((Ci-C6)alkyl)2. The substituents are themselves optionally substituted. Furthermore, when containing two fused rings, the aryl groups optionally have an unsaturated or partially saturated ring fused with a fully saturated ring. Exemplary ring systems of these aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, anthracenyl, phenalenyl, phenanthrenyl, indanyl, indenyl, tetrahydronaphthalenyl, tetrahydrobenzoannulenyl, and the like.

[0088] Unless otherwise specifically defined, “heteroaryl” means a monovalent monocyclic aromatic radical of 5 to 24 ring atoms or a polycyclic aromatic radical, containing one or more ring heteroatoms selected from N, O, orS, the remaining ring atoms being C. Heteroaryl as herein defined also means a bicyclic heteroaromatic group wherein the heteroatom is selected from N, O, or S. The aromatic radical is optionally substituted independently with one or more substituents described herein. Examples include, but are not limited to, furyl, thienyl, pyrrolyl, pyridyl, pyrazolyl, pyrimidinyl, imidazolyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazinyl, indolyl, thiophen-2-yl, quinolyl, benzopyranyl, isothiazolyl, thiazolyl, thiadiazole, indazole, benzimidazolyl, thieno[3,2-b]thiophene, triazolyl, triazinyl, imidazo[1 ,2-b]pyrazolyl, furo[2,3-c]pyridinyl, imidazo[1 ,2-a]pyridinyl, indazolyl, pyrrolo[2,3-c]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrazolo[3,4-c]pyridinyl, thieno[3,2-c]pyridinyl, thieno[2,3-c]pyridinyl, thieno[2,3-b]pyridinyl,Docket No. PAT059983-PCT-SEC01 benzothiazolyl, indolyl, indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, benzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, dihydrobenzoxanyl, quinolinyl, isoquinolinyl, 1 ,6-naphthyridinyl, benzo[de]isoquinolinyl, pyrido[4,3-b][1 ,6]naphthyrid inyl , thieno[2,3-b]pyrazinyl, quinazolinyl, tetrazolo[1 ,5-a]pyrid inyl , [1.2.4]triazolo[4,3-a]pyridinyl, isoindolyl, pyrrolo[2,3-b]pyridinyl, pyrrolo[3,4-b]pyridinyl, pyrrolo[3,2-b]pyridinyl, imidazo[5,4-b]pyridinyl, pyrrolo[1 ,2-a]pyrimidinyl, tetrahydropyrrolo[1 ,2-a]pyrimidinyl, 3,4-dihydro-2H-1A2-pyrrolo[2,1-b]pyrimidine, dibenzo[b,d]thiophene, pyridin-2-one, furo[3,2-c]pyridinyl, furo[2,3-c]pyridinyl, 1 H-pyrido[3,4-b][1 ,4]thiazinyl, benzooxazolyl, benzoisoxazolyl, furo[2,3-b]pyridinyl, benzothiophenyl, 1 ,5-naphthyridinyl, furo[3,2-b]pyridine, [1.2.4]triazolo[l,5-a]pyridinyl, benzo[1 ,2,3]triazolyl, imidazo[1 ,2-a]pyrimidinyl, [1 ,2,4]triazolo[4,3-b]pyridazinyl, benzo[c][1 ,2,5]thiadiazolyl, benzo[c][1 ,2,5]oxadiazole, 1 ,3-dihydro-2H-benzo[d]imidazol-2-one, 3,4-dihydro-2H-pyrazolo[1 ,5-b][1 ,2]oxazinyl, 4, 5,6,7-tetrahydropyrazolo[1 ,5-a]pyridinyl, thiazolo[5,4 d]thiazolyl, imidazo[2,1-b][1 ,3 ,4]thiadiazolyl , thieno[2,3-b]pyrrolyl, 3H-indolyl, and derivatives thereof. Furthermore, when containing two fused rings the aryl groups herein defined may have an unsaturated or partially saturated ring fused with a fully saturated ring. Exemplary ring systems of these heteroaryl groups include indolinyl, indolinonyl, dihydrobenzothiophenyl, dihydrobenzofuran, chromanyl, thiochromanyl, tetrahydroquinolinyl, dihydrobenzothiazine, 3, 4-dihydro-IH-isoquinolinyl, 2,3-dihydrobenzofuran, indolinyl, indolyl, and dihydrobenzoxanyl.

[0089] The term “halogen” or “halo” as used herein means fluorine, chlorine, bromine, or iodine.

[0090] The term “alkyl” as used herein means a straight or branched chain saturated hydrocarbon containing 1-12 carbon atoms. Examples of a (Ci-C6)alkyl group include, but are not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, te / Y-butyl, isopentyl, neopentyl, and isohexyl.

[0091] The term “alkoxy” as used herein means a straight or branched chain saturated hydrocarbon containing 1-12 carbon atoms containing a terminal “O” in the chain, e.g., -O(alkyl). Examples of alkoxy groups include, without limitation, methoxy, ethoxy, propoxy, butoxy, t-butoxy, or pentoxy groups.

[0092] The term “alkenyl” means a straight or branched chain unsaturated hydrocarbon containing 2-12 carbon atoms. The “alkenyl” group contains at least one double bond in the chain. The double bond of an alkenyl group can be unconjugated or conjugated to another unsaturated group. Examples of alkenyl groups include ethenyl, propenyl, n-butenyl, iso-butenyl, pentenyl, or hexenyl. An alkenyl group can be unsubstituted or substituted and may be straight or branched.

[0093] The term “alkynyl” means a straight or branched chain unsaturated hydrocarbon containing 2-12 carbon atoms. The “alkynyl” group contains at least one triple bond in the chain.Docket No. PAT059983-PCT-SEC01 Examples of alkenyl groups include ethynyl, propargyl, n-butynyl, iso-butynyl, pentynyl, or hexynyl. An alkynyl group can be unsubstituted or substituted.

[0094] The term “alkylene” or “alkylenyl” means a divalent alkyl radical. Any of the above mentioned monovalent alkyl groups may be an alkylene by abstraction of a second hydrogen atom from the alkyl. As herein defined, alkylene may also be a (Ci-C6)alkylene. An alkylene may further be a (Ci-C4)alkylene. Typical alkylene groups include, but are not limited to, -CH2-, -CH(CH3)-, -C(CH3)2-, -CH2CH2-, -CH2CH(CH3)-, -CH2C(CH3)2-, -CH2CH2CH2-, -CH2CH2CH2CH-, and the like.

[0095] The term “cycloalkyl” or “carbocyclyl” means a monocyclic or polycyclic saturated carbon ring containing 3-18 carbon atoms. Examples of cycloalkyl groups include, without limitations, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl, cyclooctanyl, norboranyl, norborenyl, bicyclo[2.2.2]octanyl, or bicyclo[2.2.2]octenyl and derivatives thereof. A (C3-C8)cycloalkyl is a cycloalkyl group containing between 3 and 8 carbon atoms. A cycloalkyl group can be fused (e.g., decalin) or bridged (e.g., norbomane).

[0096] The term “heterocyclyl” or “heterocycloalkyl” means a saturated or partially saturated monocyclic or polycyclic ring containing carbon and at least one heteroatom selected from oxygen, nitrogen, or sulfur (O, N, or S) and wherein there is not delocalized n electrons (aromaticity) shared among the ring carbon or heteroatoms. The heterocycloalkyl ring structure may be substituted by one or more substituents. The substituents can themselves be optionally substituted. Examples of heterocyclyl rings include, but are not limited to, oxetanyl, azetadinyl, tetra hydro furanyl, tetrahydropyranyl, pyrrolidinyl, oxazolinyl, oxazolidinyl, thiazolinyl, thiazolidinyl, pyranyl, thiopyranyl, tetrahydropyranyl, dioxalinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S-dioxide, piperazinyl, azepinyl, oxepinyl, diazepinyl, tropanyl, oxazolidinonyl, 1 ,4-dioxanyl, di hydrofuranyl, 1 ,3-dioxolanyl, imidazolidinyl, imidazolinyl, dithiolanyl, and homotropanyl.

[0097] The term “hydroxyalkyl” means an alkyl group substituted with one or more -OH groups. Examples of hydroxyalkyl groups include HO-CH2-, HO-CH2CH2-, and CH2-CH(OH)-.

[0098] The term “haloalkyl” means an alkyl group substituted with one or more halogens. Examples of haloalkyl groups include, but are not limited to, trifluoromethyl, difluoromethyl, pentafluoroethyl, trichloromethyl, etc.

[0099] The term “haloalkoxy” means an alkoxy group substituted with one or more halogens. Examples of haloalkyl groups include, but are not limited to, trifluoromethoxy, difluoromethoxy, pentafluoroethoxy, trichloromethoxy, etc.

[0100] The term “cyano” means a substituent having a carbon atom joined to a nitrogen atom by a triple bond, e.g., CEN.

[0101] The term “amino” means a substituent containing at least one nitrogen atom (e.g., NH2).Docket No. PAT059983-PCT-SEC01

[0102] The term “salt” as used herein means an ionic form of the parent compound or the product of the reaction between the parent compound with a suitable acid or base to make the acid salt or base salt of the parent compound. Salts of the compounds of the present disclosure can be synthesized from the parent compounds which contain a basic or acidic moiety by conventional chemical methods. Generally, the salts are prepared by reacting the free base or acid parent compound with stoichiometric amounts or with an excess of the desired salt-forming inorganic or organic acid or base in a suitable solvent or various combinations of solvents.

[0103] The term “pharmaceutically acceptable salt” as used herein means a salt of a compound of the disclosure which is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit / risk ratio, generally water or oil-soluble or dispersible, and effective for their intended use. The term includes pharmaceutically-acceptable acid addition salts and pharmaceutically-acceptable base addition salts. As the compounds of the present disclosure are useful in both free base and salt form, in practice, the use of the salt form amounts to use of the base form. Lists of suitable salts are found in, e.g., S.M. Birge et al., J. Pharm. Sci., 1977, 66, pp. 1-19, which is hereby incorporated by reference in its entirety. For example, the term “pharmaceutically-acceptable acid addition salt” means those salts which retain the biological effectiveness and properties of the free bases and which are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, nitric acid, phosphoric acid, and the like, and organic acids such as acetic acid, trichloroacetic acid, trifluoroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 2-acetoxybenzoic acid, butyric acid, camphoric acid, camphorsulfonic acid, cinnamic acid, citric acid, digluconic acid, ethanesulfonic acid, glutamic acid, glycolic acid, glycerophosphoric acid, hemisulfic acid, heptanoic acid, hexanoic acid, formic acid, fumaric acid, 2-hydroxyethanesulfonic acid (isethionic acid), lactic acid, maleic acid, hydroxymaleic acid, malic acid, malonic acid, mandelic acid, mesitylenesulfonic acid, methanesulfonic acid, naphthalenesulfonic acid, nicotinic acid, 2-naphthalenesulfonic acid, oxalic acid, pamoicacid, pectinic acid, phenylacetic acid, 3-phenylpropionic acid, picric acid, pivalicacid, propionic acid, pyruvic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, sulfanilic acid, tartaric acid, p-toluenesulfonic acid, undecanoic acid, and the like. Further, for example, the term “pharmaceutically-acceptable base addition salt” means those salts which retain the biological effectiveness and properties of the free acids and which are not biologically or otherwise undesirable, formed with inorganic bases such as ammonia or hydroxide, carbonate, or bicarbonate of ammonium or a metal cation such as sodium, potassium, lithium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived fromDocket No. PAT059983-PCT-SEC01 pharmaceutically-acceptable organic nontoxic bases include salts of primary, secondary, and tertiary amines, quaternary amine compounds, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion-exchange resins, such as methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, isopropylamine, tripropylamine, tributylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, tetramethylammonium compounds, tetraethylammonium compounds, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, dibenzylamine, N,N-dibenzylphenethylamine, 1-ephenamine, N,N’-dibenzylethylenediamine, polyamine resins, and the like. Particularly preferred organic nontoxic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine.

[0104] The term “isomers” means compounds having the same number and kind of atoms, and hence the same molecular weight, but differing with respect to the arrangement or configuration of the atoms in space. The term includes stereoisomers and geometric isomers.

[0105] The term “stereoisomer” or “optical isomer” mean a stable isomer that has at least one chiral atom or restricted rotation giving rise to perpendicular dissymmetric planes (e.g., certain biphenyls, allenes, and spiro compounds) and can rotate plane-polarized light. Because asymmetric centers and other chemical structure exist in the compounds of the disclosure, which may give rise to stereoisomerism, the disclosure contemplates stereoisomers and mixtures thereof. The compounds of the disclosure and their salts include asymmetric carbon atoms and may therefore exist as single stereoisomers, racemates, and as mixtures of enantiomers and diastereomers. Typically, such compounds will be prepared as a racemic mixture. If desired, however, such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers, or as stereoisomer-enriched mixtures. As discussed in more detail below, individual stereoisomers of compounds are prepared by synthesis from optically active starting materials containing the desired chiral centers or by preparation of mixtures of enantiomeric products followed by separation or resolution, such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, use of chiral resolving agents, or direct separation of the enantiomers on chiral chromatographic columns. Starting compounds of particular stereochemistry are either commercially available or are made by the methods described below and resolved by techniques well-known in the art.

[0106] The term “enantiomers” means a pair of stereoisomers that are non-superimposable mirror images of each other.

[0107] The term “diastereoisomers” or “diastereomers” mean optical isomers, which are notDocket No. PAT059983-PCT-SEC01 mirror images of each other.

[0108] The term “racemic mixture” or “racemate” mean a mixture containing equal parts of individual enantiomers.

[0109] The term “non-racemic mixture” means a mixture containing unequal parts of individual enantiomers.

[0110] The term “geometrical isomer” means a stable isomer, which results from restricted freedom of rotation about double bonds (e.g., cis-2-butene and trans-2-butene) or in a cyclic structure (e.g., cis-1 ,3-dichlorocyclobutane and trans-1 ,3-dichlorocyclobutane). Because carbon-carbon double (olefinic) bonds, C=N double bonds, cyclic structures, and the like may be present in the compounds of the disclosure, the disclosure contemplates each of the various stable geometric isomers and mixtures thereof resulting from the arrangement of substituents around these double bonds and in these cyclic structures. The substituents and the isomers are designated using the cis / trans convention or using the E orZ system, wherein the term “E” means higher order substituents on opposite sides of the double bond, and the term “Z” means higher order substituents on the same side of the double bond. A thorough discussion of E and Z isomerism is provided in J. March, Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 4th ed., John Wiley & Sons, 1992, which is hereby incorporated by reference in its entirety. Several of the following examples represent single E isomers, single Z isomers, and mixtures of E / Z isomers. Determination of the E and Z isomers can be done by analytical methods such as x-ray crystallography,1H NMR, and13C NMR.

[0111] Some of the compounds of the disclosure can exist in more than one tautomeric form. As mentioned above, the compounds of the disclosure include all such tautomers.

[0112] It is well-known in the art that the biological and pharmacological activity of a compound is sensitive to the stereochemistry of the compound. Thus, for example, enantiomers often exhibit strikingly different biological activity including differences in pharmacokinetic properties, including metabolism, protein binding, and the like, and pharmacological properties, including the type of activity displayed, the degree of activity, toxicity, and the like. Thus, one skilled in the art will appreciate that one enantiomer may be more active or may exhibit beneficial effects when enriched relative to the other enantiomer or when separated from the other enantiomer. Additionally, one skilled in the art would know how to separate, enrich, or selectively prepare the enantiomers of the compounds of the disclosure from this disclosure and the knowledge of the prior art.

[0113] Thus, although the racemic form of drug may be used, it is often less effective than administering an equal amount of enantiomerically pure drug; indeed, in some cases, one enantiomer may be pharmacologically inactive and would merely serve as a simple diluent. For example, although ibuprofen had been previously administered as a racemate, it has been shown that only the S-isomer of ibuprofen is effective as an anti-inflammatory agent (in the caseDocket No. PAT059983-PCT-SEC01 of ibuprofen, however, although the R-isomer is inactive, it is converted in vivo to the S-isomer, thus, the rapidity of action of the racemic form of the drug is less than that of the pure S-isomer). Furthermore, the pharmacological activities of enantiomers may have distinct biological activity. For example, S-penicillamine is a therapeutic agent for chronic arthritis, while R-penicillamine is toxic. Indeed, some purified enantiomers have advantages over the racemates, as it has been reported that purified individual isomers have faster transdermal penetration rates compared to the racemic mixture.

[0114] Thus, if one enantiomer is pharmacologically more active, less toxic, or has a preferred disposition in the body than the other enantiomer, it would be therapeutically more beneficial to administer that enantiomer preferentially. In this way, the patient undergoing treatment would be exposed to a lower total dose of the drug and to a lower dose of an enantiomer that is possibly toxic or an inhibitor of the other enantiomer.

[0115] Preparation of pure enantiomers or mixtures of desired enantiomeric excess (ee) or enantiomeric purity are accomplished by one or more of the many methods of (a) separation or resolution of enantiomers, or (b) enantioselective synthesis known to those of skill in the art, or a combination thereof. These resolution methods generally rely on chiral recognition and include, for example, chromatography using chiral stationary phases, enantioselective hostguest complexation, resolution or synthesis using chiral auxiliaries, enantioselective synthesis, enzymatic and nonenzymatic kinetic resolution, or spontaneous enantioselective crystallization. Such methods are disclosed generally in Chiral Separation Techniques: A Practical Approach (2nd Ed.), G. Subramanian (ed.), Wiley-VCH, 2000; T.E. Beesley and R.P.W. Scott, Chiral Chromatography, John Wiley & Sons, 1999; and Satinder Ahuja, Chiral Separations by Chromatography, Am. Chem. Soc., 2000. Furthermore, there are equally well-known methods for the quantitation of enantiomeric excess or purity, for example, GC, HPLC, CE, or NMR, and assignment of absolute configuration and conformation, for example, CD ORD, X-ray crystallography, or NMR.

[0116] In general, all tautomeric forms and isomeric forms and mixtures, whether individual geometric isomers or stereoisomers or racemic or non-racemic mixtures, of a chemical structure or compound is intended, unless the specific stereochemistry or isomeric form is specifically indicated in the compound name or structure.

[0117] A term “patient,” “subject,” “patient in need thereof,” and “subject in need thereof’ are herein used interchangeably and refer to a living organism suffering from or prone to a disease or condition that can be treated by administration of a pharmaceutical composition as provided herein. Non-limiting examples include humans, other mammals, bovines, rats, mice, dogs, monkeys, goat, sheep, cows, deer, and other non-mammalian animals. In some embodiments, a patient is human (e.g., human patient).

[0118] An “effective amount” or “therapeutically effective amount” when used inDocket No. PAT059983-PCT-SEC01 connection with a compound means an amount of a compound of the present disclosure in combination with the second therapeutic agent that (i) treats or prevents the particular disease, condition, or disorder, (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of the particular disease, condition, or disorder described herein. In certain aspects, for the given parameter (e.g., biomarker), a therapeutically effective amount will show an increase or decrease of at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100%. Therapeutic efficacy can also be expressed as “-fold” increase or decrease. For example, a therapeutically effective amount can have at least a 1.2-fold, 1.5-fold, 2-fold, 5-fold, or more effect over a control.

[0119] As used herein, the terms “pharmaceutical formulation” or “pharmaceutical composition” refers to a composition comprising one or more pharmaceutically active ingredients (e.g., HDAC inhibitor or HDAC6 inhibitor). Particularly, the pharmaceutical formulation or pharmaceutical composition comprises at least one pharmaceutically acceptable excipient or carrier. In certain aspects, the pharmaceutically acceptable excipient or carrier does not react with the pharmaceutically active ingredients.

[0120] As used herein, the term “carrier” encompasses carriers, excipients, and diluents and means a material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting a pharmaceutical agent from one organ, or portion of the body, to another organ, or portion of the body of a subject.

[0121] As used herein, a patient is “in need of’ a treatment if such subject would benefit biologically, medically, or in quality of life from such treatment (e.g., a human).

[0122] As used herein, the term “inhibit”, “inhibition”, or “inhibiting” refers to negatively affecting (e.g. decreasing) activity, expression or function relative to the activity, expression or function in the absence of an inhibitor. The term “inhibitor” also refers to a compound, composition, or substance capable of detectably negatively affecting (e.g. decreasing or reducing) activity, expression or function of a given protein or gene. For example, an inhibitor may decrease activity, expression or function by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or greater in comparison to a control in the absence of the inhibitor. Inhibitors include, for example, synthetic or biological molecules, such as oligonucleotides. In some embodiments, the inhibitors include small molecules having low molecular weight (e.g., less than 1000 Da).

[0123] In certain aspects, the term “inhibit”, “inhibition”, or “inhibiting” may also refer to reduction or suppression of a given condition, symptom, or disorder, or disease, ora significant decrease in the baseline activity of a biological activity or process.

[0124] The term “reducing” or “reduce,” as used herein, refers to decrease in number, level, volume, severity, fraction, amount, degree, frequency, or size, which can be measurable inDocket No. PAT059983-PCT-SEC01 comparison to a control group (e.g., prior to or without treatment), for example, by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or greater.

[0125] The term “histone deacetylase 6,” or “HDAC6” refers to an enzyme that regulates many cellular processes, including cell migration, DNA damage repair, and protein degradation and can be identified with, for example, UniProt ID: Q9UBN7 (human) or Q9Z2V5 (mouse). It has been reported that HDAC6 is related to acetylation of alpha-tubulin. For example, in vivo the overexpression of HDAC6 induces a global deacetylation of alpha-tubulin whereas a decrease in HDAC6 increased alpha-tubulin acetylation.

[0126] As used herein, the term “treat”, “treating", or "treatment" of any disease or disorder refers to alleviating or ameliorating the disease or disorder (i.e., slowing or arresting the development of the disease or at least one of the clinical symptoms thereof); or alleviating or ameliorating at least one physical parameter or biomarker associated with the disease or disorder, including those which may not be discernible to the patient. In yet another embodiment, “treat”, "treating" or "treatment" refers to modulating the disease, disorder, or condition, either physically, (e.g., stabilization of at least one discernible or non-discernible symptom), physiologically (e.g., stabilization of a physical parameter) or both. In some embodiments, “treat”, "treating" or "treatment" refers to preventing or delaying the onset or development or progression of the disease, disorder, or condition or of at least one symptoms or pathological features associated thereof. In some embodiments, “treat”, "treating" or "treatment" refers to preventing or delaying progression of the disease, disorder, or condition to a more advanced stage or a more serious condition. The benefit to a patient to be treated is either statistically significant or at least perceptible to the patient or to the physician.

[0127] As used herein, the term “prevent”, “preventing", or “prevention” of any disease or disorder refers to proactive measures and interventions of the disease or disorder for reducing the incidence or delaying the onset or progression of the disease or disorder, or symptom thereof.

[0128] Unless otherwise indicated herein, the term “treatment” of a disease or disorder does not include or encompass the meaning of “prevention” of a disease or disorder.

[0129] As used herein, the term “pharmaceutically acceptable” means that the substance or composition must be compatible chemically and / or toxicologically, with the other ingredients comprising a formulation, and / or the mammal being treated therewith. For example, when it is “pharmaceutically acceptable”, it is physiologically acceptable and does not conventionally cause gastrointestinal disturbance, an allergic response such as dizziness or other responses similar thereto, when being administered to a subject (e.g., human patient).

[0130] As used herein, the term “administer”, “administering”, or “administration” means to either directly administering a disclosed compound or pharmaceutically acceptable salt of the disclosed compound or a composition to a subject, or administering a prodrug derivative orDocket No. PAT059983-PCT-SEC01 analog of the compound or pharmaceutically acceptable salt of the compound, formulation, or combination comprising a compound or formulation to the subject, which can form an equivalent amount of active compound within the subject’s body.

[0131] A “therapeutic agent” as used herein refers to a therapy, e.g., a molecule, including but not limited to, a chemical compound, peptide, antibody, antibody fragment, antibody conjugate, or nucleic acid; a gene or cell therapy; or a radiation therapy, which is therapeutically active or enhances the therapeutic activity when administered to a patient in combination with a compound of the present disclosure or which reduces one or more side effects of the compound of the present disclosure when administered to a patient in combination with a compound of the present disclosure.

[0132] The term “preparation” is intended to include the formulation of the active compound (e.g., compounds of Formula(l) or pharmaceutically acceptable salts thereof) with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

[0133] The term “CHA2DS2-VASc score” as used herein to a score system with 1 point for congestive heart failure, hypertension, age 65-74 years, diabetes, vascular disease, female sex; 2 points for age 75 years or older, prior stroke or transient ischemic attack.

[0134] The term “BMI” as used herein is a value calculated as body weight (kg) divided by height (m) squared.

[0135] The term “guideline-directed stroke prevention treatment” as used herein refers to a multiple approach treatment (e.g., medical and / or lifestyle approach) for purpose of prevention of stroke, as proposed or guided by healthcare experts, physicians or clinicians, for example, as provided in “A Guideline From the American Heart Association / American Stroke Association” published in 2024.

[0136] The term “NT-proBNP level” as used herein refers to a measurement of N-terminal pro b-type natriuretic peptide (NT-proBNP) obtained from a biological sample (e.g., blood). In some embodiments, the level of NP-proBNP may indicate absence or presence of a protein brain natriuretic peptide (BNP) that may be released from heart cells and be used for detecting possible heart failure.Pharmaceutical Compositions

[0137] The present disclosure provides a pharmaceutical composition for preventing or treating atrial fibrillation (AF). In one aspect, the pharmaceutical composition may include an HDAC6 inhibitor.

[0138] In certain aspects, the HDAC6 inhibitor as described herein is a selective inhibitor,Docket No. PAT059983-PCT-SEC01 for example, having inhibition activities from at least about 10- to a few thousand-fold higher against HDAC6 than against other HDAC family (e.g., pan-HDAC or HDAC1). In certain aspects, the HDAC6 inhibitor as described herein also can increase the acetylation of tubulin (e.g., cc-tubu lin), which is a major substrate of HDAC6, for example, by about 1.1 , 1.5, 2.0, 2.5, 3.0, 3.5, 34.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.O., 8.5, 9.0, 9.5, 10.0 or higher in a cell or in a subject (e.g., as measured from a biological sample such as plasma or serum).

[0139] In certain aspects, the HDAC6 inhibitor is a compound of Formula (I),'0 (I),or a pharmaceutically acceptable salt thereof,wherein:Li, L2or L3are each independently a bond or -(Ci-C2alkylene)-;Ri is -CX2H or -CX3;-OH, -O(Ci-C4alkyl), -NRDRE, -(Ci-C4alkyl), -CF3, -CF2H, -CN, -aryl, -heteroaryl, -(Ci- C4alkyl)-aryl or -(Ci-C4alkyl)-heteroaryl, wherein at least one H of the -aryl, - heteroaryl, -(Ci-C4alkyl)-aryl or -(Ci-C4alkyl)-heteroaryl may be substituted with -X, - OH, -CF3or -CF2H;R3is -H, -(Ci-C4alkyl), -(Ci-C4alkyl)-O-(Ci-C4alkyl), -(Ci-C4alkyl)-C(=O)-O-(Ci-C4alkyl), -(C3-C7cycloalkyl), -(C2-C6cycloheteroalkyl), -aryl, -heteroaryl, -adamantyl,at least one H of -(Ci-C4alkyl) may be substituted with -X or -OH,at least one H of -aryl or -heteroaryl each independently may be substituted with -X, - OH, -O(Ci-C4alkyl), -OCF3, -O-aryl, -NRDRE, -(Ci-C4alkyl), -CF3, -CF2H, -C(=O)- (Ci-C4alkyl), -C(=O)-O(Ci-C4alkyl), -C(=O)-NRDRE, -S(=O)2-(C C4alkyl), aryl,Docket No. PAT059983-PCT-SEC01, wherein atleast one H of < may be substituted with -X, -(Ci-C4alkyl), - NRDRE, -CF3or-CF2H, andat least one H of -(C3-C7cycloalkyl), -(C2-C6cycloheteroalkyl), adamantyl,may be each independently substituted with - X, -OH or -(Ci-C4alkyl);Yi, Y2and Y4are each independently -CH2-, -NRF-, -O-, -C(=O)- or -S(=O)2-;Y3is -CH- or -N-;Zi to Z4are each independently N or CRZ, wherein at least three of Zi to Z4may not be simultaneously N, and Rzis -H, -X or -O(Ci-C4alkyl);Z5and Z6are each independently -CH2- or-O-;Z7and Z8are each independently =CH- or =N-;Zg is -NRG- or-S-;RAand RBare each independently -H, -(Ci-C4alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)- NRDRE, -aryl, -(Ci-C4alkyl)-aryl, -heteroaryl, -(Ci-C4aryl)-heteroaryl, -(C3-C7 / A <^4 / G HjeQ-l - cycloalkyl), -(C2-C6heterocycloalkyl) or '15, wherein:at least one H of the -(Ci-C4alkyl), -(Ci-C4alkyl)-OH or -(Ci-C4alkyl)-NRDREmay be substituted with -X,at least one H of the -aryl, -(Ci-C4alkyl)-aryl, -heteroaryl, -(Ci-C4alkyl)-heteroaryl, - (C3-C7cycloalkyl) or-(C2-C6heterocycloalkyl) may be substituted with -X, -OH, - O(Ci-C4alkyl), -(C C4alkyl), -CF3, -CF2H or-CN, andat least oneH of ? may be substituted with n-X, -OH, -O(Cr C4alkyl), -(Ci-C4alkyl), -CF3, -CF2H, -CN, -(C2-C6heterocycloalkyl), -aryl, -(Ci-C4alkyl)-aryl, -heteroaryl or -heteroaryl-(Ci-C4alkyl);Docket No. PAT059983-PCT-SEC01 Rcis -(C1-C4 alkyl), -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or -(Ci-C4alkyl)-heteroaryl, wherein at least one H of -(C1-C4 alkyl) may be substituted with -X or -OH, at least one H of -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or -(Ci-C4alkyl)-heteroaryl may be substituted with -X, -OH, -CF3or -CF2H;RDand REare each independently -H, -(C1-C4 alkyl), -aryl or -(Ci-C4alkyl)-aryl, wherein, at least one H of -(Ci-C4alkyl) may be substituted with -X or -OH, at least one H of - aryl or -(C1-C4 alkyl)-aryl may be substituted with -X, -OH, -CF3or -CF2H;RFis -H, -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(C1-C4 alkyl)-O-(Ci-C4alkyl), -C(=O)-(Ci-C4alkyl), -C(=O)-O-(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O-(Ci-C4alkyl), -(C1-C4 alkyl)- NRDRE, -S(=O)2-(Ci-C4alkyl), -aryl, -(Ci-C4alkyl)-aryl, -(C2-C4alkenyl)-aryl, - heteroaryl, -(C1-C4 alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -(C2-C6 heterocycloalkyl) or -(C1-C4 alkyl)-C(=O)-(C2-C6heterocycloalkyl), wherein:at least one H of -(Ci-C6alkyl), -(C1-C4 alkyl)-OH, -(Ci-C4alkyl)-O-(Ci-C4 alkyl), - C(=O)-(Ci-C4alkyl), -C(=O)-O-(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O-(Ci-C4alkyl), -(Ci-C4alkyl)-NRDREor -S(=O)2-(Ci-C4alkyl) may be substituted with - X, andat least one H of -aryl, -(Ci-C4alkyl)-aryl, -(C2-C4alkenyl)-aryl, -heteroaryl, -(C C4alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -C2-C6heterocycloalkyl or-(Cr C4alkyl)-C(=0)-(C2-C6heterocycloalkyl) may be substituted with -X, -OH, -CF3or -CF2H;RGis -H or -(C1-C4 alkyl);Q is -O- or a bond;> is a single bond or double bond, provided that, > is a double bond, Y1 is =CH-;a to e are each independently an integer of 0, 1 , 2, 3 or 4, provided that, a and b may not be simultaneously 0, and c and d may not be simultaneously 0; andX is each independently F, Cl, Br or I.

[0140] In some embodiments, in the compound of Formula (I),Li, L2or L3are each independently a bond or -(Ci-C2alkylene)-;R1 is -CX2H or -CX3;Docket No. PAT059983-PCT-SEC01OH, -NRDRE, -(C1-C4 alkyl);Rs is -(C1-C4 alkyl), -(C3-C7 cycloalkyl), -aryl, -heteroaryl, -adamantyl,, wherein:at least one H of -aryl or -heteroaryl may be each independently substituted with -X, -O(Ci-C4alkyl), -OCF3, -O-aryl, -NRDRE, -(C1-C4 alkyl), -CF3, -S(=O)2-(Ci-'J b3 , wherein at least one H of may be substituted with -NRDREor -(C1-C4 alkyl); and / Zg r ' p / / Zr ’-^ r^pzX iiat least oneH of \ ^6 X J or A B maybe each independently substituted with -(C1-C4 alkyl);Y1, Y2and Y4are each independently -CH2-, -NRF-, -O-, -C(=O)- or -S(=O)2-;Y3is -CH- or -N-;Z1 to Z4is each independently N or CRZ, wherein at least three of Z1 to Z4may not be simultaneously N, and Rzis -H, -X or -O(Ci-C4alkyl);Z5and Z6are each independently -CH2- or-O-;Z7and Z8are each independently =CH- or =N-;Zg is -NRG- or-S-;Docket No. PAT059983-PCT-SEC01 RAand RBare each independently -H, -(C1-C4 alkyl), -(Ci-C4alkyl)-OH, -(C1-C4 alkyl)- aNRDRE, -aryl, -(C1-C4 alkyl)-aryl, -(C3-C7cycloalkyl)or < , whereinat least oneH of ? may be substituted with -X, -(C1-C4 alkyl), -CF3, -(C2-C6heterocycloalkyl), -(C1-C4 alkyl)-aryl, -heteroaryl or heteroaryl-(Ci-C4alkyl); Rcis -(C1-C4 alkyl) or -aryl;RDand REare each independently -H, -(C1-C4 alkyl) or -(Ci-C4alkyl)-aryl;RFis -H, -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(C1-C4 alkyl)-O-(Ci-C4alkyl), -C(=O)-(Ci- C4alkyl), -C(=O)-O(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O(Ci-C4alkyl), -(Ci-C4alkyl)- NRDRE, -S(=O)2-(Ci-C4alkyl), -aryl, -(Ci-C4alkyl)-aryl, -(C2-C4alkenyl)-aryl, - heteroaryl, -(C1-C4 alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -(C2-C6heterocycloalkyl) or -(C1-C4 alkyl)-C(=O)-(C2-C6heterocycloalkyl), wherein at least one H of -(Ci-C4alkyl) or-C(=0)-0(Ci-C4alkyl) may be substituted with -X, and at least one H of -aryl may be substituted with -X};RGis -(C1-C4 alkyl);Q is -O- or a bond;> is a single bond or a double bond, provided that > is a double bond, Y1 is - CH-;a to e are each independently an integer of 0, 1 , 2, 3 or 4, provided that a and b may not be simultaneously 0, and c and d may not be simultaneously 0; andX is each independently F, Cl, Br or I.

[0141] In some embodiments, the compound of Formula (I) may have the structure of Formula (la)(la), oran optical isomer or a pharmaceutically acceptable salt thereof,wherein:Docket No. PAT059983-PCT-SEC01zl / xbYJXN— i- % / R2is ;Rais -aryl, wherein, at least one H of -aryl may be each independently substituted with - X;Yi is -O- or -S(=O)2-;Zi is N or CRZ, wherein, Rzis -X;a and b are each independently an integer of 0, 1 , 2, 3 or 4, wherein, a and b may not be simultaneously 0; andX is each independently F, Cl, Br or I.

[0142] In some embodiments, in the compound of Formula (la):y« p—R2is \ ' ' / * ;R3is -phenyl, wherein at least one H of -phenyl each independently is substituted with -F or -Cl;Yi is -O- or -S(=O)2-; andZi is N or CF.

[0143] In some embodiments, the HDAC6 inhibitor compound may be a compound of Formula (I) selected from the compounds in Table A below, or a pharmaceutically acceptable salt thereof.Docket No. PAT059983-PCT-SEC01 Table ADocket No. PAT059983-PCT-SEC01Docket No. PAT059983-PCT-SEC01IL1 X u Ci oo 18 i .K <I r ^.r 'o 0 YC o o r i ; ■ ; \s / 2 - r C?r ? o-\ a, \.. A3A / 1 / iM N~NZ. .N ,...„> !W / \ \ x1 V2 \£ / c \ _ _ O\ \ / 2 W ' i \ x N-H1 i'" _ JI >-CF Q A A3y6 ' i) o / / x( oQ A'NQJ n ° / zo Q <5:.. — —* r < ) < cz-'V’ X..^W'— - \;::::: / ' O 0 "^DN-N oo ' bJ 3 ■'. O^JCCy6 5 O o i O TI Ow - ’TJ 1 Cl i CM 1 Ifi A 1 J o 1 / T-a V VCP, ti. I AAN"N ui 1.o?xz1 Cl W / 1 « 1 i 11 / ^,A- CC\ .,o / \ / 1 HN' A ^°X__CF3r *wFT >-CF3B>xA ^"N | A ’M Boe,p <zAO- -x - , JF‘aA 1 (21 AN\J cci < 'N' "O N i ° '^ / yO M1 OL -x32 | ( 1 "J| ^xY°-y_.cF3IHAAN~NDocket No. PAT059983-PCT-SEC01Docket No. PAT059983-PCT-SEC01Docket No. PAT059983-PCT-SEC01 uT Ci AY u Q 0 0 "ft 00° 66O OH II =. n.W S— _v_ _ ,. > N-NoYv / x / 7x(>> zQ p7 V V % 4 p zZS 7 ■—, Z \X IZ\-- V Lr )' o o ) / _ 68 p \ z / =\5 < } X / p V y _ Y f\A \zH - P Y zoo / k.„. / \ZTXXX-Lo° z o° ZZXY 70b xr Y n nFn"n ,>"n 73 G?wXA r T rr oXX- •'< o ■■.. ,rsZ‘ 72| | i! if- opo-A N~N' kY o "ps X TJz OcV A ° y Oil / / -.<2_Y< o- o O°5v ? a074 / S HG 0JDs*x A_---’XV'-- x! 5 N < 0] D Lit L L si / V / . ”’^3 u 6' >Q' 0O ( > CJP3C-, 0 * j6 O .. ...F3C' N Y Y r; 176 727= 1A LA O d r i! p r < N Q A 1?"oZs. n\ _ 7 n T? f0YY 1 I ! / ?— O ^ TSF'NGJO-A N-ZM-N 71-3'fA —78F!CI X O .0r f ° “ "f >-C F= op N-N Ll A80 X 'XXl o[ V ° V / >™CF3o~s^ N-No82Docket No. PAT059983-PCT-SEC01Fx,<x _F m X 1 o Q i LU 9 (x? uu X _ o t' '’ 84 1 ~ ’l l Vz:I Oz’ l ]\ ° X >-CF3C o-s.^ N-N' If° 51Jf h C--^ Q^J l o?5 < N-J$7 / X / - O O"Of . fb 4- 7 X Cl o C5 Xb Z u.“r “ ° -' d b XO^> J'yN-lL 0 - t { y) > , V - — z - x\ COUCl ~ b 03 o 0>5 i ^xxx X X IXa88i r> °r “0~ x 1 / K> «--N HNCM1 1 °X ?Cl ...0( / ■■■ p-xx„x ic .o / (Z / Ao \ ' 1,CF’ Ci2 -'■■•”><- d"bQ n bx 1 4 ?) 1 T O \ ' ;® 1 / '">Y° ^> MX I5-VN -^1 ) 'i1 a C’l Ti ( OC~1 FCc, x / " yl >TO>--.C^H1-J “■« / CTrA> C^-oV ^~NN„ bx ^x.i ix _or f '°N-CDocket No. PAT059983-PCT-SEC01Docket No. PAT059983-PCT-SEC01Docket No. PAT059983-PCT-SEC01X iL LL‘ u O 1 ‘ A„0 i- O Wp5vx~' Z >=:='■ —- / \Z / Z~ \ s Z / “Z6 }00F0,.... ., ,.< Br-' A nX ^A134 ; zis—1' > < | o-~ I ■ / / \ Ax. 1 r ° 3 >-CF;iH | P i N-N 1 1 f- Sr. A n~n | Q | 'N ~ V 1 p U Ik' X^X. , . _<A. 0 it? ai? 136Q UC 1; A- CRH 6N -Nzzi .AXA M-N 1 _ cA2\ _ ; yz=n 0 0 p a / 9 X \ ;P( .zx.. / / r \pz'z,^ / ........x) z z - ' —— '4 ° / 0 O'”7” 00,,... / \ x= / O V'XI I \ ii wa-■■ ' 0sAx t A x.r ? x >~CF2HZNAN"Nn Z^z°x X n 1x.’« r°' x x wr r '!0Pi A -,,P?i'N | _^<Zx.^.- ''x.N / xs1 . JO144O'' i.-P:A O i pxNXQ -x- Pf 1 [ ° -X.^-^CF2Hi O=S^.,J N~N?1 O — S > N - d 6'146i ,,--x A LA 0 1 i 14 0U P--CF; 1 i 0=8 X AN-N I d |Docket No. PAT059983-PCT-SEC01Docket No. PAT059983-PCT-SEC01m u crA / \ x 1 i Cl - A . 1o"1 S3 1 164\ ,v i o4, — \A O 0 I Z"f N V 1' y- CFjHi< > o.s ?■;N| HN-J r T ° u. / - k I \ I <% F fl L / 1 11 A“ / 7 \ \ 2- _ / — — Lz\ A L o 166r j ° - j < > ) <z.0>-0^ 1 / A y=x 707 xcixX7\XN"N IMJ I r c o AOP i' ry N'NLi w b.^°v Q . 1167 i rj ~n ! IO G 1 1 X „w r- •---''XrA '° ~ kr- n T Lk ik*Sl 1 QXN ^XXj_ A A":69 Xy > - > | ITO \T;H[ f Iz A N-N I 3£-- / ““v\ / -- : \■ ( -' N-N>—y. ;s „« JY*^ _ / \ 1 2S ““Oz'o 0 / J ( \ fi L!""Cl > 77 <o oz\ \ / C 2S‘=^— x r r 71?A>z"” “ z \171 (T \_ a <i_ \7 / ^Vtl o 1 172 7r. ,1 IZ\ 0 X 0vAo-~xraxY u > C^H s -H- '-o / 'Y°y-er, 0=S J N-N :\ ° o 0-?^> H -NQ 7 / / / O 2AY73 bJX 1LA I i^75k ■ A N 0 IA T| ..<> X-CF,H iI0=8. J N-p / i0 I177aO , . AX. I 1 1 O r 7 ° - YVC F3 O=S^A N-N6Docket No. PAT059983-PCT-SEC01uT I tl - X' I I . 1 1 I 1 I ? A180 1 N [. •-*! Az- c i r ioi .. 1. 11 -I. J zee / <"> f X ° Y A" I 1 ?f >Uk 1— J V ? > a O ^S.^ A N-N i O-S. .1 7 — N-j / o 1 ° \NC-> < S - Z r / — -- kA / \ / / 1 / V < )O-- N . >r I Y r\ °^,,'Cn YC .0«0“ T> \-CF,H I IO-S \ / A A6 c -'KCl . I J fo cXAa~~‘ icF’ d?" AUF,c. ri .. i Lc f J• 0 '> N :< i 1 - O - M Y ^*1X Al O 186i i \ ,1, 'L or Y ° ! t *' ° "' Q \J „ .. Y .> <•- ■ A> -«=;.H ~S^ > N -wI O S J N -N'O / 1 0 o0r._ ^Ss. / \ Y F. . / zxI .1 \\ / \ / / AA 2 ... X °i er 1 '- I' NA .. Y I.cr 'N jl | --i2\nn>..., \188I x $ L / Ai [ N ° '' ... ,oC\“ AL^° Y°>-ch 1 I—CFzH O 1 i = S. > NJ i O =S. J N -N- / I1,1ovK.V zs. Oo 1 Fh> LA -s A X ,.. 1190A A Ac / \„zC. Yl.... / -1i N ° 1 \^CF,H I ' r N0' Y C- CFzHI »:N- >. / °AN"NA1Q .. Io' ’ Y \=:=-!192I O T O o.. X ll A oA0' I XC^Hi r A° i ■CF-H_r ! . >N-N 1 ^N xX Cj. Il . 1 1 . ... Al .. X194I L L J 1 x I A o ( I I. I ll 0 i N f 'w 0 '-' V c=,H N f N 'O \_CF,Hi / i | ;; / / *-■I xN'XN~N1 Cl ..i i i ;136I C TO oI i!AtJ~ I 1- CF?H I ,.rA N..N'Docket No. PAT059983-PCT-SEC01Docket No. PAT059983-PCT-SEC01 X Xlu* 1yOI - 0 ° '■ 0 A,- ^N"c^ 1 A w 1 / / “\ / I Z-x / =, / y| v„ y S QQ I Q V Iz- I > ° M°CX X zx— vx 1 215 | Ao 0^Sr° \C FoHI 2 :6 xx A y - — - / 0 N0A Si » )>— CF-H i I M \i / i / • M / V \ A M - r / “ I A 0 2 4 i \ & 1 I ,X00^iy- iF' v - : F i 0 ii A A A i i X C£ <>J "A " ■ IM ! ! f- !217 iANAftXA / ’K i . - ii / N 0 Y X-C^H i2181 1 -s A N A LL? i I I1 — -N U ; ix ii; \ i £ id1 Q „ 4 ^- r 11 L - rtTj ““A X z !--xI x 1 1 - I M 'C 6V I -o " £> !<> / 0 A> A | '; / 2: -’ H I . 1 ANA f"N '0 - >-C P <;.H 1 o00- ^ / Y A\x6HNA I o ;J ° 1i A A Fx x^ J A 4 zH^i J 17 v\ / l A .x--. „N,i CK ^ N Y : I X _X 1221 I u V Ai ... 0 Z 1 V . o i 222A l X o i i r y '° ~ A 0'M r ° "■•'■ if xcf.H i H : iOAAN- N i vYXA V I r? | (X! o a ■ Ti j fx 1 T3 N* 1i F._ Xi-X i 1 X X. .-- X : X I XX X I X _ ,x 1 223 IU“ H 1 2241 x-''x„. xX-„. AAx xO ! A X A . J : f N V YCF3 i r N o - Yi \Y xAN-N i 6 A M A 1Docket No. PAT059983-PCT-SEC011 X S 1 l 1 lJ!I‘.‘ “ A,i. tuCo UI ■229 230H f !z A 1 A1 / ;A "C) ) : z>A I nX ■ :V 17ap A \ O i / :Ci4 I X z- -' 'X> 23 : 3F.o' 'X.N- 1 2 2 .».r$ r <> A 1r\ ? Ax I A O| Q d |‘ "° K X-CF,H ) ZL \ 1 i O^A N -XAA '’ C '? / iSN- / V%233 234X« A Ado.rf 0t ACF2H o=s ^ N-N- 1^i kL3! <■• X 3 X oi£U u U ■A'"^^ AA A ,zA A2 ? o A3S "°'CAxyz A ! O 17z~- 236 ^uy^. 1H^ ^ N (—A A HW ^A ^A W-A2 z / 4~ »~N / 1 o.A X(~~G <^A o z / / —vp / x o X““ I" LANN— x Y| . A■S / 238 NO Q / A\ / s"~d h. , A'ZC FJH dZ A —— ' ' ' '>< M 0-s A N -N y r U. / LU ~ ' =‘ Qz,XvJA •»■ ^-x. As A. xx^c K M d r N N A x239 240XMMAnUCo ^Y°H°FI r " ° L >-c^H=,?^N-NH0=8, A N-N'6 ON ;L Ak A ,N.241 242r N < ° L "A ¥ O X- CF^HO^S. A ^-NdOL243 244 A Ax ,., .«.A„ O _of N ° Yi \-CF.H X r AuA v .« A^H <xA N~NZ«=SxA N -N0oA x245 246.^.N d^A^Ac" N-NZ / Docket No. PAT059983-PCT-SEC01CiA ,F UL y F o AX A248Ay x. A XX.Q o’ i J Y°>-CF-. f N 0 - Y >-CF2H \ y (( / yn- y— r . M-N— N \ «. / - / sX " ^ \Ci ( ) OA. ¥\'~ ..... y _kJ ... L p- > 7 / ( 258 y y z —■' '\ z=) k X AAO^Xy-CF, / S3bX yj a-N 1n ~n X WX 252 X zN C u. &U u7 u Ut A i / / ~ n / : X Y X A \z= k 7 Fxx5s. ^.C! \ i< z— -x= A'A'C!F M2AZ\ \ I / / / i c r~\”<> ' JA" (I ., 1 y u. — / / \ i \Zy2__ V w / N' Y \ b ;. —o - \ W=y ““ / 254 A kA. oA X 2A )r / ■•'rXo XX-A.Hi ( ° p < ° Y Y-CFaH d ) A NA^ Z~ N-N I— N"’ — NX i 'f 0'” A” QQ - o\J "~ 0 OJr~.„. x~.x\ \ JI l , A bT ~N' Y256 n n Ao•AT1(i -fl 501 ’i ° I 1 w i X;A M-No'F. xx.1 1 ... 1 Br' N V -y 258 A IL A o r N C« y \„.CRH \X0A NA “260F1 -FH VF262rSAA° 'A-O3\xN^N-hiDocket No. PAT059983-PCT-SEC01F'X1Cl--'FX364i / N O x^X-o K.„CF,H 2 „ ’x r> i vJNYW ' ‘Tj - ■F’\ X \Y\t5 O2x x \...... F -.4 )r ) O 1 ■ cr Ix--'-I N A A X / 266^„AnX -A ^.oV / -n : ( ? ° Il X--CF2H C / "- yzj_ i A NYx f?\-~ F Foo z z,v,. i FG X>-GX r 0>C'RXIN- - A .1 “n ■n 1M i cr X I ’N’ AY GJ if AX2b8 ; Y'fX° Xf°A-CF-, V N-N X<Ai'UN F Fi, X 1IL’ HQ'"’O i OX I 1i 2:— - znn XN-- cj 1' r\',J!0| C ( C22’ / 7 \ v i -g _C _ A> IVU--~ i X v A- oA fZ'■ O0> "' A7 i A '-AN~N / A F2 1'< zK.= i z~- H7 / 7" N-. A Jy ? i o / ) \ A >. i■ / i \ □: (X 1! It, ™ '^Lp sVS 1 °- x i. i xof A '° X J-CF.H n O N - MXXj-N(tf X I ’fTX tr i i x „2Ki ' Cr rr? C °A' - f - ° ' Y >-<5H xcF)HN~N i OA N-Noi xAck xA 7 02'"6Ax '*° ';;^AOAC F2HJ! — N Xrx J 1 XX AlX ^ A o - r X XX orAXN° Y >--CF.>H i r-N o Y ACFPHdC7^- | a J "NCDocket No. PAT059983-PCT-SEC01X X uf iA <i o u U G !' r N A '. - o 280o Y V-CF?H z: A' / "C.P A >s::A%- oR. \ (= / l<\ _ / \PA u.- MA -i p w - I lJ VC y CO.cr N' If H t u 1pA LA O 282 I X3 <° O. o( N 0 ) 0 Yr i-CF,H r / oCl 47 z \ X o'z° ' Y >- cCEX / \H°”,s-A r A o=,?- dz- 6 \ ) ) \ / A >N-Ni \j"1y- OII x / II II IJ -A w-i r■ 'O u oAVnCI ~ 1X 2841 10cvf N Y \-CF?H■3=5 J0A. i1 X Cl o 286 1 \ «<j j ° T,rF>" > 41 < ;y vz......0\ O<CCA M A&x, C C\_,.O 288[ N0~ V K-CF^HO=fA N~r / 0A ’T! A1 X. A - 290r y ° T C-C^H rri ° if 1-CF,H O=S^> N~fjG AAN-Yo292L !1 . CA,XI 294 A2 1 O. o O 3 7N° ;i' ;>--CF2H PA 'O AP\--< F1H o=sA NHo=X J r^M d6' ^Docket No. PAT059983-PCT-SEC01X X X X Xu. L£ A lUif U u U o!44U A YA o if N ' 'O Y \_CF,H I296q o°=?A N-N I j \ C4-'*° ICis i A zA / r^A ■ o ■ A O2 8M4 / Zl 52 y A ( °L - . ......C F;HI |9Y-. ■-1O=Ss A J- W-N ™' i . J sr- Q i yoQ V„ — o rj O> X- A <>>rAi< ''0 A c —FQ G LUou.V^ F i XA T -»S I A .- 1 ,1 "i 1 300\<As / > 1 ox-xA rs. i kn 0 i1r *jf 0Y Ac p5 i o £}r ■T r x'0"" T AC f;2H^.. / A' 1 <>A 1 u. UL COot UJ Q■ A ci. ...o rX Os A i / Y —> -Xn AL 1 A 1 \ x~-s .A YAXAA ' VY* r ° Y >-CF2H I A ( o D - — ' ' r A A>' A 1 °AAo -N~N | ulA Arxs A Xo U -z'- 0w.:\ “°x>N~N |CI s^-^, M . AA V - N S ,.S i ;I ft 1 i 308Z^MA, ASAX-O i[0Y AC F3IN-N Ick in s U. A ,! H 1 i 310 =Anx i ,A> ^0 !f o y-cR, i pA ^XryC F!„ | 0-s.A AzI Os / A |Docket No. PAT059983-PCT-SEC01U. li, n 0* s u u 1 <1. N 1 314 ? cdf0ddx T-A• 1 11131 -CF2H 1A r ,W z51 \ / ._\ x dx / - j < 0 <1 1 .. I ^315 ^ z- X X 11 .0\N 0' v CF>HdJ V / _ 1 QJ {... (>>O N Nx / / 0 ) u \ JF xxF0 X 107* , 318X 1. 1 1 or " '» f >-M©Y N-N SH' pyx° ^SrVcFs IL 11? O^> N-X0 1 it iL?I 0 P 1 u ''X A 1^ 1 Y q 0 0":x,H Y 2 I=~ 0 320 T1< < / O”~\ / =V 7 1 4 -11^ !' \ / X / .p d \— / '1:: / X \ \\ '< p .0 0 p<Q z1- * r )\rH H > 0M1 x / \\ 7 \ r \ / . fi f \ 7 1t"~ 322z\_\= Vz x) r 1»v?) 1 ;ub 2 pCK x<xl°v11 - H p ^ll324 d n s''"--- fj Pspi . X <1^. _es T5rK cTt >-CF3rN'° ' ■ x >-CF3X^l N~N'ri i 0 - -X326 F N Y 3rt FTI.1"T '° xr°>-cf:3 r yv°1'xv'd--cF3 X / NlN"N X^-N ^l N-N?fx xx1 1 Ftik 1328r •''■■■'- ! N -i w- d ~ -^1 X "°H / • / F-' x„^x^N-N330Docket No. PAT059983-PCT-SEC01Docket No. PAT059983-PCT-SEC01Xb q / ;x XS2’Z— 7 / l” \ / / \ / ''XI Q 2£ i p: <Ptk o—z. A—X-.. 352,. / Ll . 17 Oi X«o\^J... \-~ k kr 7 p ° Y >-cf7H ''Xfl-CFkl\-z- i \ 0 \,X NY \ / X N~M' \ 6' z— / lk... / \~ x )> V / --, i A J [I .1 .xA kn _ f354 i A J A n' S0 / I I" N0A --CF-.H XAXk> ^^XP-''5^ i o=AA ^AT | ►: 6 VXN-N / 3 'cok rriii . i w . rrc_ i ! / N X Y O a1-i o co i 356 j k. 1 ck o < ; i n » TfN 15Y[ \--CRH i 1N / x-rF-sfe : M" i °xxHP ,:j ; 6 / \ I < o / z: —xX Z i—\sLU 1 / - < >(J\\X o \ 9 ^ OW— ^ .- / r<■ &~— ’ S \ 7 ( > 7 yOWt___y ,„ A« •'A'A F ( O / kXJ UYX \% ' x \ / / , AsA ■>£ -' / X'11X •?0A1 -CI5H ’ / } 0 = $.X N-N / Ax r dy ■1 X1 Q .H. 131■i s: _3621 1 1 Xoi f X° !’ >-c^H;r_XkkN' ML N X^F / k \ F i r-XX p;1 / k / 1 i F?AANAA)364 i .... L X X oi (N 0"■^ V k-CF2H XpX ^XP-CF^ o=s.X X' o.^J N-N- 0HI IFskis i366 i!‘ A 1. X oFl 7 1 1 .1 .0r A0 / y-cF?H i ., f X" ' ° IXCF^ c>X N-N : ''A'-"’' ^-Ni d1 / / '’Vi p USS 1 N < 'R ■ -N v- N ,, k t Ar368 i A. X A. oi r -«• ° A A CFJH r xx° Y > CF;H°A'-A N-fj : O-S^AiDocket No. PAT059983-PCT-SEC01 ITTI . i X o rdo i IAM C X ? U. I 9 Z I I I o 370 uA M 0 r0=8 [... *? "° " l Ni ” '> x-j AjCF?H0=8.X A o N-(iV-CFA | 6 o Az__A i H i’\ N / X'Ar'X / y / V_ M1 o, - .■ A F 1 372 ^ 0 / 0 !7 C~ N0" A-CF-.H! •3-S„o N-M' ' :W"” 0 < O o5u.n3 374 O" 'YnJ*XrQ F X5 376^ l lTXXo XYTASr ° ~ v H~S>AA t-CF, CJ '° ! n / Fu.,- 7 ' \ zA-'[7 L-v. 1.A-A o A < ?o A7 Q„ 378 w o d1NVl >"CF:3 -A YA ? >”CF!Hi ° ~N" o ’ ) ° i ^ / \I> J 2 _ - AAA J LUA9 4 / > IAA'A A U I -XA o 380T0ft yx-xj-io^ , -!N-N- L d X <>• n AF'X^^NX\XA1 ^..As-rt 382 ■X-^AQ xIyOy_CF Hi rf 0YN~rf >-<AH < J o i / y ; o-J O-J i F. .<x1 1 ..3 384: i u o¥ J xr*Fcr xx ~ i N if A x5 386 A A AA ZX ,O i f ** ° ¥ y-cFjH r0ii X-CF.H irV'tj'A > N-ff ■ 1o¥ d-J iDocket No. PAT059983-PCT-SEC01C.XXX x i388 i U ii. i4XXJ2x d~ >SGJ _Z<X.pCz / ~I Yx a.x389 / x X Ux,o 3’30I A N Ci '-’ X y~CF,H 'NX 'XfYc^H I J M-f.;''I ^NJp -5<Q M-Na~J d o iI ‘U y. 1 X 0 i ° O395 i X X 0 392 'X ITX oi r x° if r N O ' X V-CF.H I n-yNX N'-N N-r.jZ6-J oji I .0 £> N A ''oXANfi %'i393 I X 11 X n 394 ,-. x LX o1 ( *? ° Xl >- CFjH f N O '- y-CF2H 1 r-.rX N-NO-J ATI "c'X X'lN'XAS395 1 r - p 1 A oi ° < 3'36YV CF2H X f XX0' v Y p-CF2H 1 N-NXXN~NUJ1 "°U .397 I I [ / x.N AO X X'xXfi 0 y..CFoH358 x ~n oX-y -VQ Y°y_ CF,H 1 ^NJ N-H' r- N-N'1 0 J dj1 Q X O. X3» \ 40 ' HN x — QX XX. -CRHI 1 ,'J!f L0IX 01 y-CFjH rX1 N-N'oJ NV_J1 aHx Y» AX«, 1 | .1 - IX A »r,.„ HN-^O ^ XV-CF.H402 > N~NDocket No. PAT059983-PCT-SEC01Docket No. PAT059983-PCT-SEC01 Q. -X CL I' X U- 1 11 o"(j X-CF-’H i 416 HN 'O C l- CF2H=\ / f,-J| / X / \:E \ / __o PF i ..CFjY) oCl I (1 AN' if iNX X Y Y C Z >-CF.H i C '° A C-CF2H W. ' | 418 / ' N-N76 ,N'T-Srr-.c? x:xLFfe K>Ci 1 Ci 1I I 1 oHff '° 'If VCF2H "X'"O ^X'VcF2H N-N 420R-' "-N",..N .xNxYo i HQ II ll oHN -0 YC>--CF2HL N J YFCi - 1x Lx o i YHf4 o"L ' O ■■CF„H ™ Xi C~CF2HCN~n / 424N, i rNiuOHDocket No. PAT059983-PCT-SEC01Docket No. PAT059983-PCT-SEC01Docket No. PAT059983-PCT-SEC01

[0144] In some embodiments, the HDAC6 inhibitor compound may be a compound of Formula (I) selected from the compounds in Table B below, or a pharmaceutically acceptable salt thereof.Docket No. PAT059983-PCT-SEC01 Table BCompound StructureO.. ... .140 Y T "115 o<5 / 0 -rto43 T T~\JJ \ \ I 1r y “ 'odlr y1239 X I 1Af >-C XF2Hii sL.^'0285LX xx .»x295 . Ass,. L X -O1 *0' h >~CL^dfl ..X, ,-^X.?' y296 •LL<\<>-$, J6'

[0145] In some embodiments, the compound of Formula (I) is Compound 40. In some embodiments, the compound of Formula (I) is Compound 43 (“Compound A”). In someDocket No. PAT059983-PCT-SEC01 embodiments the compound of Formula (I) is Compound 239. In some embodiments the compound of Formula (I) is Compound 285. In some embodiments, the compound of Formula (I) is Compound 295. In some embodiments, the compound of Formula (I) is Compound 296.

[0146] In some embodiments, the pharmaceutical composition including a compound of Table B, or pharmaceutically acceptable salts thereof as an active ingredient may prevent or treat atrial fibrillation.

[0147] In some embodiments, the compounds of Formula (I) are 1 ,3,4-oxadiazole derivative compounds. In some embodiments, the compound of Formula (I) is selected from:N-(4-(5-(difluoromethyl)-1 ,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-phenylthiomorpholine-4- carboxamide 1,1 -dioxide;N-((5-(5-(difluoromethyl)-1 ,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N- phenylthiomorpholine-4-carboxamide 1 ,1 -dioxide;N-(3-chlorophenyl)-N-((5-(5-(difluoromethyl)-1 ,3,4-oxadiazol-2-yl)pyridin-2- yl)methyl)thiomorpholine-4-carboxamide 1 ,1-dioxide;N-(4-(5-(difluoromethyl)-1 ,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(4- fluorophenyl)thiomorpholine-4-carboxamide 1 ,1-dioxide;N-((5-(5-(difluoromethyl)-1 ,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(4- fluorophenyl)thiomorpholine-4-carboxamide 1,1-dioxide; andN-((5-(5-(difluoromethyl)-1 ,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-(3- fluorophenyl)thiomorpholine-4-carboxamide 1 ,1-dioxide.

[0148] In some embodiments, the compound of Formula (I) or its subordinates (e.g., Formula (la)) may contain at least one asymmetric carbon, and thus may be present as a racemic mixture, a single enantiomer (optical isomer), a mixture of diastereomers, and a single diastereomer. Such isomer may be separated by being split according to the prior art, for example, column chromatography, HPLC or the like. Alternatively, the isomer may be stereo-specifically synthesized with a known array of optically pure starting materials and / or reagents. Particularly, said isomer may be an optical isomer (enantiomer).

[0149] The compounds represented by Formula (I) or its subordinates (e.g., compounds of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) may be prepared, but not limited thereto, by synthesis methods and processes as described in US Pat No. 10,717,716 or WO2017 / 023133, which are incorporated by reference.

[0150] In some embodiments, the compound of Formula (I) or its subordinates (e.g., Formula (la)) is prepared or present in a pharmaceutically acceptable salt form. In some embodiments, the pharmaceutically acceptable salts may include, for example, inorganic ion salts prepared from calcium, potassium, sodium, magnesium, etc.; inorganic acid salts prepared from hydrochloric acid, nitric acid, phosphoric acid, bromic acid, iodic acid, perchloric acid, sulfuric acid, hydroiodic acid, etc.; organic acid salts prepared from acetic acid, trifluoroaceticDocket No. PAT059983-PCT-SEC01 acid, citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, propionic acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanillic acid, etc.; sulfonic acid salts prepared from methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalene sulfonic acid, etc.; amino acid salts prepared from glycine, arginine, lysine, etc.; amine salts prepared from trimethylamine, triethylamine, ammonia, pyridine, picoline, etc.; and the like, but are not limited thereto. In some embodiments, salts may include hydrochloric acid, trifluoroacetic acid, citric acid, bromic acid, maleic acid, phosphoric acid, sulfuric acid, tartaric acid or a mixture thereof.

[0151] In certain aspects, the pharmaceutical composition is administered orally. In some embodiments, the pharmaceutical composition is in oral preparation. Oral preparations include tablets, pills, powder, dragees, capsules, liquids, lozenges, cachets, gels, syrups, slurries, suspensions, etc., suitable for ingestion by the patient. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water / propylene glycol solutions. For example, solid forms of Compound 43 (e.g., Crystalline form I, II or III in WO 2025 / 003974) can be prepared, but not limited thereto, by synthesis methods and processes as described in WO 2025 / 003974, entire contents of which are incorporated by reference.

[0152] In some embodiments, the pharmaceutical composition may additionally include components to provide sustained release and / or comfort. For example, the components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides and finely-divided drug carrier substrates. In some embodiments, the pharmaceutical composition described herein can also be delivered as microspheres for slow release in the body, e.g., microspheres for oral administration.

[0153] In some embodiments, the pharmaceutical composition is formulated in a tablet. In some embodiments, the pharmaceutical composition is formulated in a capsule.

[0154] In some embodiments, the compounds of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or pharmaceutically acceptable salts thereof may be provided as crystalline powder in the pharmaceutical composition, e.g., tablet or capsule.

[0155] In some embodiments, the excipients in the tablet form may include, but not limited to, lactose monohydrate, microcrystalline cellulose, hydroxypropyl cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate. In some embodiments, the oral preparation for the pharmaceutical composition as described herein may include a film coating agent. In some embodiments, the oral preparation in tablet form may include hypromellose (e.g., HPMC 2910). In some embodiments, the oral preparation in tablet form may includeDocket No. PAT059983-PCT-SEC01 titanium dioxide. In some embodiments, the oral preparation in tablet form may include polyethylene glycol (PEG, e.g., Macrogol). In some embodiments, the oral preparation in tablet form may include hypromellose, titanium dioxide and PEG. In some embodiments, the oral preparation in tablet form may include, for example, HPMC 2910 as hypromellose, titanium dioxide, and Macrogol as PEG.

[0156] In some embodiments, the pharmaceutical composition is administered once, twice, three times, or four times daily. In some embodiments, the pharmaceutical composition is administered twice daily. In some embodiments, the pharmaceutical composition is administered three times daily. In some embodiments, the pharmaceutical composition is administered four times daily.

[0157] In some embodiments, the pharmaceutical composition may include the compound of Formula (I) to be administered at a dose of about 50 mg to about 300 mg, about 50 mg to about 200 mg, about 100 mg to 300 mg, about 50 mg to about 100 mg, about 100 mg to about 200 mg, or about 200 mg to about 300 mg, or at an equivalent dose for a pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID).

[0158] In some embodiments, the pharmaceutical composition may include the compound of Formula (I) to be administered at a dose of about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, or about 300 mg, each administered twice daily (BID), or at an equivalent dose for a pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID).

[0159] In some embodiments, the pharmaceutical composition may include the compound of Formula (I) to be administered at a dose of 50 mg, or 100 mg, or at an equivalent dose for a pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID).

[0160] In some embodiments, the pharmaceutical composition including the compound of Formula (I) or the pharmaceutically acceptable salt thereof may be administered for at least 6 weeks, at least 12 weeks, at least 18 weeks, at least 24 weeks, at least 30 weeks, or at least 36 weeks. In some embodiments, the pharmaceutical composition including the compound of Formula (I) or the pharmaceutically acceptable salt thereof may be administered for at least 6 weeks. In some embodiments, the pharmaceutical composition including the compound of Formula (I) or the pharmaceutically acceptable salt thereof may be administered for at least 12 weeks. In some embodiments, the pharmaceutical composition including the compound of Formula (I) or the pharmaceutically acceptable salt thereof may be administered for at least 18 weeks. In some embodiments, the pharmaceutical composition including the compound of Formula (I) or the pharmaceutically acceptable salt thereof may be administered for at least 24 weeks. In some embodiments, the pharmaceutical composition including the compound of Formula (I) or the pharmaceutically acceptable salt thereof may be administered for at least 30 weeks. In some embodiments, the pharmaceutical composition including the compound ofDocket No. PAT059983-PCT-SEC01 Formula (I) or the pharmaceutically acceptable salt thereof may be administered for at least 36 weeks.

[0161] In some embodiments, the pharmaceutical composition including the compound of Formula (I) or the pharmaceutically acceptable salt thereof may be administered for 6 weeks, 12 weeks, 18 weeks, 24 weeks, 30 weeks, or 36 weeks. In some embodiments, the pharmaceutical composition including the compound of Formula (I) or the pharmaceutically acceptable salt thereof may be administered for 6 weeks. In some embodiments, the pharmaceutical composition including the compound of Formula (I) or the pharmaceutically acceptable salt thereof may be administered for 12 weeks. In some embodiments, the pharmaceutical composition including the compound of Formula (I) or the pharmaceutically acceptable salt thereof may be administered for 18 weeks. In some embodiments, the pharmaceutical composition including the compound of Formula (I) or the pharmaceutically acceptable salt thereof may be administered for 24 weeks. In some embodiments, the pharmaceutical composition including the compound of Formula (I) or the pharmaceutically acceptable salt thereof may be administered for 30 weeks. In some embodiments, the pharmaceutical composition including the compound of Formula (I) or the pharmaceutically acceptable salt thereof may be administered for 36 weeks.Methods of Use

[0162] In certain aspects, the present disclosure provides, inter alia, a method of treating atrial fibrillation (AF) in a patient (e.g., human patient) in need thereof comprising administering to the patient a compound inhibiting HDAC6 activity, or an HDAC6 inhibitor.

[0163] In an aspect, the disclosure provides a method of treating atrial fibrillation (AF) in a patient (e.g., human patient) in need thereof comprising administering to the patient a compound of Formula (I) or its subordinates (e.g., compounds of Table A or Table B such as Compound 40, 43, 239, 285, 295, or 296), or a pharmaceutically acceptable salt, as described herein.

[0164] In an aspect, the disclosure also provides a method of inhibiting or reducing histone deacetylase 6 (HDAC6) activity in a patient (e.g., human patient) in need thereof comprising administering to the patient a compound of Formula (I) or its subordinates (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), or a pharmaceutically acceptable salt, as described herein.

[0165] In an aspect, the disclosure also provides a method of reducing atrial fibrillation (AF) burden in a patient (e.g., human patient) in need thereof comprising administering to the patient a compound of Formula (I) or its subordinates (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), or a pharmaceutically acceptable salt, as described herein.Docket No. PAT059983-PCT-SEC01

[0166] In an aspect, the disclosure also provides a method of reducing a risk of recurrent AF episode in a patient (e.g., human patient) in need thereof comprising administering to the patient a compound of Formula (I) or its subordinates (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), or a pharmaceutically acceptable salt, as described herein.

[0167] In an aspect, the disclosure also provides a method of preventing atrial fibrillation (AF) in a patient (e.g., human patient) in need thereof comprising administering to the patient a compound of Formula (I) or its subordinates (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), or a pharmaceutically acceptable salt, as described herein.

[0168] In some embodiments, the human patient has atrial fibrillation (AF). In some embodiments, the human patient has been diagnosed with atrial fibrillation (AF). In some embodiments, the human patient has been treated for atrial fibrillation (AF).

[0169] In some embodiments, the human patient has atrial flutter. In some embodiments, the human patient has been diagnosed with atrial flutter. In some embodiments, the human patient has been treated for atrial flutter.

[0170] In some embodiments, the human patient has AF and atrial flutter. In some embodiments, the human patient has been diagnosed with AF and atrial flutter. In some embodiments, the human patient has been treated for AF and atrial flutter.

[0171] In some embodiments, AF may occur alone or in association with atrial flutter, for example, as alternating or sequential episodes. In some embodiments, atrial flutter may occur alone or in association with AF, for example, as alternating or sequential episodes.

[0172] In some embodiments, AF and atrial flutter may be treated together (e.g., simultaneously or sequentially) for certain purposes, for example, to reduce clinical risk (e.g., stroke), reduce disease burden, and / or to manage initial patient treatment plan. In some embodiments, AF and atrial flutter may be conditions that can occur in association with each other in a patient. In some embodiments, AF and atrial flutter may be conditions (e.g., medical equivalent condition in certain contexts, for example, clinical risk, disease burden, and / or initial therapeutic management of patient treatment) that can be treated together.

[0173] In certain aspects, the disclosure provides a method of treating atrial flutter in a patient (e.g., human patient) in need thereof comprising administering to the patient a compound of Formula (I) or its subordinates (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), or a pharmaceutically acceptable salt, as described herein.

[0174] In an aspect, the disclosure also provides a method of reducing atrial flutter in a patient (e.g., human patient) in need thereof comprising administering to the patient a compound of Formula (I) or its subordinates (e.g., compound of Table A or Table B, such asDocket No. PAT059983-PCT-SEC01 Compound 40, 43, 239, 285, 295, or 296), or a pharmaceutically acceptable salt, as described herein.

[0175] In an aspect, the disclosure also provides a method of preventing atrial flutter in a patient (e.g., human patient) in need thereof comprising administering to the patient a compound of Formula (I) or its subordinates (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), or a pharmaceutically acceptable salt, as described herein.

[0176] In an aspect, the disclosure also provides a method of treating atrial flutter in a patient (e.g., human patient having AF) in need thereof comprising administering to the patient a compound of Formula (I) or its subordinates (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), or a pharmaceutically acceptable salt, as described herein.

[0177] In an aspect, the disclosure also provides a method of reducing atrial flutter in a patient (e.g., human patient having AF) in need thereof comprising administering to the patient a compound of Formula (I) or its subordinates (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), or a pharmaceutically acceptable salt, as described herein.

[0178] In an aspect, the disclosure also provides a method of preventing atrial flutter in a patient (e.g., human patient having AF) in need thereof comprising administering to the patient a compound of Formula (I) or its subordinates (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), or a pharmaceutically acceptable salt, as described herein.

[0179] In an aspect, the disclosure also provides a method of treating atrial flutter in a patient (e.g., human patient diagnosed with AF) in need thereof comprising administering to the patient a compound of Formula (I) or its subordinates (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), or a pharmaceutically acceptable salt, as described herein.

[0180] In an aspect, the disclosure also provides a method of reducing atrial flutter in a patient (e.g., human patient diagnosed with AF) in need thereof comprising administering to the patient a compound of Formula (I) or its subordinates (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), or a pharmaceutically acceptable salt, as described herein.

[0181] In an aspect, the disclosure also provides a method of preventing atrial flutter in a patient (e.g., human patient diagnosed with AF) in need thereof comprising administering to the patient a compound of Formula (I) or its subordinates (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), or a pharmaceutically acceptable salt, as described herein.Docket No. PAT059983-PCT-SEC01

[0182] In an aspect, the disclosure also provides a method of treating atrial flutter in a patient (e.g., human patient being treated for AF) in need thereof comprising administering to the patient a compound of Formula (I) or its subordinates (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), ora pharmaceutically acceptable salt, as described herein.

[0183] In an aspect, the disclosure also provides a method of reducing atrial flutter in a patient (e.g., human patient being treated for AF) in need thereof comprising administering to the patient a compound of Formula (I) or its subordinates (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), ora pharmaceutically acceptable salt, as described herein.

[0184] In an aspect, the disclosure also provides a method of preventing atrial flutter in a patient (e.g., human patient being treated for AF) in need thereof comprising administering to the patient a compound of Formula (I) or its subordinates (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), ora pharmaceutically acceptable salt, as described herein.

[0185] In some embodiments, AF and atrial flutter may be detected or diagnosed, independently or in association to each other, based on clinical assessment (e.g., medical history, physical examination, and / or electrocardiographic characteristics). In some embodiments, AF and atrial flutter may be detected via various electrocardiographic characteristics, e.g., electrocardiogram (ECG), rhythm strips, wearables, intracardiac electrograms, by observing waves (e.g., absence of P waves or F waves), regularity of atrial activity (e.g., irregularity vs regularity) and / or change in isoelectric baseline.

[0186] A dose used in the methods or uses of the disclosure is based on the specific disease or condition being treated and is a therapeutically effective dose. Amounts effective for this use will depend upon the severity of the disorder being treated and the general state of the patient’s own immune system. The effective amount (e.g., therapeutically effective amount) of an HDAC6 inhibitor used in the methods or uses of the disclosure is determined by taking into account the desired dose volumes (e.g., mg) and mode(s) of administration.

[0187] In certain aspects, therapeutically effective amounts for use in humans (e.g., human patients) can also be determined from animal models. For example, a dose for humans (e.g., human patients) can be formulated to achieve a concentration that has been found to be effective in animals. The dosage in humans (e.g., human patients) can be adjusted by monitoring compounds effectiveness and adjusting the dosage upwards or downwards.

[0188] The dosage and frequency (single or multiple doses) of compounds administered can vary depending upon a variety of factors, including route of administration; size, age, sex, health, body weight, body mass index, and diet of the recipient (e.g., human patients); nature and extent of symptoms of the disease being treated; presence of other diseases or otherDocket No. PAT059983-PCT-SEC01 health-related problems; kind of concurrent treatment; and complications from any disease or treatment regimen.

[0189] Dosage amounts and intervals can be adjusted individually to provide levels of the administered HDAC6 inhibitor (e.g., compound of Formula (I), or compounds in Table A or B) that is effective forthe particular clinical indication (e.g., AF) being treated. This will provide a therapeutic regimen that is commensurate with the severity of the individual's disease state.

[0190] The effective therapeutic treatment regimen as described herein can be planned that does not cause substantial toxicity and yet is entirely effective to treat one or more clinical symptoms demonstrated by a particular patient. This planning should involve the careful choice of active compounds (e.g., HDAC6 inhibitor) by considering factors such as compound potency, relative bioavailability, patient body weight, presence and severity of adverse side effects, preferred mode of administration, and the toxicity profile of the selected agent.

[0191] In certain aspects, the HDAC6 inhibitor is a compound of Formula (I), as described herein (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), or a pharmaceutically acceptable salt thereof.

[0192] In some embodiments, a dose (e.g., therapeutically effective amount) of the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof is administered orally to a patient in need thereof (e.g., human patient).

[0193] In certain aspects, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is administered orally at a daily dose of about 100 mg / day to about 200 mg / day, about 100 mg / day to about 300 mg / day, about 100 mg / day to about 400 mg / day, about 100 mg / day to about 600 mg / day, about 100 mg / day to about 800 mg / day, or about 100 mg / day to about 1000 mg / day, or at the equivalent dose for the pharmaceutically acceptable salt thereof.

[0194] In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is administered orally at a daily dose from 100 mg / day to 150 mg / day, from 150 mg / day to 200 mg / day, from 200 mg / day to 250 mg / day, from 250 mg / day to 300 mg / day, from 350 mg / day to 400 mg / day, from 400 mg / day to 450 mg / day, from 500 mg / day to 550 mg / day, or from 550 mg / day to 600 mg / day, or at the equivalent dose for the pharmaceutically acceptable salt thereof. In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is administered orally at a daily dose of about 100 mg / day, about 150 mg / day, about 200 mg / day, about 250 mg / day, about 300 mg / day, about 350 mg / day, about 400 mg / day, about 450 mg / day, about 500 mg / day, about 550 mg / day, or about 600 mg / day, or at the equivalent dose for the pharmaceutically acceptable salt thereof.

[0195] In some embodiments, the compound of Formula (I) (e.g., compound of Table A orDocket No. PAT059983-PCT-SEC01 Table B, such as Compound 40, 43, 239, 285, 295, or 296) is administered orally at a daily dose of 100 mg / day, 150 mg / day, 200 mg / day, 250 mg / day, 300 mg / day, 350 mg / day, 400 mg / day, 450 mg / day, 500 mg / day, 550 mg / day, or 600 mg / day, or at the equivalent dose for the pharmaceutically acceptable salt thereof.

[0196] In certain aspects, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), or a pharmaceutically acceptable salt thereof, is administered one to once a day. In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), or a pharmaceutically acceptable salt thereof, is administered orally once a day. In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), or a pharmaceutically acceptable salt thereof, is administered orally twice a day (BID), e.g., about every 12 hours. In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), ora pharmaceutically acceptable salt thereof, is administered orally three times a day (T.I.D), e.g., about every 8 hours. In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296), or a pharmaceutically acceptable salt thereof, is administered orally once a day (QD), e.g., about every 6 hours.

[0197] In certain aspects, the methods described above include administering, e.g., orally, to the patient (e.g., human patient) a compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) at a dose of from about 50 mg to about 300 mg, e.g., from about 50 mg to about 200 mg, about 100 mg to 300 mg, about 50 mg to about 100 mg, about 100 mg to about 200 mg, or about 200 mg to about 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, each dose administered twice daily (BID), e.g., about every 12 hours.

[0198] In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, or about 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, or 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID).

[0199] In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 50 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, andDocket No. PAT059983-PCT-SEC01 each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 100 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 150 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 200 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 250 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of no more than about 300 mg, or the equivalent dose for the pharmaceutically acceptable salt thereof, each dose administered twice daily (BID).

[0200] In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 50 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 100 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 150 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 200 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) isDocket No. PAT059983-PCT-SEC01 orally administered at a dose of 250 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of no more than about 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of no more than 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID).

[0201] In certain aspects, the methods described above include administering, e.g., orally, to the patient (e.g., human patient) a compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 50 mg to about 600 mg, about 100 mg to about 600 mg, about 200 mg to 600 mg, about 300 mg to about 600 mg, or about 400 mg to about 600 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD).

[0202] In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 50 mg to about 600 mg, about 100 mg to about 200 mg, about 200 mg to 300 mg, about 300 mg to about 400 mg, about 400 mg to about 500 mg, or about 500 mg to about 600 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, or about 600 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, or 600 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD).

[0203] In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 50 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, andDocket No. PAT059983-PCT-SEC01 each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 100 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 150 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 200 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 250 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of no more than about 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 350 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 400 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 450 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 500 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orallyDocket No. PAT059983-PCT-SEC01 administered at a dose of about 550 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 600 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD).

[0204] In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 50 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 100 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 150 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 200 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 250 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 350 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 400 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 450 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g.,Docket No. PAT059983-PCT-SEC01 compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 500 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 550 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 600 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD).

[0205] In certain aspects, the methods described above include administering, e.g., orally, to the patient (e.g., human patient) a compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) at a dose of from about 50 mg to about 300 mg, e.g., from about 50 mg to about 200 mg, about 100 mg to 300 mg, about 50 mg to about 100 mg, about 100 mg to about 200 mg, or about 200 mg to about 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, each dose administered twice daily (BID), e.g., about every 12 hours.

[0206] In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, or about 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, or 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID).

[0207] In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 50 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 100 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 150 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 200 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, orDocket No. PAT059983-PCT-SEC01 296) is orally administered at a dose of about 250 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of no more than about 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID).

[0208] In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 50 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 100 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 150 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 200 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 250 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of no more than about 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of no more than 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID).

[0209] In certain aspects, the methods described above include administering, e.g., orally, to the patient (e.g., human patient) a compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296), or a pharmaceutically acceptable salt is orally administered at a dose ofDocket No. PAT059983-PCT-SEC01 about 50 mg to about 600 mg, about 100 mg to about 600 mg, about 200 mg to 600 mg, about 300 mg to about 600 mg, or about 400 mg to about 600 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD).

[0210] In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 50 mg to about 600 mg, about 100 mg to about 200 mg, about 200 mg to 300 mg, about 300 mg to about 400 mg, about 400 mg to about 500 mg, or about 500 mg to about 600 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, or about 600 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, or 600 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD).

[0211] In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 50 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 100 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 150 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 200 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 250 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of no more than about 300 mg, or at the equivalent doseDocket No. PAT059983-PCT-SEC01 for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 350 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 400 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 450 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 500 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 550 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 600 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD).

[0212] In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 50 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 100 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 150 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 200 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 250 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). InDocket No. PAT059983-PCT-SEC01 some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 350 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 400 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 450 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 500 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 550 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD). In some embodiments, the compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of 600 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered once a day (QD).

[0213] In certain aspects, provided herein is a method of treating AF, wherein the method comprises administering to an individual in need thereof (e.g., patient diagnosed with AF or at risk of AF) a compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or a pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) is administered at a dose of about 100 to about 600 mg per day (e.g., about 50 to about 100 mg twice per day, or 50 mg or 100 mg twice per day) or at the equivalent dose for a pharmaceutically acceptable salt thereof for 6 weeks to 36 weeks (e.g., for 6 weeks, 12 weeks, 18 weeks, 24 weeks, 30 weeks, or 36 weeks).

[0214] In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof is administered for 2 weeks to 36 weeks, 4 weeks to 36 weeks, 6 weeks to 36 weeks, 6 weeks to 30 weeks, or 6 weeks to 24 weeks. In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof is administered for 6 weeks, 12 weeks, 18 weeks, 24 weeks, 30 weeks, or 36 weeks. In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof is administered for 6 weeks. In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof is administered for 12Docket No. PAT059983-PCT-SEC01 weeks. In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof is administered for 18 weeks. In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof is administered for 24 weeks. In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof is administered for 30 weeks. In some embodiments, the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof is administered for 36 weeks.

[0215] In certain aspects, patients in need thereof subjected are human patients. In some embodiments, patients in need thereof have been diagnosed with or are diagnosed with AF. In some embodiments, patients in need thereof are at risk of AF. In some embodiments, patients in need thereof have not suffered from or is not suffering with AF. In some embodiments, patients are at risk of AF.

[0216] In some embodiments, the AF is paroxysmal atrial fibrillation, persistent atrial fibrillation, long-term persistent atrial fibrillation, valvularatrial fibrillation, non-valvularatrial fibrillation, or non-permanent atrial fibrillation. In some embodiments, the AF subjected to the treatments described above or the prevention is paroxysmal atrial fibrillation. In some embodiments, the AF subjected to the treatments described above or the prevention is persistent atrial fibrillation. In some embodiments, the AF subjected to the treatments described above or the prevention is long-term persistent atrial fibrillation. In some embodiments, the AF subjected to the treatments described above or the prevention is valvular atrial fibrillation. In some embodiments, the AF subjected to the treatments described above or the prevention is non-valvular atrial fibrillation. In some embodiments, the AF subjected to the treatments described above or the prevention is non-permanent atrial fibrillation.

[0217] In some embodiments, the patient has suffered or is suffering from paroxysmal atrial fibrillation. In some embodiments, the patient has suffered or is suffering from persistent atrial fibrillation. In some embodiments, the patient has suffered or is suffering from long-term persistent atrial fibrillation. In some embodiments, the patient has suffered or is suffering from valvular atrial fibrillation. In some embodiments, the patient has suffered or is suffering from non-valvular atrial fibrillation. In some embodiments, the AF subjected to the treatments described above or the prevention is non-permanent atrial fibrillation.

[0218] In some embodiments, the patient has been diagnosed with paroxysmal atrial fibrillation. In some embodiments, the patient has been diagnosed with persistent atrial fibrillation. In some embodiments, the patient has been diagnosed with long-term persistent atrial fibrillation. In some embodiments, the patient has been diagnosed with or is diagnosedDocket No. PAT059983-PCT-SEC01 with valvular atrial fibrillation. In some embodiments, the patient has been diagnosed with non-valvular atrial fibrillation. In some embodiments, the patient has been diagnosed with nonpermanent atrial fibrillation.

[0219] In some embodiments, the patient has been treated or is treated for paroxysmal atrial fibrillation. In some embodiments, the patient has been treated or is treated for persistent atrial fibrillation. In some embodiments, the patient has been treated or is treated for long-term persistent atrial fibrillation. In some embodiments, the patient has been treated or is treated for valvular atrial fibrillation. In some embodiments, the patient has been treated or is treated for non-valvular atrial fibrillation. In some embodiments, the patient has been treated or is treated with non-permanent atrial fibrillation.

[0220] In some embodiments, the patient may have a history of, e.g., treatment or diagnosis, paroxysmal atrial fibrillation. In some embodiments, the patient may have a history of, e.g., treatment or diagnosis, persistent atrial fibrillation. In some embodiments, the patient may have a history of, e.g., treatment or diagnosis, long-term persistent atrial fibrillation. In some embodiments, the patient may have a history of, e.g., treatment or diagnosis, valvular atrial fibrillation. In some embodiments, the patient has history of, e.g., treatment or diagnosis, valvular atrial fibrillation. In some embodiments, the patient may have been or be diagnosed with non-permanent atrial fibrillation.

[0221] In some embodiments, the patient is male or female at the age of 18 years or older. In some embodiments, the patient is male or female at the age of 18 years or older. In some embodiments, the patient is male or female at the age of 20 years or older. In some embodiments, the patient is male orfemale at the age of 25 years or older. In some embodiments, the patient is male or female at the age of 30 years or older. In some embodiments, the patient is male or female at the age of 35 years or older. In some embodiments, the patient is male or female at the age of 40 years or older. In some embodiments, the patient is male or female at the age of 45 years or older. In some embodiments, the patient is male or female at the age of 50 years or older. In some embodiments, the patient is male or female at the age of 55 years or older. In some embodiments, the patient is male or female at the age of 60 years or older. In some embodiments, the patient is male or female at the age of 65 years or older. In some embodiments, the patient is male orfemale at the age between 18 years and 65 years.

[0222] In some embodiments, the patient has a history of at least two AF episodes. In some embodiments, the patient has a history of at least two episodes of atrial fibrillation and / or atrial flutter. In some embodiments, the patient has a history of at least one episode of atrial fibrillation and at least one episode of artrial fibrillation or atrial flutter. In some embodiments, the patient has a history of at least two episodes of AF at age of 65 years or older. In some embodiments, the patient has a history of at least two episodes of atrial fibrillation and / or atrialDocket No. PAT059983-PCT-SEC01 flutter at age of 65 years or older. In some embodiments, the patient has a history of at least two episodes of atrial fibrillation and / or atrial flutter at age of 65 years or older where at least one episode is atrial fibrillation. In some embodiments, the patient has a history of at least two episodes of AF between the ages of 18 to 64 years. In some embodiments, the patient has a history of at least two episodes of atrial fibrillation and / or atrial flutter episodes between the ages of 18 to 64 years. In some embodiments, the patient has a history of at least two episodes of atrial fibrillation and / or atrial flutter episodes between the ages of 18 to 64 years where at least one episode is atrial fibrillation.

[0223] In some embodiments, at least one of the AF episodes has occurred within the last 12 months prior to the treatment (or during Screening) and documented by 12-lead ECG, Holter, or any other ECG recording method, as confirmed by the patient’s medical record (e.g., provided or confirmed by an investigator or a qualified physician).

[0224] In some embodiments, the patient had at least one AF episode within the last 6 to 24 months. In some embodiments, the patient had at least one AF episode within the last 6 months. In some embodiments, the patient had at least one AF episode within the last 12 months prior to the treatment. In some embodiments, the patient had at least one AF episode within the last 18 months. In some embodiments, the patient had at least one AF episode within the last 24 months.

[0225] In some embodiments, the episode is documented by 12-lead ECG, Holter, or any other ECG recording method, as confirmed by the patient’s medical record (e.g., provided or confirmed by an investigator or a qualified physician). In some embodiments, the investigator may include, but not limited to, doctors, scientists, nurses, and other research staff.

[0226] In some embodiments, at least one of the atrial fibrillation episode has occurred within the last 12 months prior to the treatment (or during Screening) and documented by 12-lead ECG, Holter, or any other ECG recording method, as confirmed by the patient’s medical record (e.g., provided or confirmed by an investigator or a qualified physician).

[0227] In some embodiments, the patient had at least one atrial fibrillation episode within the last 6 to 24 months. In some embodiments, the patient had at least one atrial fibrillation episode within the last 6 months. In some embodiments, the patient had at least one atrial fibrillation episode within the last 12 months prior to the treatment. In some embodiments, the patient had at least one atrial fibrillation episode within the last 18 months. In some embodiments, the patient had at least one atrial fibrillation episode within the last 24 months.

[0228] In certain aspects, provided herein are methods of treating AF, wherein the method comprises administering to an individual in need thereof a dose of a compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or a pharmaceutically acceptable salt thereof, wherein the individual (e.g., patient diagnosed with AF or at risk of AF) may be selected from the group having one or more (e.g., at least one, or atDocket No. PAT059983-PCT-SEC01 least two) of following conditions:i. AFB of 1 % or higher on a local ambulatory Holter, mobile cardiac telemetry, ECG patch monitor, or other ambulatory electrocardiographic monitor within the last 12 months prior to the treatmentii. CHA2DS2-VASc score of 2 or higher in males, 3 or higher in femalesHi. Stable heart failure or with New York Heart Association class I or II symptoms iv. NT-proBNP level of 300 pg / mL or higher on a local lab test within the last 12 months prior to the treatment,wherein the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is administered at a dose of about 100 to about 600 mg per day (e.g., about 50 to about 100 mg twice per day, or 50 mg or 100 mg twice per day) or at the equivalent dose for a pharmaceutically acceptable salt thereof.

[0229] The “CHA2DS2-VASc score” as defined herein can be scored with 1 point for congestive heart failure, hypertension, age 65-74 years, diabetes, vascular disease, female sex; 2 points for age 75 years or older, prior stroke or transient ischemic attack.

[0230] In some embodiments, the patient has one or more (e.g., at least one, or at least two) of the following conditions:i. AFB of 1 % or higher on a local ambulatory Holter, mobile cardiac telemetry, ECG patch monitor, or other ambulatory electrocardiographic monitor within the last 12 months prior to the treatmentii. CHA2DS2-VASc score of 2 or higher in males, 3 or higher in femalesHi. Stable heart failure or with New York Heart Association class I or II symptoms, iv. NT-proBNP level of 300 pg / mL or higher on a local lab test within the last 12 months prior to the treatment,wherein the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is administered at a dose of about 100 to about 600 mg per day (e.g., about 50 to about 100 mg twice per day, or 50 mg or 100 mg twice per day) or at the equivalent dose for a pharmaceutically acceptable salt thereof.

[0231] In some embodiments, the patient has sinus rhythm documented by 12-lead ECG before the treatment, e.g., before administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof.

[0232] In some embodiments, the patient is able to communicate well with the investigator, e.g., to understand and comply with the requirements or directions for the treatment. In some embodiments, the patient is able to wear an ECG patch before the treatment (e.g., monitoring period) and / or during the treatment period.

[0233] In some embodiments, the patient’s BMI may be calculated by dividing the patient’s body weight (kg) by the patient’s height (m) squared prior to the treatment. In some embodiments, the patient has a body mass index (BMI) of about 15 kg / m2or greater. In some embodiments, the patient has a body mass index (BMI) of about 16 kg / m2or greater. In some embodiments, the patient has a body mass index (BMI) of about 17 kg / m2or greater. In someDocket No. PAT059983-PCT-SEC01 embodiments, the patient has a body mass index (BMI) of about 18 kg / m2or greater. In some embodiments, the patient has a body mass index (BMI) of about 19 kg / m2or greater. In some embodiments, the patient has a body mass index (BMI) of about 20 kg / m2or greater.

[0234] In some embodiments, the patient may have sinus rhythm at the time or prior to the treatment (e.g., administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof) as documented by 12-lead ECG. In some embodiments, if the patient has persistent AF, the patient is cardioverted before treating by administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof.

[0235] In certain aspects, provided herein are methods of treating AF, wherein the method comprises administering to an individual (e.g., patient diagnosed with AF or at risk of AF) in need thereof a dose of a compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or a pharmaceutically acceptable salt thereof, wherein the individual (e.g., patient diagnosed with AF or at risk of AF) may be selected from the group not having one or more (e.g., at least one, or at least two) of following conditions:(i) Permanent AF;(ii) Ongoing reversible cause of AF (e.g., hyperthyroidism, myocarditis, alcohol use, sepsis- or infection-related AF, surgery-related AF, and pulmonary embolism);(iii) Ongoing use of antiarrhythmic therapy (Vaughan Williams class I or III anti- arrhythmic therapy must be discontinued at least 7 days before Screening phase ECG patch monitor; amiodarone must be discontinued at least 6 weeks before Screening phase ECG patch monitor);(iv) History of an AF ablation procedure (for example, within the last 6 months) without a recurrence of AF at least 2 or more months after the ablation; (v) Implanted pacemaker, defibrillator, or cardiac monitor;(vi) Infiltrative (e.g., amyloidosis, sarcoidosis) or hypertrophic cardiomyopathy; (vii) Current decompensated heart failure or hospitalization for heart failure within 3 months prior to Screening;(viii) Left ventricular ejection fraction (LVEF) of 40% or less documented within the last 12 months prior to the treatment, or during the treatment, for example, if multiple LVEF measurements are recorded within the last 12 months, the most recent LVEF measurement should be used;(ix) Severe valvular disease or planned valvular intervention during study;Docket No. PAT059983-PCT-SEC01 (x) Stroke within the last 6 months, or other neurologic or psychiatric conditions likely to affect study compliance;(xi) Cardiac surgery within the last 6 months;(xii) Unstable angina, myocardial infarction, coronary angioplasty within the last 6 months; and(xiii) Known allergic reactions to adhesives or hydrogels,wherein the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is administered at a dose of about 100 to about 600 mg per day (e.g., about 50 to about 100 mg twice per day, or 50 mg or 100 mg twice per day) or at the equivalent dose for a pharmaceutically acceptable salt thereof.

[0236] In some embodiments, the patient (e.g., patient diagnosed with AF or at risk of AF) does not have one or more (e.g., at least one, or at least two) of the following conditions:(i) Permanent AF;(ii) Ongoing reversible cause of AF (e.g., hyperthyroidism, myocarditis, alcohol use, sepsis- or infection-related AF, surgery-related AF, and pulmonary embolism);(iii) Ongoing use of antiarrhythmic therapy (Vaughan Williams class I or III anti- arrhythmic therapy must be discontinued at least 7 days before Screening phase ECG patch monitor; amiodarone must be discontinued at least 6 weeks before Screening phase ECG patch monitor);(iv) History of an AF ablation procedure (for example, within the last 6 months) without a recurrence of AF at least 2 or more months after the ablation; (v) Implanted pacemaker, defibrillator, or cardiac monitor;(vi) Infiltrative (e.g., amyloidosis, sarcoidosis) or hypertrophic cardiomyopathy; (vii) Current decompensated heart failure or hospitalization for heart failure within 3 months prior to Screening;(viii) Left ventricular ejection fraction (LVEF) of 40% or less documented within the last 12 months prior to the treatment, or during the treatment, for example, if multiple LVEF measurements are recorded within the last 12 months, the most recent LVEF measurement should be used;(ix) Severe valvular disease or planned valvular intervention during study;(x) Stroke within the last 6 months, or other neurologic or psychiatric conditions likely to affect study compliance;(xi) Cardiac surgery within the last 6 months;Docket No. PAT059983-PCT-SEC01 (xii) Unstable angina, myocardial infarction, coronary angioplasty within the last 6 months; and(xiii) Known allergic reactions to adhesives or hydrogels,wherein the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is administered at a dose of about 100 to about 600 mg per day (e.g., about 50 to about 100 mg twice per day, or 50 mg or 100 mg twice per day) or at the equivalent dose for a pharmaceutically acceptable salt thereof.

[0237] In some embodiments, the patient has not suffered or is not suffering from permanent AF. In some embodiments, the patient does not have a history of diagnosis of permanent AF. In some embodiments, the patient does not have (e.g., have a symptom of) permanent AF.

[0238] In some embodiments, the patient has not suffered or is not suffering from ongoing reversible cause of AF (e.g., hyperthyroidism, myocarditis, alcohol use, sepsis- or infection-related AF, surgery-related AF, and pulmonary embolism). In some embodiments, the patient has not suffered or is not suffering from one or more of hyperthyroidism, myocarditis, alcohol use, sepsis- or infection-related AF, surgery-related AF, and pulmonary embolism. In some embodiments, the patient has not suffered or is not suffering from hyperthyroidism. In some embodiments, the patient has not suffered or is not suffering from myocarditis. In some embodiments, the patient has not suffered or is not suffering from alcohol use. In some embodiments, the patient has not suffered or is not suffering from sepsis- or infection-related AF. In some embodiments, the patient has not suffered or is not suffering from surgery- related AF. In some embodiments, the patient has not suffered or is not suffering from pulmonary embolism.

[0239] In some embodiments, the patient does not have a history of diagnosis of ongoing reversible cause of AF (e.g., hyperthyroidism, myocarditis, alcohol use, sepsis- or infection-related AF, surgery-related AF, and pulmonary embolism). In some embodiments, the patient does not have a history of diagnosis of one or more of hyperthyroidism, myocarditis, alcohol use, sepsis- or infection-related AF, surgery-related AF, and pulmonary embolism. In some embodiments, the patient does not have a history of diagnosis of hyperthyroidism. In some embodiments, the patient does not have a history of diagnosis of myocarditis. In some embodiments, the patient does not have a history of diagnosis of alcohol use. In some embodiments, the patient does not have a history of diagnosis of sepsis- or infection-related AF. In some embodiments, the patient does not have a history of diagnosis of surgery-related AF. In some embodiments, the patient does not have a history of diagnosis of pulmonary embolism.

[0240] In some embodiments, the patient does not have (e.g., have a symptom of) ongoing reversible cause of AF (e.g., hyperthyroidism, myocarditis, alcohol use, sepsis- or infection-related AF, surgery-related AF, and pulmonary embolism). In some embodiments, the patientDocket No. PAT059983-PCT-SEC01 does not have (e.g., have a symptom of) of one or more of hyperthyroidism, myocarditis, alcohol use, sepsis- or infection-related AF, surgery-related AF, pulmonary embolism. In some embodiments, the patient does not have (e.g., have a symptom of) an ongoing reversible cause of hyperthyroidism. In some embodiments, the patient does not have (e.g., have a symptom of) ongoing reversible cause of myocarditis. In some embodiments, the patient does not have (e.g., have a symptom of) an ongoing reversible cause of alcohol use. In some embodiments, the patient does not have (e.g., have a symptom of) ongoing reversible cause of sepsis- or infection-related AF. In some embodiments, the patient does not have (e.g., have a symptom of) ongoing reversible cause of surgery-related AF. In some embodiments, the patient does not have (e.g., have a symptom of) an ongoing reversible cause of pulmonary embolism.

[0241] In some embodiments, the patient does not have ongoing use of antiarrhythmic therapy (e.g., Vaughan Williams class I or III anti-arrhythmic therapy, or amiodarone treatment). In some embodiments, the patient has not been or is not treated with antiarrhythmic therapy (e.g., Vaughan Williams class I or III anti-arrhythmic therapy, or amiodarone treatment). In some embodiments, the patient was treated with antiarrhythmic therapy (e.g., Vaughan Williams class I or III anti-arrhythmic therapy, or amiodarone treatment) but discontinued the treatment.

[0242] In some embodiments, the patient does not have ongoing use of Vaughan Williams class I or III anti-arrhythmic therapy. In some embodiments, the patient has not been or is not treated with Vaughan Williams class I or III anti-arrhythmic therapy or drug. In some embodiments, the patient was treated with Vaughan Williams class I or III anti-arrhythmic therapy ordrug but discontinued the treatment (e.g., at least 7 days before pre-dose ECG patch monitor through the end of treatment (EOT)).

[0243] In some embodiments, the patient does not have ongoing use of amiodarone treatment. In some embodiments, the patient has not been or is not treated with amiodarone. In some embodiments, the patient was treated with amiodarone but discontinued the treatment (e.g., at least 6 weeks before Screening phase ECG patch monitor).

[0244] In some embodiments, the patient does not have a history of AF ablation procedure within the last 12 months prior to the treatment without a recurrence of AF after ablation. In some embodiments, the patient does not have a history of AF ablation procedure within the last 11 months without a recurrence of AF after ablation. In some embodiments, the patient does not have a history of AF ablation procedure within the last 10 months without a recurrence of AF after ablation. In some embodiments, the patient does not have a history of AF ablation procedure within the last 9 months without a recurrence of AF after ablation. In some embodiments, the patient does not have a history of AF ablation procedure within the last 8 months without a recurrence of AF after ablation. In some embodiments, the patient does not have a history of AF ablation procedure within the last 7 months without a recurrence of AF after ablation. In some embodiments, the patient does not have a history of AF ablation procedureDocket No. PAT059983-PCT-SEC01 within the last 6 months without a recurrence of AF after ablation. In some embodiments, the patient does not have a history of AF ablation procedure within the last 5 months without a recurrence of AF after ablation. In some embodiments, the patient does not have a history of AF ablation procedure within the last 4 months without a recurrence of AF after ablation. In some embodiments, the patient does not have a history of AF ablation procedure within the last 3 months without a recurrence of AF after ablation.

[0245] In some embodiments, the patient does not have an implanted pacemaker, defibrillator, or cardiac monitor. In some embodiments, the patient does not have an implanted pacemaker. In some embodiments, the patient does not have a defibrillator. In some embodiments, the patient does not have a cardiac monitor.

[0246] In some embodiments, the patient does not have (e.g., have a symptom) infiltrative (e.g., amyloidosis, sarcoidosis) or hypertrophic cardiomyopathy. In some embodiments, the patient does not have (e.g., have a symptom) infiltrative (e.g., amyloidosis, sarcoidosis) cardiomyopathy. In some embodiments, the patient does not have (e.g., have a symptom) amyloidosis cardiomyopathy. In some embodiments, the patient does not have (e.g., have a symptom) sarcoidosis cardiomyopathy. In some embodiments, the patient does not have (e.g., have a symptom) hypertrophic cardiomyopathy.

[0247] In some embodiments, the patient has not suffered or is not suffering from infiltrative (e.g., amyloidosis, sarcoidosis) or hypertrophic cardiomyopathy. In some embodiments, the patient has not suffered or is not suffering from infiltrative (e.g., amyloidosis, sarcoidosis) cardiomyopathy. In some embodiments, the patient has not suffered or is not suffering from amyloidosis cardiomyopathy. In some embodiments, the patient has not suffered or is not suffering from sarcoidosis cardiomyopathy. In some embodiments, the patient has not suffered or is not suffering from hypertrophic cardiomyopathy.

[0248] In some embodiments, the patient has not been diagnosed with infiltrative (e.g., amyloidosis, sarcoidosis) or hypertrophic cardiomyopathy.

[0249] In some embodiments, the patient has not been diagnosed with infiltrative (e.g., amyloidosis, sarcoidosis) or hypertrophic cardiomyopathy. In some embodiments, the patient has not been diagnosed with infiltrative (e.g., amyloidosis, sarcoidosis) cardiomyopathy. In some embodiments, the patient has not been diagnosed with amyloidosis cardiomyopathy. In some embodiments, the patient has not been diagnosed with sarcoidosis cardiomyopathy. In some embodiments, the patient has not been diagnosed with hypertrophic cardiomyopathy.

[0250] In some embodiments, the patient does not have unstable heart failure or New York Heart Association Class III or IV symptoms. In some embodiments, the patient does not have unstable heart failure symptom. In some embodiments, the patient does not have or New York Heart Association Class III or IV symptoms.

[0251] In some embodiments, the patient does not have left ventricular ejection fractionDocket No. PAT059983-PCT-SEC01 (LVEF) less than 50% based on the most recent echocardiographic assessment (e.g., within the last 12 months, or prior to the treatment). In some embodiments, the patient does not have left ventricular ejection fraction (LVEF) less than 45% based on the most recent echocardiographic assessment (e.g., within the last 12 months, or prior to the treatment). In some embodiments, the patient does not have left ventricular ejection fraction (LVEF) less than 40% based on the most recent echocardiographic assessment (e.g., within the last 12 months, or prior to the treatment). In some embodiments, the patient does not have left ventricular ejection fraction less than 35% based on the most recent echocardiographic assessment (e.g., within the last 12 months, or prior to the treatment). In some embodiments, the patient does not have left ventricular ejection fraction (LVEF) less than 30% based on the most recent echocardiographic assessment (e.g., within the last 12 months, or prior to the treatments). In some embodiments, multiple LVEF measurements are recorded within the last 12 months, the most recent LVEF measurement should be used.

[0252] In some embodiments, the patient does not have (e.g., have a symptom of) severe valvular disease. In some embodiments, the patient does not have a plan for valvular intervention within the period of the treatments.

[0253] In some embodiments, the patient does not have (e.g., have a symptom of) stroke within the last 12 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) stroke within the last 11 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) stroke within the last 10 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) stroke within the last 9 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) a stroke within the last 8 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) stroke within the last 7 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) stroke within the last 6 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) stroke within the last 5 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) stroke within the last 4 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) stroke within the last 3 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) a stroke within the last 2 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) stroke within the last 1 month prior to the treatments.

[0254] In some embodiments, the patient does not have (e.g., have a symptom of) any neurologic or psychiatric conditions likely to affect the treatments within the last 12 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) any neurologic or psychiatric conditions likely to affect the treatments within the last 11 monthsDocket No. PAT059983-PCT-SEC01 prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) any neurologic or psychiatric conditions likely to affect the treatments within the last 10 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) any neurologic or psychiatric conditions likely to affect the treatments within the last 9 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) any neurologic or psychiatric conditions likely to affect the treatments within the last 8 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) any neurologic or psychiatric conditions likely to affect the treatments within the last 7 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) any neurologic or psychiatric conditions likely to affect the treatments within the last 6 months prior to the treatments. In some embodiments, the patient does not have (e.g., have symptoms of) any neurologic or psychiatric conditions likely to affect the treatments within the last 5 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) any neurologic or psychiatric conditions likely to affect the treatments within the last 4 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) any neurologic or psychiatric conditions likely to affect the treatments within the last 3 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) any neurologic or psychiatric conditions likely to affect the treatments within the last 2 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) any neurologic or psychiatric conditions likely to affect the treatments within the last 1 month prior to the treatments.

[0255] In some embodiments, the patient has no history of cardiac surgery within the last 12 months prior to the treatments. In some embodiments, the patient has no history of cardiac surgery within the last 11 months prior to the treatments. In some embodiments, the patient has no history of cardiac surgery within the last 10 months prior to the treatments. In some embodiments, the patient has no history of cardiac surgery within the last 9 months prior to the treatments. In some embodiments, the patient has had no history of cardiac surgery within the last 8 months prior to the treatments. In some embodiments, the patient has no history of cardiac surgery within the last 7 months prior to the treatments. In some embodiments, the patient has no history of cardiac surgery within the last 6 months prior to the treatments. In some embodiments, the patient has no history of cardiac surgery within the last 5 months prior to the treatments. In some embodiments, the patient has no history of cardiac surgery within the last 4 months prior to the treatments. In some embodiments, the patient has no history of cardiac surgery within the last 3 months prior to the treatments. In some embodiments, the patient has no history of cardiac surgery within the last 2 months prior to the treatments. In some embodiments, the patient has no history of cardiac surgery within the last 1 month prior toDocket No. PAT059983-PCT-SEC01 the treatments.

[0256] In some embodiments, the patient does not have (e.g., have a symptom of) unstable angina within the last 12 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) unstable angina within the last 11 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) unstable angina within the last 10 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) unstable angina within the last 9 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) unstable angina within the last 8 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) unstable angina within the last 7 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) unstable angina within the last 6 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) unstable angina within the last 5 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) unstable angina within the last 4 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) unstable angina within the last 3 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) unstable angina within the last 2 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) unstable angina within the last 1 month prior to the treatments.

[0257] In some embodiments, the patient does not have (e.g., have a symptom of) myocardial infarction within the last 12 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) myocardial infarction within the last 11 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) myocardial infarction within the last 10 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) myocardial infarction within the last 9 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) myocardial infarction within the last 8 months prior to the treatments. In some embodiments, the patient does not have (e.g., have symptoms of) myocardial infarction within the last 7 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) myocardial infarction within the last 6 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) myocardial infarction within the last 5 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) myocardial infarction within the last 4 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) myocardial infarction within the last 3 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) myocardial infarction withinDocket No. PAT059983-PCT-SEC01 the last 2 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) myocardial infarction within the last 1 month prior to the treatments.

[0258] In some embodiments, the patient does not have (e.g., have a symptom of) coronary angioplasty within the last 12 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) coronary angioplasty within the last 11 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) coronary angioplasty within the last 10 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) coronary angioplasty within the last 9 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) coronary angioplasty within the last 8 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) coronary angioplasty within the last 7 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) coronary angioplasty within the last 6 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) coronary angioplasty within the last 5 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) coronary angioplasty within the last 4 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) coronary angioplasty within the last 3 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) coronary angioplasty within the last 2 months prior to the treatments. In some embodiments, the patient does not have (e.g., have a symptom of) unstable angina within the last 1 month prior to the treatments.

[0259] In some embodiments, the patient does not have a history or knowledge of allergic reactions to adhesives or hydrogels.

[0260] In some embodiments, the patient does not have (e.g., have symptoms of) clinically significant electrocardiogram (ECG) abnormalities. In some embodiments, the patient does not have a heart rate less than 50 bpm. In some embodiments, the patient does not have QT interval corrected by Fridericia’s formula (QTcF) greater than about 450 msec in a male patient or QTcF greater than about 460 msec in a female patient. In some embodiments, the patient does not have heart rage less than 50 bpm and QT interval corrected by Fridericia’s formula (QTcF) greater than about 450 msec in a male patient or QTcF greater than about 460 msec in a female patient.

[0261] In some embodiments, the patient has not had any drug abuse or unhealthy alcohol use within the past 3 to 24 months. In some embodiments, the term “unhealthy alcohol use” is defined as a history of, or current alcohol misuse / abuse, defined as five or more drinks on the same occasion on each of 5 or more days in the past 30 days. In some embodiments, the patient has not had any drug abuse or unhealthy alcohol use within the past 3 months. In some embodiments, the patient does not have any drug abuse or unhealthy alcohol use within theDocket No. PAT059983-PCT-SEC01 past 6 months. In some embodiments, the patient does not have any drug abuse or unhealthy alcohol use within the past 12 months. In some embodiments, the patient has not had any drug abuse or unhealthy alcohol use within the past 18 months. In some embodiments, the patient has not had any drug abuse or unhealthy alcohol use within the past 24 months.

[0262] In some embodiments, the patient is (a) not pregnant, (b) a nursing or lactating woman, or (c) a woman having child-bearing potential unless she is using effective methods of contraception during the treatment.

[0263] In some embodiments, the patient is not pregnant. In some embodiments, the patient is not nursing. In some embodiments, the patient is not lactating.

[0264] In some embodiments, the patient is not a woman nor a female patient having childbearing potential . In some embodiments, the patient is in use of effective methods of contraception such as total abstinence, female sterilization, total hysterectomy, or bilateral tubal ligation (e.g., at least six weeks before taking investigational drug), male sterilization (at least 6 months prior to screening), barrier methods of contraception: male orfemale condom or occlusive cap, diaphragm or cervical / vault caps, or hormonal intrauterine devices (IUDs), except oral or systemic hormonal contraceptive methods.

[0265] In some embodiments, the patient does not have liver disease or liver injury. In some embodiments, the liver disease or the liver injury may be indicated by abnormal liver function tests at screening stage. In some embodiments, the patient does not have ALT (SGPT), AST (SGOT), GGT, or alkaline phosphatase exceeding the level two times of upper limit of normal (ULN). In some embodiments, the patient does not have serum bilirubin exceeding 1.2 time of the ULN. In some embodiments, the patient does not have serum bilirubin exceeding 1.3 time of the ULN. In some embodiments, the patient does not have serum bilirubin exceeding 1.4 time of the ULN. In some embodiments, the patient does not have serum bilirubin exceeding 1.5 time of the ULN. In some embodiments, the patient does not have serum bilirubin exceeding 1.6 time of the ULN. In some embodiments, the patient does not have serum bilirubin exceeding 1.7 time of the ULN. In some embodiments, the patient does not have serum bilirubin exceeding 1.8 time of the ULN. In some embodiments, the patient does not have serum bilirubin exceeding 1.9 time of the ULN. In some embodiments, the patient does not have serum bilirubin exceeding 2.0 time of the ULN.

[0266] In some embodiments, the patient does not have a history or presence of impaired renal function. In some embodiments, the patient does not have (e.g., have symptoms of) impaired renal function. In some embodiments, the patient has not suffered from or is not suffering from impaired renal function. In some embodiments, the patient has not been diagnosed with impaired renal function.

[0267] In some embodiments, the patient does not have a history or presence of impaired renal function, e.g., indicated by eGFR <60 mL / min / 1 ,73m2calculated using the CKD-EPIDocket No. PAT059983-PCT-SEC01 formula. The “CKD-EPI formula” may be calculated using the website "https: / / www.kidney.org / professionals / gfr_calculator”. In some embodiments, the patient does not have (e.g., have symptoms of) impaired renal function indicated by eGFR <60 mL / min / 1 ,73m2calculated using the CKD-EPI formula. In some embodiments, the patient has not suffered from or is not suffering from impaired renal function indicated by eGFR <60 mL / min / 1 ,73m2calculated using the CKD-EPI formula. In some embodiments, the patient has not been diagnosed or is not diagnosed with impaired renal function indicated by eGFR <60 mL / min / 1 ,73m2calculated using the CKD-EPI formula.

[0268] In some embodiments, the patient has not been used or is not in use of other drugs or therapies within 5 half-lives of the other drugs or therapies of Day 1 , or until the expected PD effect of the other drugs or therapies has returned to baseline, whichever is longer; or longer if required by local regulations.

[0269] In some embodiments, prior to administering, the patient has not been in ongoing treatment with a drug that is a CYP3A4 inhibitor (e.g., moderate or strong CYP3A4 inhibitor). In some embodiments, the CYP3A4 inhibitor (e.g., moderate or strong CYP3A4) is selected from boceprevir, ceritinib, clarithromycin, cobicistat, conivaptan, danoprevir / ritonavir, elvitegravir / ritonavir, grapefruit or grapefruit juice, idelalisib, indinavir, indinavir, ritonavir, itraconazole, josamycin, ketoconazole, lopinavir / ritonavir, mibefradil, mifepristone, nefazodone, nelfinavir, ombitasvir / paritaprevir / dasabuvir / ritonavir (Viekira Pak), posaconazole, ribociclib, ritonavir, saquinavir, saquinavir / ritonavir, telaprevir, telithromycin, tipranavir / ritonavir, troleandomycin, tucatinib, voriconazole, aprepitant, amprenavir, atazanavir, atazanavir / ritonavir, casopitant, cimetidine, ciprofloxacin, crizotinib, darunavir, darunavir / ritonavir, diltiazem, dronedarone, duvelisib, erythromycin, faldaprevir, fedratinib, fluconazole, imatinib, isavuconazole, istradefylline, lefamulin, letermovir, Magnolia vine (Schisandra sphenanthera), netupitant, nilotinib, ravuconazole, tofisopam, verapamil, and voxelotor.

[0270] In some embodiments, the patient has not been treated with a drug that is a moderate or strong CYP3A4 inhibitor. In some embodiments, the patient has not been treated with one or more selected from boceprevir, ceritinib, clarithromycin, cobicistat, conivaptan, danoprevir / ritonavir, elvitegravir / ritonavir, grapefruit or grapefruit juice, idelalisib, indinavir, indinavir, ritonavir, itraconazole, josamycin, ketoconazole, lopinavir / ritonavir, mibefradil, mifepristone, nefazodone, nelfinavir, ombitasvir / paritaprevir / dasabuvir / ritonavir (Viekira Pak), posaconazole, ribociclib, ritonavir, saquinavir, saquinavir / ritonavir, telaprevir, telithromycin, tipranavir / ritonavir, troleandomycin, tucatinib, voriconazole, aprepitant, amprenavir, atazanavir, atazanavir / ritonavir1, casopitant, cimetidine, ciprofloxacin, crizotinib, darunavir, darunavir / ritonavir1, diltiazem, dronedarone, duvelisib, erythromycin, faldaprevir, fedratinib, fluconazole, imatinib, isavuconazole, istradefylline, lefamulin, letermovir, Magnolia vine (Schisandra sphenanthera), netupitant, nilotinib, ravuconazole, tofisopam, verapamil, andDocket No. PAT059983-PCT-SEC01 voxel oto r.

[0271] In some embodiments, prior to administration, the patient has not been in ongoing treatment with a drug that is a CYP3A4 inducer (e.g., strong CYP3A4 inducer). In some embodiments, the CYP3A4 inducer (e.g., strong CYP3A4 inducer) is selected from aprepitant, amprenavir, atazanavir, atazanavir / ritonavir, casopitant, cimetidine, ciprofloxacin, crizotinib, darunavir, darunavir / ritonavir, diltiazem, dronedarone, duvelisib, erythromycin, faldaprevir, fedratinib, fluconazole, imatinib, isavuconazole, istradefylline, lefamulin, letermovir, Magnolia vine (Schisandra sphenanthera), netupitant, nilotinib, ravuconazole, tofisopam, verapamil, voxelotor, apalutamide, avasimibe, carbamazepine, enzalutamide, ivosidenib, lumacaftor, mitotane, phenytoin, rifampicin, rifapentine, and St. John’s wort (Hypericum perforatum).

[0272] In some embodiments, the patient (e.g., patient being administered the compounds of Formula (I), e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt) has not been treated with a drug that may inhibit one or more moderate or strong cytochromes P450 (CYP) inhibitors.

[0273] In some embodiments, the patient (e.g., patient being administered the compounds of Formula (I), e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt) has not been treated with a drug that is a CYP3A4 inhibitor (e.g., moderate or strong CYP3A4 inhibitor). In some embodiments, the patient may have been treated with but discontinued a drug that is a moderate or strong CYP3A4 inhibitor (e.g., moderate or strong CYP3A4 inhibitor). In some embodiments, the patient may have been treated with but discontinued a drug known that is a CYP3A4 inhibitor (e.g., moderate or strong CYP3A4 inhibitor) at least 14 days prior to the treatment (e.g., randomization). In some embodiments, the patient may have been treated with but discontinued a drug that is a CYP3A4 inhibitor (e.g., moderate or strong CYP3A4 inhibitor) at least 7 days prior to the treatment (e.g., randomization). In some embodiments, the patient may have been treated with but discontinued a drug that is a CYP3A4 inhibitor (e.g., moderate or strong CYP3A4 inhibitor) at least 5 days prior to the treatment (e.g., randomization). In some embodiments, the patient may have been treated with but discontinued a drug that is a CYP3A4 inhibitor (e.g., moderate or strong CYP3A4 inhibitor) at least 3 days prior to the treatment (e.g., randomization).

[0274] In some embodiments, the patient (e.g., patient being administered the compounds of Formula (I), e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt) has not been treated with a drug that is a CYP3A4 inducer (e.g., strong CYP3A4 inducer). In some embodiments, the patient may have been treated with but discontinued a drug that is a CYP3A4 inducer (e.g., strong CYP3A4 inducer). In some embodiments, the patient may have been treated with but discontinued a drug known that is a CYP3A4 inducer (e.g., strong CYP3A4 inducer) at least 14 days priortoDocket No. PAT059983-PCT-SEC01 the treatment (e.g., randomization). In some embodiments, the patient may have been treated with but discontinued a drug that is a CYP3A4 inducer (e.g., strong CYP3A4 inducer) at least 7 days prior to the treatment (e.g., randomization). In some embodiments, the patient may have been treated with but discontinued a drug that is a CYP3A4 inducer (e.g., strong CYP3A4 inducer) lat least 5 days prior to the treatment (e.g., randomization). In some embodiments, the patient may have been treated with but discontinued a drug that is a CYP3A4 inducer (e.g., strong CYP3A4 inducer) at least 3 days prior to the treatment (e.g., randomization).

[0275] In some embodiments, the patient (e.g., patient being administered the compounds of Formula (I), e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt) has not been treated with a drug known to prolong the QT interval. In some embodiments, the patient may have been treated with but discontinued a drug known to prolong the QT interval. In some embodiments, the patient may have been treated with but discontinued a drug known to prolong the QT interval at least 14 days prior to the treatment (e.g., randomization). In some embodiments, the patient may have been treated with but discontinued a drug known to prolong the QT interval at least 7 days prior to the treatment (e.g., randomization). In some embodiments, the patient may have been treated with but discontinued a drug known to prolong the QT interval at least 5 days prior to the treatment (e.g., randomization). In some embodiments, the patient may have been treated with but discontinued a drug known to prolong the QT interval at least 3 days before the treatment (e.g., administering the compound of Formula (I), e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt).

[0276] In some embodiments, the patient (e.g., patient being administered the compounds of Formula (I), e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt) has not been treated with a drug that is a CYP3A4 inhibitor (e.g., moderate or strong CYP3A4 inhibitor). In some embodiments, the patient may have been treated with but discontinued a drug that is a CYP3A4 inhibitor (e.g., moderate or strong CYP3A4 inhibitor). In some embodiments, the patient may have been treated with but discontinued a drug known that is a CYP3A4 inhibitor (e.g., moderate or strong CYP3A4 inhibitor) at least 14 days priorto the treatment (e.g., randomization) and before the treatment (e.g., administering the compound of Formula (I), e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt). In some embodiments, the patient may have been treated with but discontinued a drug that is a CYP3A4 inhibitor (e.g., moderate or strong CYP3A4 inhibitor) at least 7 days priorto the treatment (e.g., randomization) and before the treatment (e.g., administering the compound of Formula (I), e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt). In some embodiments, the patient may have been treated with but discontinued a drug that is a CYP3A4 inhibitor (e.g., moderate or strongDocket No. PAT059983-PCT-SEC01 CYP3A4 inhibitor) at least 5 days prior to the treatment (e.g., randomization) and before the treatment (e.g., administering the compound of Formula (I), e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt). In some embodiments, the patient may have been treated with but discontinued a drug that is a CYP3A4 inhibitor (e.g., moderate or strong CYP3A4 inhibitor) at least 3 days prior to the treatment (e.g., randomization) and before the treatment (e.g., administering the compound of Formula (I), e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt).

[0277] In some embodiments, the patient (e.g., patient being administered the compounds of Formula (I), e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt) has not been treated with a drug that is a CYP3A4 inducer (e.g., strong CYP3A4 inducer). In some embodiments, the patient may have been treated with but discontinued a drug that is a CYP3A4 inducer (e.g., strong CYP3A4 inducer). In some embodiments, the patient may have been treated with but discontinued a drug known that is a CYP3A4 inducer (e.g., strong CYP3A4 inducer) at least 14 days prior to the treatment (e.g., randomization) and before the treatment (e.g., administering the compound of Formula (I), e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt). In some embodiments, the patient may have been treated with but discontinued a drug that is a CYP3A4 inducer (e.g., strong CYP3A4 inducer) at least 7 days prior to the treatment (e.g., randomization) and before the treatment (e.g., administering the compound of Formula (I), e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt). In some embodiments, the patient may have been treated with but discontinued a drug that is a CYP3A4 inducer (e.g., strong CYP3A4 inducer) at least 5 days prior to the treatment (e.g., randomization) and before the treatment (e.g., administering the compound of Formula (I), e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt). In some embodiments, the patient may have been treated with but discontinued a drug that is a CYP3A4 inducer (e.g., strong CYP3A4 inducer) at least 3 days prior to the treatment (e.g., randomization) and before the treatment (e.g., administering the compound of Formula (I), e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt).

[0278] In some embodiments, the patient (e.g., patient being administered the compounds of Formula (I), e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt) has not been treated with a drug known to prolong the QT interval. In some embodiments, the patient may have been treated with but discontinued a drug known to prolong the QT interval. In some embodiments, the patient may have been treated with but discontinued a drug known to prolong the QT interval at least 14Docket No. PAT059983-PCT-SEC01 days prior to the treatment (e.g., randomization) and before the treatment (e.g., administering the compound of Formula (I), e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt). In some embodiments, the patient may have been treated with but discontinued a drug known to prolong the QT interval at least 7 days prior to the treatment (e.g., randomization) and before the treatment (e.g., administering the compound of Formula (I), e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt). In some embodiments, the patient may have been treated with but discontinued a drug known to prolong the QT interval at least 5 days prior to the treatment (e.g., randomization) and before the treatment (e.g., administering the compound of Formula (I), e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt). In some embodiments, the patient may have been treated with but discontinued a drug known to prolong the QT interval at least 3 days before the treatment (e.g., administering the compound of Formula (I), e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt).

[0279] In some embodiments, the patient (e.g., patient being administered the compounds of Formula (I), e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt) has not suffered from or is not suffering from any significant illness which has not resolved within four weeks prior to the treatment (e.g., administering the compound of Formula (I), e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt). In some embodiments, the patient has not suffered from or is not suffering from any significant illness which has not resolved within three weeks prior to the treatment (e.g., administering the compounds of Formula (I), e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt). In some embodiments, the patient has not suffered from or is not suffering from any significant illness which has not resolved within two weeks prior to the treatment (e.g., first administering the compound of Formula (I), e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt). In some embodiments, the patient has not suffered from or is not suffering from any significant illness which has not resolved within one week prior to the treatment (e.g., first administering the compound of Formula (I), e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt).

[0280] In some embodiments, the patient (e.g., patient being administered the compounds of Formula (I), e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt) does not eat, consume or take grapefruit or grapefruit juice from the start of treatment (administering the compound of Formula (I), e.g.,Docket No. PAT059983-PCT-SEC01 compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt) until completing the end of the treatment (EOT) visit. In some embodiments, the patient does not eat or take St. John's wort (Hypericum perforatum) 14 days before the start of treatment (administering the compound of Formula (I), e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296, or its pharmaceutically acceptable salt) and until the EOT visit.

[0281] In some embodiments, the methods include assessing the treatment (e.g., efficacy of the treatment) by measuring AF burden, AF recurrence, ventricular arrhythmias, or QTc duration using an ECG Patch, a 12-lead ECG, a mobile handheld ECG, or a photoplethysmography (PPG) wearable device. In some embodiments, the methods include assessing the treatment (e.g., efficacy of the treatment) by measuring AF burden. In some embodiments, the methods include assessing the treatment (e.g., efficacy of the treatment) by measuring (e.g., calculating, or observing) a risk of AF recurrence (e.g., time to recurrent AF episode).

[0282] In some embodiments, the methods include assessing the treatment (e.g., efficacy of the treatment) by measuring ventricular arrhythmias, or QTc duration using an ECG Patch. In some embodiments, the ECG patch can monitor and collect cardiac rhythm parameters such as AF recurrences and AF burden. In some embodiments, a change in AF burden compared with baseline may be obtained to assess the efficacy by using ECG patch monitor data. In some embodiments, time to recurrent AF and proportion of participants with recurrent AF may be obtained to assess the efficacy by using the ECG patch monitor data. In some embodiments, the cardiac rhythm safety assessments may be obtained using the ECG patch monitor data.

[0283] In some embodiments, the methods include assessing the treatment (e.g., efficacy of the treatment) with a 12-lead (12L) ECG. In some embodiments, the 12-lead ECG can assess the cardiac rhythm for AF periodically. In some embodiments, the 12-lead ECG can assess cardiac rhythms for quantifying time to recurrent AF and proportion with recurrent AF.

[0284] In some embodiments, the methods include assessing the treatment (e.g., efficacy of the treatment) using a mobile handheld ECG, or a photoplethysmography (PPG) wearable device. In some embodiments, the mobile handheld ECG may communicate with a smartphone app. In some embodiments, the mobile handheld ECG can assess the cardiac rhythm for AF periodically. In some embodiments, the mobile handheld ECG can assess time to recurrent AF and proportion with recurrent AF.

[0285] In some embodiments, the method includes assessing the treatment by measuring a level of a biomarker from a blood sample obtained from the patient. In some embodiments, the biomarker may include peripheral acetylated alpha tubulin (AAT), NT-proBNP, cardiac troponin, FGF23 or BMPIO.

[0286] In some embodiments, the methods provided herein result in an increase in peripheral AAT in the patient (e.g., serum). In some embodiments, the biomarker for theDocket No. PAT059983-PCT-SEC01 treatment is peripheral acetylated alpha tubulin (AAT) and a fold change of the peripheral AAT is measured based on a baseline AAT level (e.g., AAT level prior to the treatment or administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof). In some embodiments, the patient treated with the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or its pharmaceutically acceptable salt thereof may have increased peripheral AAT, e.g., the fold may increase by about 1.1 to 15.0-fold, or higher. In some embodiments, the fold may increase by about 1.1, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0-fold, or higher, compared to the baselineAAT level.

[0287] In certain aspects, provided herein is a method of treating AF, wherein the method comprises administering to an individual in need thereof (e.g., patient diagnosed with AF or at risk of AF) a compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or a pharmaceutically acceptable salt thereof, wherein the method results in increases in circulating acetylated alpha-tubulin (AAT) (e.g., increase by about 1.1 to 15.0 fold, or higher, compared to the baseline AAT level) and wherein the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is administered (e.g., orally administered) at a dose of about 100 to about 600 mg per day (e.g., about 50 to about 100 mg twice per day, or 50 mg or 100 mg twice per day) or at the equivalent dose for a pharmaceutically acceptable salt thereof.

[0288] In some embodiments, provided herein is a method of increasing circulating AAT in a patient (e.g., patient diagnosed with AF or at risk of AF), wherein the method comprises administering to the patient a compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or a pharmaceutically acceptable salt thereof, wherein the method increases the circulating AAT by about 1.1 to 15.0-fold, or higher, compared to the baseline AAT level, and wherein the compound is orally administered at a dose of about 100 mg to about 600 mg per day (e.g., a dose of about 50 mg BID, about 100 mg BID, or about 50 to 300 mg BID), or at the equivalent dose for the pharmaceutically acceptable salt thereof.

[0289] In some embodiments, the patient treated with the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or its pharmaceutically acceptable salt thereof may have increased circulating AAT level, e.g., the fold may increase by about 1.1- to 15.0-fold, or higher, compared to the baseline AAT level. In some embodiments, the patient treated with the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or its pharmaceutically acceptable salt thereof may have increased circulating AAT, e.g., the fold may increase byDocket No. PAT059983-PCT-SEC01 about 1.1, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0 fold, or higher, compared to the baseline AAT level.

[0290] In some embodiments, the effect of the treatment (e.g., by administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof) on target engagement from peripheral Acetylated Alpha Tubulin (AAT) may be assessed by obtaining or measuring AAT levels by flow cytometry assay and immunoassay from whole blood samples. In some embodiments, the methods provided herein result in a decrease in NT-proBNP and / or cardiac troponin in the patient (e.g., serum). In some embodiments, the biomarker for the treatment is NT-proBNP and / or cardiac troponin and a serum level of the NT-proBNP and / or cardiac troponin is measured. In some embodiments, the patient treated with the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or its pharmaceutically acceptable salt thereof may have unchanged NT-proBNP. In some embodiments, the patient treated with the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or its pharmaceutically acceptable salt thereof may have decreased NT-proBNP, e.g., the level of NT-proBNP may decrease by about 3%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% or higher. In some embodiments, the patient treated with the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or its pharmaceutically acceptable salt thereof may have unchanged cardiac troponin. In some embodiments, the patient treated with the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or its pharmaceutically acceptable salt thereof may have decreased cardiac troponin, e.g., the level of cardiac troponin may decrease by about 3%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% or higher.

[0291] In some embodiments, the methods provided herein result in an increase in NT-proBNP and / or cardiac troponin in the patient (e.g., serum). In some embodiments, the biomarker for the treatment is NT-proBNP and / or cardiac troponin and a serum level of the NT-proBNP and / or cardiac troponin is measured. In some embodiments, the patient treated with the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or its pharmaceutically acceptable salt thereof may have unchanged NT-proBNP. In some embodiments, the patient treated with the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or its pharmaceutically acceptable salt thereof may have increased NT-proBNP, e.g., the level of NT-proBNP may increase by about 1.1 , 1.3, 1.5, 1.7, 2.0, 2.3, 2.5, 2.7, 3.0, or higher, compared to the baseline NT-proBNP level. In some embodiments, the patient treated with the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, orDocket No. PAT059983-PCT-SEC01 296) or its pharmaceutically acceptable salt thereof may have unchanged cardiac troponin. In some embodiments, the patient treated with the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or its pharmaceutically acceptable salt thereof may have increased cardiac troponin, e.g., the level of cardiac troponin may increase by about 1.1 , 1.3, 1.5, 1.7, 2.0, 2.3, 2.5, 2.7, 3.0, or higher, compared to the baseline cardiac troponin.

[0292] In some embodiments, the methods provided herein result in a decrease in FGF23 and / or BMP10 in the patient (e.g., serum). In some embodiments, the biomarker is FGF23 and / or BMP10 and a serum level of the FGF23 and / or BMP10 is measured. In some embodiments, the patient treated with the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or its pharmaceutically acceptable salt thereof may have unchanged FGF23. In some embodiments, the patient treated with the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or its pharmaceutically acceptable salt thereof may have decreased FGF23, e.g., the level of FGF23 may decrease by about 3%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% or higher. In some embodiments, the patient treated with the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or its pharmaceutically acceptable salt thereof may have unchanged BMP10. In some embodiments, the patient treated with the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or its pharmaceutically acceptable salt thereof may have decreased BMP10, e.g., the level of BMP10 may decrease by about 3%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50% or higher.

[0293] In some embodiments, the methods provided herein result in an increase in FGF23 and / or BMP10 in the patient (e.g., serum). In some embodiments, the biomarker is FGF23 and / or BMP10 and a serum level of the FGF23 and / or BMP10 is measured. In some embodiments, the patient treated with the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or its pharmaceutically acceptable salt thereof may have unchanged FGF23. In some embodiments, the patient treated with the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or its pharmaceutically acceptable salt thereof may have increased FGF23, e.g., the level of FGF23 may increase by about 1.1 , 1.3, 1.5, 1.7, 2.0, 2.3, 2.5, 2.7, 3.0, or higher, compared to the baseline FGF23 level. In some embodiments, the patient treated with the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or its pharmaceutically acceptable salt thereof may have unchanged BMP10. In some embodiments, the patient treated with the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, orDocket No. PAT059983-PCT-SEC01 296) or its pharmaceutically acceptable salt thereof may have increased BMP10, e.g., the level of BMP10 may increase by about 1.1 , 1.3, 1.5, 1.7, 2.0, 2.3, 2.5, 2.7, 3.0, or higher, compared to the baseline BMP10 level.

[0294] In some embodiments, the effect of the treatment (e.g., by administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof) on pharmacodynamic and AF prognostic biomarkers may be assessed by measuring NT-proBNP, cardiac Troponin, BMP10 and / or FGF23.

[0295] In certain aspects, provided herein is a method of treating AF, wherein the method comprises administering to an individual in need thereof (e.g., patient diagnosed with AF or at risk of AF) a compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or a pharmaceutically acceptable salt thereof, wherein the method achieves reduction in AF burden (e.g., reduction by at least about 15% to 45%), and wherein the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is administered (e.g., orally administered) at a dose of about 100 to about 600 mg per day (e.g., about 50 to about 100 mg twice per day, or 50 mg or 100 mg twice per day) or at the equivalent dose for a pharmaceutically acceptable salt thereof.

[0296] In some embodiments, the AFB may be measured based on the duration (e.g., amount of time a patient or individual spends or experiences atrial fibrillation) during a predetermined or specific period. In some embodiments, the AFB can be measured using statistical model and / or hypothesis data or information from ECG patch monitors. In some embodiments, the AF burden may be defined as the amount of time spent in AF as a proportion of the analyzable monitoring time using the data or information received from ECG patch monitor. In some embodiments, the AF burden is a primary endpoint that is analyzed using a linear model applied to the logarithm-transformed data.

[0297] For example, the linear model for the primary endpoint (e.g., AF burden) may include fixed effects of treatment and of AF type (paroxysmal or persistent) and a covariate for baseline AFB. Both the baseline and post-baseline AFB will be logarithm-transformed prior to the analysis. Any zero AFB values will be set to one-half of the lowest non-zero AFB value prior to the logarithm transformation. The interaction between treatment and AF type will be explored. For a patch period to be considered as complete, at least 96 hours of analyzable data will be required for analysis. Only data from patients with at least two completed post-baseline patch periods can be included in the analysis. For patients included in the analysis, all analyzable data from the ECG patches can be used in the analysis regardless of whether the ECG patch period was considered complete or not.

[0298] In some embodiments, provided herein is a method of reducing AF burden in a patient (e.g., patient diagnosed with AF or at risk of AF), wherein the method comprisesDocket No. PAT059983-PCT-SEC01 administering to the patient a compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or a pharmaceutically acceptable salt thereof, wherein the method achieves at least about 15 to 45% reduction in the AF burden, and wherein the compound is orally administered at a dose of about 100 mg to about 600 mg per day (e.g., a dose of about 50 mg BID, about 100 mg BID, or about 50 to 300 mg BID), or at the equivalent dose for the pharmaceutically acceptable salt thereof.

[0299] In some embodiments, administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or its pharmaceutically acceptable salt may reduce AF burden in the patient in need thereof by at least 15% to 45%. In some embodiments, AF burden in the patient is reduced by at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, or 45%, over the treatment (e.g., after or during administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof). In some embodiments, AF burden in the patient is reduced by at least about 25% over the treatment (e.g., during administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof). In some embodiments, AF burden in the patient is reduced by at least about 30% over the treatment (e.g., during administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof). In some embodiments, AF burden in the patient is reduced by at least about 35% over the treatment (e.g., during administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof). In some embodiments, AF burden in the patient is reduced by at least about 40% over the treatment (e.g., during administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof). In some embodiments, AF burden in the patient is reduced by at least about 45% over the treatment (e.g., during administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof).

[0300] In some embodiments, the AF burden in the patient is reduced by at least about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, or 45%, over 6 weeks, 12 weeks, 18 weeks, 24 weeks, 30 weeks, or 36 weeks of the treatment (e.g., during administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof). In some embodiments, the AF burden in the patient is reduced by at least about 25%, 30%, 35%,Docket No. PAT059983-PCT-SEC01 40%, or 45 % over 6 weeks of the treatment (e.g., during administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof). In some embodiments, the AF burden in the patient is reduced by at least about 25%, 30%, 35%, 40%, or 45 % after 12 weeks from the administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof. In some embodiments, the AF burden in the patient is reduced by at least about 25%, 30%, 35%, 40%, or 45 % over 18 weeks of the treatment (e.g., during administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof). In some embodiments, the AF burden in the patient is reduced by at least about 25%, 30%, 35%, 40%, or 45 % after 24 weeks from the administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof. In some embodiments, the AF burden in the patient is reduced by at least about 25%, 30%, 35%, 40%, or 45 % over 30 weeks of the treatment (e.g., during administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof). In some embodiments, the AF burden in the patient is reduced by at least about 25%, 30%, 35%, 40%, or 45 % over 36 weeks of the treatment (e.g., during administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof).

[0301] In certain aspects, provided herein is a method of treating AF, wherein the method comprises administering to an individual in need thereof (e.g., patient diagnosed with AF or at risk of AF) a compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or a pharmaceutically acceptable salt thereof, wherein the method achieves reduction in a risk of recurrent AF (e.g., reduction by at least about 10% to 40%), and wherein the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is administered (e.g., orally administered) at a dose of about 100 to about 600 mg per day (e.g., about 50 to about 100 mg twice per day, or 50 mg or 100 mg twice per day) or at the equivalent dose for a pharmaceutically acceptable salt thereof.

[0302] In some embodiments, the time to first AF recurrence (e.g., time (d) from the date of the treatment (e.g., randomization) to first AF recurrence and presence (or absence) of AF recurrence after the treatment (e.g., randomization)) can be measured and analyzed using a statistical model. For example, the time to first recurrence of AF can be analyzed using a stratified Cox model, in which treatment will be used as a fixed effect and AF type (persistent vs paroxysmal AF) will be used as a stratification factor. In some embodiments, presence orDocket No. PAT059983-PCT-SEC01 absence of AF recurrence can be summarized by treatment as proportion of participants with at least one recurrence of AF. In some embodiments, the time (d) from the date of the treatment (e.g., randomization) to first AF recurrence and presence (or absence) of AF recurrence after the treatment (e.g., randomization)) can be detected by ECG patch monitor, 12-lead ECG, handheld ECG, or other protocol-approved method for ascertainment individually and as a composite.

[0303] In some embodiments, provided herein is a method of reducing a risk of recurrent AF in a patient (e.g., patient diagnosed with AF or at risk of AF), wherein the method comprises administering to the patient a compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) or a pharmaceutically acceptable salt thereof, wherein said method achieves at least about 10 to 40% reduction in the risk of recurrent AF, and wherein the compound is orally administered at a dose of about 100 mg to about 600 mg per day (e.g., a dose of about 50 mg BID, about 100 mg BID, or about 50 to 300 mg BID), at the equivalent dose for the pharmaceutically acceptable salt thereof.

[0304] In some embodiments, administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or its pharmaceutically acceptable salt may reduce a risk of recurrent AF episode in the patient in need thereof by at least 10% to 40%. In some embodiments, the risk of recurrent AF episode in the patient is reduced by at least about 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, or 40%, after the administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof. In some embodiments, the risk of recurrent AF episode in the patient is reduced by at least about 15% after the administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof. In some embodiments, the risk of recurrent AF episode in the patient is reduced by at least about 20% after the administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof. In some embodiments, the risk of recurrent AF episode in the patient is reduced by at least about 25% over the treatment (e.g., during administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof). In some embodiments, the risk of recurrent AF episode in the patient is reduced by at least about 30% over the treatment (e.g., during administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof).

[0305] In some embodiments, the risk of recurrent AF episode in the patient is reduced byDocket No. PAT059983-PCT-SEC01 at least about 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, or 40%, over 6 weeks, 12 weeks, 18 weeks, 24 weeks, 30 weeks, or 36 weeks from the administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof. In some embodiments, the risk of recurrent AF episode in the patient is reduced by at least about 15%, 20%, 25%, or 30% over 6 weeks from the administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof. In some embodiments, the risk of recurrent AF episode in the patient is reduced by at least about 15%, 20%, 25%, or 30% over 12 weeks from the administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof. In some embodiments, the risk of recurrent AF episode in the patient is reduced by at least about 15%, 20%, 25%, or 30% over 18 weeks from the administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof. In some embodiments, the risk of recurrent AF episode in the patient is reduced by at least about 15%, 20%, 25%, or 30% over 24 weeks from the administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof. In some embodiments, the risk of recurrent AF episode in the patient is reduced by at least about 15%, 20%, 25%, or 30% over 30 weeks from the administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof. In some embodiments, the risk of recurrent AF episode in the patient is reduced by at least about 15%, 20%, 25%, or 30% over 36 weeks from the administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof.

[0306] In certain aspects, provided herein is a method of treating AF, wherein the method comprises administering to an individual in need thereof (e.g., patient diagnosed with AF or at risk of AF) a compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or a pharmaceutically acceptable salt thereof, wherein the method achieves reduction in AF recurrence (e.g., as measured by time (d) from the treatment to first AF recurrence and presence (or absence) of AF recurrence), and wherein the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is administered (e.g., orally administered) at a dose of about 100 to about 600 mg per day (e.g., about 50 to about 100 mg twice per day, or 50 mg or 100 mg twice per day) or at the equivalent dose for a pharmaceutically acceptable salt thereof.

[0307] In some embodiments, the method achieves reduction in AF recurrence asDocket No. PAT059983-PCT-SEC01 measured by time (d) from the treatment to first AF recurrence and presence of AF recurrence (e.g., reduction by at least about 10% to 40%), and wherein the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is administered (e.g., orally administered) at a dose of about 100 to about 600 mg per day (e.g., about 50 to about 100 mg twice per day, or 50 mg or 100 mg twice per day) or at the equivalent dose for a pharmaceutically acceptable salt thereof.

[0308] In some embodiments, provided herein is a method of reducing AF recurrence in a patient (e.g., patient diagnosed with AF or at risk of AF), wherein the method comprises administering to the patient a compound of Formula (I) (e.g., Compound 40, 43, 239, 285, 295, or 296) or a pharmaceutically acceptable salt thereof, wherein said method achieves at least about 10 to 40% reduction in AF recurrence (e.g., as measured by time (d) from the treatment to first AF recurrence and presence of AF recurrence), and wherein the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) is orally administered at a dose of about 100 to about 600 mg per day (e.g., about 50 to about 100 mg twice per day, or 50 mg or 100 mg twice per day) or at the equivalent dose for a pharmaceutically acceptable salt thereof..

[0309] In some embodiments, administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or its pharmaceutically acceptable salt may reduce AF recurrence (e.g., as measured by time (d) from the treatment to first AF recurrence and presence of AF recurrence) in the patient in need thereof by at least 10% to 40%. In some embodiments, the AF recurrence in the patient (e.g., as measured by time (d) from the treatment to first AF recurrence and presence of AF recurrence) is reduced by at least about 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, or 40%, after the administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof. In some embodiments, the AF recurrence in the patient (e.g., as measured by time (d) from the treatment to first AF recurrence and presence of AF recurrence) is reduced by at least about 15% after the administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof. In some embodiments, the AF recurrence in the patient (e.g., as measured by time (d) from the treatment to first AF recurrence and presence of AF recurrence) is reduced by at least about 20% after the administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof. In some embodiments, the AF recurrence in the patient (e.g., as measured by time (d) from the treatment to first AF recurrence and presence of AF recurrence) is reduced by at least about 25% over the treatment (e.g., during administering the compound ofDocket No. PAT059983-PCT-SEC01 Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof). In some embodiments, the AF recurrence in the patient (e.g., as measured by time (d) from the treatment to first AF recurrence and presence of AF recurrence) is reduced by at least about 30% over the treatment (e.g., during administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof).

[0310] In some embodiments, the AF recurrence in the patient (e.g., as measured by time (d) from the treatment to first AF recurrence and presence of AF recurrence) is reduced by at least about 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, or 40%, over 6 weeks, 12 weeks, 18 weeks, 24 weeks, 30 weeks, or 36 weeks from the administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof. In some embodiments, the AF recurrence in the patient (e.g., as measured by time (d) from the treatment to first AF recurrence and presence of AF recurrence) is reduced by at least about 15%, 20%, 25%, or 30% over 6 weeks from the administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof. In some embodiments, the AF recurrence in the patient (e.g., as measured by time (d) from the treatment to first AF recurrence and presence of AF recurrence) is reduced by at least about 15%, 20%, 25%, or 30% over 12 weeks from the administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof. In some embodiments, the AF recurrence in the patient (e.g., as measured by time (d) from the treatment to first AF recurrence and presence of AF recurrence) is reduced by at least about 15%, 20%, 25%, or 30% over 18 weeks from the administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof. In some embodiments, the AF recurrence in the patient (e.g., as measured by time (d) from the treatment to first AF recurrence and presence of AF recurrence) is reduced by at least about 15%, 20%, 25%, or 30% over 24 weeks from the administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof. In some embodiments, the AF recurrence in the patient (e.g., as measured by time (d) from the treatment to first AF recurrence and presence of AF recurrence) is reduced by at least about 15%, 20%, 25%, or 30% over 30 weeks from the administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof. In some embodiments, the AF recurrence in the patient (e.g., as measured by time (d) from the treatment to first AF recurrence and presence ofDocket No. PAT059983-PCT-SEC01 AF recurrence) is reduced by at least about 15%, 20%, 25%, or 30% over 36 weeks from the administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof.

[0311] In some embodiments, the safety and tolerability of the treatment (e.g., by administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof) may be assessed by observing or measuring adverse events, vital signs, 12-lead ECG parameters (including QTcF), and / or laboratory assessments.

[0312] In some embodiments, the pharmacokinetics of the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof in the patient with AF may be assessed by measuring the plasma concentration of the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof, e.g., Ctrough (pre-dose), C2h, orC4h.

[0313] In some embodiments, the effect of the treatment (e.g., by administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof) on the frequency of AF episodes may be assessed by observing or measuring number of AF episodes measured by ECG patch monitor over analyzable ECG patch monitoring period. In some embodiments, the number of the AF episodes may decrease by at least 1 , at least 2, at least 3, or at least 5 times.

[0314] In some embodiments, the effect of the treatment (e.g., by administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof) on the duration of AF episodes may be assessed by observing or measuring duration of AF episodes measured by ECG patch monitor over analyzable ECG patch monitoring period. In some embodiments, the duration of the AF episode may decrease by at least about 10 seconds, at least about 30 seconds, at least about 1 minute, at least about 2 minutes, or at least about 3 minutes.

[0315] In some embodiments, the effect of the treatment (e.g., by administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof) on the frequency and duration of AF episodes may be assessed by observing or measuring number and duration of AF episodes measured by ECG patch monitor over analyzable ECG patch monitoring period.

[0316] In some embodiments, the effect of the treatment (e.g., by administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof) on clinically relevant AF-related endpoints may be assessed by measuring time (d) from the date of the treatment (e.g., randomization) to first cardioversion, ablation for AF, initiation of antiarrhythmic therapy, hospitalDocket No. PAT059983-PCT-SEC01 visits, both individually and as a composite, and number of cardioversions, hospital visits. In some embodiments, the time (d) from the date of the treatment (e.g., randomization) to first cardioversion, ablation for AF, initiation of antiarrhythmic therapy, hospital visits, both individually and as a composite, and number of cardioversions, hospital visits may increase by at least 6 hours, at least by 12 hours, at least 1 day, at least 2 days, at least 3 days, or at least 5 days.

[0317] In some embodiments, the effect of the treatment (e.g., by administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof) on supraventricular and ventricular arrhythmia risk may be assessed by measuring number of episodes of supraventricular arrhythmia, ventricular arrhythmia, premature atrial contractions, and / or premature ventricular contractions, all measured by the ECG patch monitor. In some embodiments, the number of the episodes of supraventricular arrhythmia, ventricular arrhythmia, premature atrial contractions, and / or premature ventricular contractions may decrease by at least 1 , at least 2, at least 3, or at least 5 times.

[0318] In some embodiments, the effect of the treatment (e.g., by administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof) on quality of life may be assessed by obtaining or measuring Atrial Fibrillation Effect on Quality of Life (AFEQT) score and European Heart Rhythm Association (EHRA) score.

[0319] The AFEQT evaluates health-related quality of life (HRQoL) and provides an overall score; plus scores for symptoms, daily activities, treatment concerns, and treatment satisfaction. For example, the AFEQT includes 20 questions on 7-point Likert scale and the change in AFEQT scores relative to baseline treatment will be assessed as a secondary endpoint. The questions may cover symptoms experienced, daily activities affected, concerns about treatment, satisfaction with the effectiveness of treatment, or the like. The score can be calculated by averaging the responses to the questions and a higher score can indicate that the patient is experiencing a better quality of life despite the presence of AF.

[0320] The EHRA symptom score classifies the severity of AF-related symptoms during the time when the participant feels they are in AF (Kirchhof et al 2007). For example, patients (e.g., being administered to or treated with the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof) may be classified based on their symptoms into one of four categories outlines below.• EHRA I: No symptoms• EHRA II: Mild symptoms, Normal daily activity not affected• EHRA III: Severe symptoms, Normal daily activity affectedDocket No. PAT059983-PCT-SEC01 • EHRA IV: Disabling symptoms, Normal daily activity discontinued

[0321] In some embodiments, the efficacy of the treatment (e.g., by administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof) may be assessed using European Heart Rhythm Association (EHRA) symptom scores. In some embodiments, any change in EHRA scores can indicate improvement of the AF symptoms, e.g., from higher EHRA symptom score to lower EHRA symptom score. In some embodiments, the patient may have EHRA symptom score of I or II over or after the treatment. In some embodiments, the patient may have EHRA symptom score of I or II over or after the treatment (e.g., by administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof). In some embodiments, the patient may have EHRA symptom score of I over or after the treatment (e.g., by administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof). In some embodiments, the patient may have EHRA symptom score of II over or after the treatment (e.g., by administering the compound of Formula (I) (e.g., compound of Table A or Table B, such as Compound 40, 43, 239, 285, 295, or 296) or the pharmaceutically acceptable salt thereof).

[0322] In certain aspects, the efficacy of the treatments (e.g., reducing or preventing each AF burden, recurrence, and ventricular arrhythmias) may be assessed or evaluated by adjusting, combining, selecting and / or deselecting various values obtained using the different techniques (e.g., an ECG Patch, a 12-lead ECG, a mobile handheld ECG, a photoplethysmography (PPG) wearable device, or EHRA symptom score) as described above. In some embodiments, each AF burden, recurrence, and ventricular arrhythmias may be independently measured, calculated or evaluated in combination of various values obtained using the different techniques (e.g., an ECG Patch, a 12-lead ECG, a mobile handheld ECG, a photoplethysmography (PPG) wearable device, or EHRA symptom score) as described above. In some embodiments, each AF burden, recurrence, and ventricular arrhythmias may be independently measured, calculated or evaluated independently or dominantly based on a single assessment aside from the other values obtained using the different techniques as described above.

[0323] In some embodiments, a supplementary analysis may be performed on monthly AFB. In some embodiments, monthly AFB may be calculated based on the ECG patch monitoring associated with the particular month.Embodiments

[0324] Embodiment 1 : A method of treating atrial fibrillation (AF) in a patient in need thereof,Docket No. PAT059983-PCT-SEC01 the method comprising administering to the patient a compound of Formula (I)or a pharmaceutically acceptable salt thereof,wherein:Li, L2or L3are each independently a bond or -(Ci-C2alkylene)-;Ri is -CX2H or -CX3;R2is -NRARB, -ORC, , wherein at leastN <one H of or may be substituted with -X, -OH, -O(Ci-C4alkyl), -NRDRE, -(Ci-C4alkyl), -CF3, -CF2H, -CN, -aryl, -heteroaryl, -(Ci- C4alkyl)-aryl or -(Ci-C4alkyl)-heteroaryl, wherein at least one H of the -aryl, - heteroaryl, -(Ci-C4alkyl)-aryl or -(Ci-C4alkyl)-heteroaryl may be substituted with -X, - OH, -CF3or -CF2H;R3is -H, -(Ci-C4alkyl), -(C C4alkyl)-O-(Ci-C4alkyl), -(Ci-C4alkyl)-C(=O)-O-(Ci-C4alkyl), -(C3-C7cycloalkyl), -(C2-C6cycloheteroalkyl), -aryl, -heteroaryl, -adamantyl,, wherein:at least one H of -(Ci-C4alkyl) may be substituted with -X or -OH,at least one H of -aryl or -heteroaryl each independently may be substituted with -X, - OH, -O(Ci-C4alkyl), -OCF3, -O-aryl, -NRDRE, -(Ci-C4alkyl), -CF3, -CF2H, -C(=O)- (Ci-C4alkyl), -C(=O)-O(Ci-C4alkyl), -C(=O)-NRDRE, -S(=O)2-(CrC4alkyl), aryl,heteroaryl,, wherein atDocket No. PAT059983-PCT-SEC01least oneH of may be substituted with -X, -(C1-C4 alkyl), - NRDRE, -CF3or-CF2H, andat least one H of -(C3-C7cycloalkyl), -(C2-C6cycloheteroalkyl), adamantyl,7,. Z,<, x J A i^6 or ^9 may be each independently substituted with - X, -OH or -(Ci-C4alkyl);Y1, Y2and Y4are each independently -CH2-, -NRF-, -O-, -C(=O)- or -S(=O)2-;Y3is -CH- or -N-;Z1 to Z4are each independently N or CRZ, wherein at least three of Z1 to Z4may not be simultaneously N, and Rzis -H, -X or -O(Ci-C4 alkyl);Z5and Z6are each independently -CH2- or-O-;Z7and Z8are each independently =CH- or =N-;Zg is -NRG- or-S-;RAand RBare each independently -H, -(C1-C4 alkyl), -(C1-C4 alkyl)-OH, -(C1-C4 alkyl)- NRDRE, -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl, -(C1-C4 aryl)-heteroaryl, -(C3-C7>'"U< .\ / X >I Qcycloalkyl), -(C2-C6heterocycloalkyl) ors$ , wherein:at least one H of the -(C1-C4 alkyl), -(C1-C4 alkyl)-OH or -(Ci-C4alkyl)-NRDREmay be substituted with -X,at least one H of the -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl, -(C1-C4 alkyl)-heteroaryl, - (C3-C7cycloalkyl) or-(C2-C6heterocycloalkyl) may be substituted with -X, -OH, - O(Ci-C4alkyl), -(C1-C4 alkyl), -CF3, -CF2H or-CN, andv / H\ , ,b .at least oneH of 's may be substituted with n-X, -OH, -O(Cr C4alkyl), -(C1-C4 alkyl), -CF3, -CF2H, -CN, -(C2-C6heterocycloalkyl), -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or -heteroaryl-(Ci-C4alkyl);Rcis -(C1-C4 alkyl), -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or -(Ci-C4alkyl)-heteroaryl, wherein at least one H of -(C1-C4 alkyl) may be substituted with -X or -OH, at leastDocket No. PAT059983-PCT-SEC01 one H of -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or -(Ci-C4alkyl)-heteroaryl may be substituted with -X, -OH, -CF3or -CF2H;RDand REare each independently -H, -(C1-C4 alkyl), -aryl or -(Ci-C4alkyl)-aryl, wherein, at least one H of -(Ci-C4alkyl) may be substituted with -X or -OH, at least one H of - aryl or -(C1-C4 alkyl)-aryl may be substituted with -X, -OH, -CF3or -CF2H;RFis -H, -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(C1-C4 alkyl)-O-(Ci-C4alkyl), -C(=O)-(Ci-C4alkyl), -C(=O)-O-(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O-(Ci-C4alkyl), -(C1-C4 alkyl)- NRDRE, -S(=O)2-(Ci-C4alkyl), -aryl, -(Ci-C4alkyl)-aryl, -(C2-C4alkenyl)-aryl, - heteroaryl, -(C1-C4 alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -(C2-C6heterocycloalkyl) or -(C1-C4 alkyl)-C(=O)-(C2-C6heterocycloalkyl), wherein:at least one H of -(C1-C4 alkyl), -(C1-C4 alkyl)-OH, -(Ci-C4alkyl)-O-(Ci-C4 alkyl), -C(=O)-(Ci-C4alkyl), -C(=O)-O(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)- O(Ci-C4alkyl), -(Ci-C4alkyl)-NRDREor -S(=O)2-(Ci-C4alkyl) may be substituted with -X, andat least one H of -aryl, -(Ci-C4alkyl)-aryl, -(C2-C4alkenyl)-aryl, -heteroaryl, - (Ci-C4alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -C2-C6heterocycloalkyl or -(Ci-C4alkyl)-C(=0)-(C2-C6heterocycloalkyl) may be substituted with - X, -OH, -CF3or-CF2H;RGis -H or -(C1-C4 alkyl);Q is -O- or a bond;isasingle bond or double bond, provided that, “ “ ” is a double bond, Y1 is =CH-;a to e are each independently an integer of 0, 1 , 2, 3 or 4, provided that, a and b may not be simultaneously 0, and c and d may not be simultaneously 0; andX is each independently F, Cl, Br or I,wherein the compound of Formula (I) is administered at a dose of about 100 to about 600 mg per day or at the equivalent dose for a pharmaceutically acceptable salt thereof.

[0325] Embodiment 2: The method according to Embodiment 1 , wherein, in the compound of Formula (I):Li, L2or L3are each independently a bond or -(Ci-C2alkylene)-;R1 is -CX2H or -CX3;Docket No. PAT059983-PCT-SEC01OH, -NRDRE, -(C1-C4 alkyl);Rs is -(C1-C4 alkyl), -(C3-C7 cycloalkyl), -aryl, -heteroaryl, -adamantyl,, wherein:at least one H of -aryl or -heteroaryl may be each independently substituted with -X, -O(Ci-C4alkyl), -OCF3, -O-aryl, -NRDRE, -(C1-C4 alkyl), -CF3, -S(=O)2-(Ci-'J b3 , wherein at least one H of may be substituted with -NRDREor -(C1-C4 alkyl); and / Zg r ' p / / Zr ’-^ r^pzX iiat least oneH of \ ^6 X J or A B maybe each independently substituted with -(C1-C4 alkyl);Y1, Y2and Y4are each independently -CH2-, -NRF-, -O-, -C(=O)- or -S(=O)2-;Y3is -CH- or -N-;Z1 to Z4is each independently N or CRZ, wherein at least three of Z1 to Z4may not be simultaneously N, and Rzis -H, -X or -O(Ci-C4alkyl);Z5and Z6are each independently -CH2- or-O-;Z7and Z8are each independently =CH- or =N-;Zg is -NRG- or-S-;Docket No. PAT059983-PCT-SEC01 RAand RBare each independently -H, -(C1-C4 alkyl), -(Ci-C4alkyl)-OH, -(C1-C4 alkyl)-NRDRE, -aryl, -(C1-C4 alkyl)-aryl, -(C3-C7 cycloalkyl)or wherein / "'Na< X+Je] b ?at least oneH ofb? may be substituted with -X, -(C1-C4 alkyl), -CF3, -(C2-C6heterocycloalkyl), -(C1-C4 alkyl)-aryl, -heteroaryl or heteroaryl-(Ci-C4alkyl); Rcis -(C1-C4 alkyl) or -aryl;RDand REare each independently -H, -(C1-C4 alkyl) or -(Ci-C4alkyl)-aryl;RFis -H, -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(C1-C4 alkyl)-O-(Ci-C4alkyl), -C(=O)-(Ci- C4alkyl), -C(=O)-O(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O(Ci-C4alkyl), -(Ci-C4alkyl)- NRDRE, -S(=O)2-(Ci-C4alkyl), -aryl, -(Ci-C4alkyl)-aryl, -(C2-C4alkenyl)-aryl, - heteroaryl, -(C1-C4 alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -(C2-C6heterocycloalkyl) or -(C1-C4 alkyl)-C(=O)-(C2-C6heterocycloalkyl), wherein at least one H of -(Ci-C4alkyl) or-C(=0)-0(Ci-C4alkyl) may be substituted with -X, and at least one H of -aryl may be substituted with -X};RGis -(C1-C4 alkyl);Q is -O- or a bond;"""""""""""" is a single bond or a double bond, provided that """""""is a double bond, Y1 is - CH-;a to e are each independently an integer of 0, 1 , 2, 3 or 4, provided that a and b may not be simultaneously 0, and c and d may not be simultaneously 0; andX is each independently F, Cl, Br or I.

[0326] Embodiment 3: The method according to Embodiment 1 or 2, wherein the compound of Formula I has the structure of Formula (la):or a pharmaceutically acceptable salt thereof,wherein:Docket No. PAT059983-PCT-SEC01Rais -aryl, wherein, at least one H of -aryl may be each independently substituted with - X;Yi is -O- or -S(=O)2-;Zi is N or CRZ, wherein, Rzis -X;a and b are each independently an integer of 0, 1 , 2, 3 or 4, wherein, a and b may not be simultaneously 0; andX is each independently F, Cl, Br or I.

[0327] Embodiment 4: The method according to Embodiment 3, wherein, in the compound of Formula (la):R3is -phenyl, wherein at least one H of -phenyl each independently is substituted with -F or -Cl;Yi is -O- or -S(=O)2-; andZi is N or CF.

[0328] Embodiment 5: The method according to Embodiment 1 , wherein the compound of Formula (I) is one selected from the compounds in Table A.

[0329] Embodiment 6: The method according to Embodiment 1 , wherein the compound of Formula (I) is selected from the group consisting of:Docket No. PAT059983-PCT-SEC01

[0330] Embodiment 7: The method according to any one of Embodiments 1 to 6, wherein the AF is paroxysmal atrial fibrillation, persistent atrial fibrillation, long-term persistent atrial fibrillation, valvular atrial fibrillation, non-valvular atrial fibrillation, or non-permanent atrial fibrillation.

[0331] Embodiment 8: The method according to any one of Embodiments 1 to 7, wherein the compound of Formula (I), ora pharmaceutically acceptable salt thereof, is administered orally.

[0332] Embodiment 9: The method according to any one of Embodiments 1 to 8, wherein the compound of Formula (I) or a pharmaceutically acceptable salt thereof, is administered in a form of tablet or capsule.

[0333] Embodiment 10: The method according to any one of Embodiments 1 to 9, wherein the compound of Formula (I) or a pharmaceutically acceptable salt thereof, is administered twice daily (BID).

[0334] Embodiment 11 : The method according to any one of Embodiments 1 to 10, wherein the compound of Formula (I) is administered at a dose of about 50 mg to about 300 mg, about 50 mg to about 200 mg, about 100 mg to 300 mg, about 50 mg to about 100 mg, about 100 mg to about 200 mg, or about 200 mg to about 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID).

[0335] Embodiment 12: The method according to any one of Embodiments 1 to 11 , wherein the compound of Formula (I) is administered at a dose of about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, or about 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID).

[0336] Embodiment 13: The method according to any one of Embodiments 1 to 12, wherein the compound of Formula (I) is administered at a dose of 50 mg, or 100 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID).

[0337] Embodiment 14: The method according to any one of Embodiments 1 to 13, wherein the compound of Formula (I) or the pharmaceutically acceptable salt thereof is administered for at least 6 weeks, at least 12 weeks, at least 18 weeks, at least 24 weeks, at least 30 weeks, or at least 36 weeks.

[0338] Embodiment 15: The method according to any one of Embodiments 1 to 14, wherein the patient is a human patient.Docket No. PAT059983-PCT-SEC01

[0339] Embodiment 16: The method according to any one of Embodiments 1 to 15, wherein the patient is male orfemale 18 years old or older.

[0340] Embodiment 17: The method according to any one of Embodiments 1 to 16, wherein the patient has a history of at least two AF episodes.

[0341] Embodiment 18: The method according to Embodiment 17, wherein at least one of the AF episodes occur within the last 12 months prior to the treatment and documented by 12-lead ECG, Holter, or any other ECG recording method, as confirmed by patient’s medical record.

[0342] Embodiment 19: The method according to any one of Embodiments 1 to 18, wherein the patient has one or more of the following conditions:i. atrial fibrillation burden (AFB) of 1% or higher on a local ambulatory Holter, mobile cardiac telemetry, ECG patch monitor, or other ambulatory electrocardiographic monitor within the last 12 months prior to the treatment ii. CHA2DS2-VASc score of 2 or higher in males, 3 or higher in femalesHi. Stable heart failure or with New York Heart Association class I or II symptoms iv. NT-proBNP level of 300 pg / mL or higher on a local lab test within the last 12 months prior to the treatment.

[0343] Embodiment 20: The method according to any one of Embodiments 1 to 19, wherein the patient is on guideline-directed stroke prevention treatment, as confirmed by the patient’s medical record.

[0344] Embodiment 21 : The method according to any one of Embodiments 1 to 20, wherein the patient has a body mass index (BMI) is about or greater than 18.

[0345] Embodiment 22: The method according to any one of Embodiments 1 to 21 , wherein the patient has sinus rhythm documented by 12-lead ECG before administering the compound of Formula (I) or the pharmaceutically acceptable salt thereof.

[0346] Embodiment 23: The method according to any one of Embodiments 1 to 22, wherein if the patient has persistent AF, the patient is cardioverted before administering the compound of Formula (I) or the pharmaceutically acceptable salt thereof.

[0347] Embodiment 24: The method according to any one of Embodiments 1 to 23, wherein the patient does not have one or more of the following conditions:(i) Permanent AF;(ii) Ongoing reversible cause of AF selected from hyperthyroidism, myocarditis, alcohol use, sepsis- or infection-related AF, surgery-related AF, and pulmonary embolism;(iii) Ongoing use of antiarrhythmic therapy;(iv) History of an AF ablation procedure within the last 6 months without a recurrence of AF at least 2 or more months after the ablation;Docket No. PAT059983-PCT-SEC01 (v) Implanted pacemaker, defibrillator, or cardiac monitor;(vi) Infiltrative or hypertrophic cardiomyopathy;(vii) Current decompensated heart failure or hospitalization for heart failure within 3 months prior to the treatment;(viii) Left ventricular ejection fraction of 40% or less documented within the last 12 months prior to the treatment, or during the treatment period;(ix) Severe valvular disease or planned valvular intervention during study;(x) Stroke within the last 6 months, or other neurologic or psychiatric conditions likely to affect study compliance;(xi) Cardiac surgery within the last 6 months;(xii) Unstable angina, myocardial infarction, coronary angioplasty within the last 6 months; and(xiii) Known allergic reactions to adhesives or hydrogels.

[0348] Embodiment 25: The method according to any one of Embodiments 1 to 24, wherein the patient does not have known history of or current clinically significant ventricular arrhythmias, personal history of an inherited arrhythmia syndrome, long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, idiopathic ventricular fibrillation, or arrhythmogenic cardiomyopathy.

[0349] Embodiment 26: The method according to any one of Embodiments 1 to 25, wherein the patient does not have:(i) history of or current significant ECG abnormalities that indicate a high safety risk for participants in the study, or(ii) HR < 50 bpm, QTcF > 450 msec (males) or QTcF > 460 msec (females).

[0350] Embodiment 27: The method according to any one of Embodiments 1 to 26, wherein the patient does not have a history of drug abuse or unhealthy alcohol use within 12 months prior to the treatment.

[0351] Embodiment 28: The method according to any one of Embodiments 1 to 27, wherein the patient is not (a) pregnant, (b) a nursing or lactating woman, or (c) a woman having childbearing potential unless the patient is using effective methods of contraception during the treatment.

[0352] Embodiment 29: The method according to any one of Embodiments 1 to 28, wherein the patient does not have Liver disease or liver injury indicated by abnormal liver function tests.

[0353] Embodiment 30: The method according to any one of Embodiments 1 to 29, wherein the patient does not have a history or presence of impaired renal function.

[0354] Embodiment 31 : The method according to any one of Embodiments 1 to 30,Docket No. PAT059983-PCT-SEC01 wherein, just prior to administering, the patient has not used other drugs or therapies within 5 half-lives of the other drugs or therapies on the day of administering, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer.

[0355] Embodiment 32: The method according to any one of Embodiments 1 to 31 , wherein the patient has not been treated with any apalutamide or III anti-arrhythmic drug.

[0356] Embodiment 33: The method according to any one of Embodiments 1 to 32, wherein the patient has not been treated with amiodarone.

[0357] Embodiment 34: The method according to any one of Embodiments 1 to 33, wherein, prior to administering, the patient has not been in ongoing treatment with a drug that is a CYP3A4 inhibitor.

[0358] Embodiment 35: The method according to any one of Embodiments 1 to 34, wherein prior to administering, the patient has not been in ongoing treatment with a drug that is a CYP3A4 inducer.

[0359] Embodiment 36: The method according to any one of Embodiments 1 to 35, wherein the patient has not been treated with one or more selected from boceprevir, ceritinib, clarithromycin, cobicistat, conivaptan, danoprevir / ritonavir, elvitegravir / ritonavir, grapefruit or grapefruit juice, idelalisib, indinavir, indinavir, ritonavir, itraconazole, josamycin, ketoconazole, lopinavir / ritonavir, mibefradil, mifepristone, nefazodone, nelfinavir, ombitasvir / paritaprevir / dasabuvir / ritonavir (Viekira Pak), posaconazole, ribociclib, ritonavir, saquinavir, saquinavir / ritonavir, telaprevir, telithromycin, tipranavir / ritonavir, troleandomycin, tucatinib, voriconazole, aprepitant, amprenavir, atazanavir, atazanavir / ritonavir, casopitant, cimetidine, ciprofloxacin, crizotinib, darunavir, darunavir / ritonavir, diltiazem, dronedarone, duvelisib, erythromycin, faldaprevir, fedratinib, fluconazole, imatinib, isavuconazole, istradefylline, lefamulin, letermovir, Magnolia vine (Schisandra sphenanthera), netupitant, nilotinib, ravuconazole, tofisopam, verapamil, voxelotor, apalutamide, avasimibe, carbamazepine, enzalutamide, ivosidenib, lumacaftor, mitotane, phenytoin, rifampicin, rifapentine, and St. John’s wort (Hypericum perforatum).

[0360] Embodiment 37: The method according to any one of Embodiments 1 to 36, wherein the patient has not been treated with a drug known to prolong the QT interval.

[0361] Embodiment 38: The method according to any one of Embodiments 1 to 37, wherein the patient does not have significant illness which has not resolved within two weeks prior to administering the compound of Formula (I) or the pharmaceutically acceptable salt thereof.

[0362] Embodiment 39: The method according to any one of Embodiments 1 to 38, wherein the method further comprises assessing the treatment by measuring AF burden, time to recurrent AF, presence or absence of AF recurrence, ventricular arrhythmias, or QTc duration using an ECG Patch, a 12-lead ECG, a mobile handheld ECG, or a photoplethysmography (PPG) wearable device.Docket No. PAT059983-PCT-SEC01

[0363] Embodiment 40: The method according to any one of Embodiments 1 to 39, wherein the method further comprises assessing the treatment by measuring a level of a biomarker from a blood sample obtained from the patient.

[0364] Embodiment 41 : The method according to Embodiment 40, wherein the biomarker is peripheral acetylated alpha tubulin (AAT) and a fold change of the peripheral AAT is measured based on a baseline AAT level measured prior to the administering the compound of Formula (I) or the pharmaceutically acceptable salt thereof .

[0365] Embodiment 42: The method according to Embodiment 40 or 41 , wherein the biomarker is NT-proBNP and / or cardiac troponin and a serum level of the NT-proBNP and / or cardiac troponin is measured.

[0366] Embodiment 43: The method according to any one of Embodiments 40 to 42, wherein the biomarker is FGF23 and / or BMP10 and a serum level of the FGF23 and / or BMP10 is measured.

[0367] Embodiment 44: The method according to any one of Embodiments 1 to 43, wherein the method of treating AF results in increases in the peripheral AAT in the patient by about 1.1 to 15.0 fold compared to a baseline AAT level measured prior to the administering the compound of Formula (I) or the pharmaceutically acceptable salt thereof.

[0368] Embodiment 45: The method according to any one of Embodiments 1 to 44, wherein AF burden in the patient measured by the ECG patch is reduced by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 35%, at least about 40%, or by at least about 45 % after administering the compound of Formula (I) or the pharmaceutically acceptable salt thereof.

[0369] Embodiment 46: The method according to any one of Embodiments 1 to 45, wherein AF recurrence in the patient is reduced by at least about 10%, at least about 15%, at least about 20%, by at least about 25%, or by at least about 30% after administering the compound of Formula (I), or the pharmaceutically acceptable salt thereof wherein the AF recurrence is measured by a time (d) from the date of the treatment to the time of a first recurrent AF episode.

[0370] Embodiment 47: A method of inhibiting or reducing histone deacetylase 6 (HDAC6) activity in a patient in need thereof, the method comprising administering to the patient a compound of Formula (I),or a pharmaceutically acceptable salt thereof,wherein:Docket No. PAT059983-PCT-SEC01 Li, L2or L3are each independently a bond or -(Ci-C2alkylene)-;Ri is -CX2H or -CX3;R2is -NRARB, -ORC, , wherein at leastone H of may be substituted with -X, -OH, -O(Ci-C4alkyl), -NRDRE, -(C1-C4 alkyl), -CF3, -CF2H, -CN, -aryl, -heteroaryl, -(C1- C4alkyl)-aryl or -(Ci-C4alkyl)-heteroaryl, wherein at least one H of the -aryl, - heteroaryl, -(C1-C4 alkyl)-aryl or -(Ci-C4alkyl)-heteroaryl may be substituted with -X, - OH, -CF3or -CF2H;R3is -H, -(C1-C4 alkyl), -(C1-C4 alkyl)-O-(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O-(Ci-C4alkyl), -(C3-C7cycloalkyl), -(C2-C6cycloheteroalkyl), -aryl, -heteroaryl, -adamantyl,ZrA or A , wherein:at least one H of -(C1-C4 alkyl) may be substituted with -X or -OH,at least one H of -aryl or -heteroaryl each independently may be substituted with -X, - OH, -O(Ci-C4alkyl), -OCF3, -O-aryl, -NRDRE, -(C1-C4 alkyl), -CF3, -CF2H, -C(=O)- (C1-C4 alkyl), -C(=O)-O(Ci-C4alkyl), -C(=O)-NRDRE, -S(=O)2-(Ci-C4alkyl), aryl,,aZgQ--j- heteroaryl,or b s , wherein at aleast one Hof be substituted with -X, -(C1-C4 alkyl), - NRDRE, -CF3or-CF2H, andat least one H of -(C3-C7cycloalkyl), -(C2-C6cycloheteroalkyl), adamantyl,A- ,Z7"- li ^8*•6 or s may be each independently substituted with - X, -OH or -(Ci-C4alkyl);Y1, Y2and Y4are each independently -CH2-, -NRF-, -O-, -C(=O)- or -S(=O)2-;Docket No. PAT059983-PCT-SEC01 Y3is -CH- or -N-;Z1 to Z4are each independently N or CRZ, wherein at least three of Z1 to Z4may not be simultaneously N, and Rzis -H, -X or -O(Ci-C4alkyl);Z5and Z6are each independently -CH2- or-O-;Z7and Z8are each independently =CH- or =N-;Zg is -NRG- or-S-;RAand RBare each independently -H, -(C1-C4 alkyl), -(C1-C4 alkyl)-OH, -(C1-C4 alkyl)- NRDRE, -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl, -(C1-C4 aryl)-heteroaryl, -(C3-C7cycloalkyl), -(C2-C6heterocycloalkyl)or - , wherein:at least one H of the -(C1-C4 alkyl), -(C1-C4 alkyl)-OH or -(Ci-C4 alkyl)-NRDREmay be substituted with -X,at least one H of the -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl, -(C1-C4 alkyl)-heteroaryl, - (C3-C7cycloalkyl) or-(C2-C3heterocycloalkyl) may be substituted with -X, -OH, - O(Ci-C4alkyl), -(C1-C4 alkyl), -CF3, -CF2H or-CN, and'iaY4 eat least oneH of b may be substituted with n-X, -OH, -O(Cr C4 alkyl), -(C1-C4 alkyl), -CF3, -CF2H, -CN, -(C2-Ce heterocycloalkyl), -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or -heteroaryl-(Ci-C4alkyl);Rcis -(C1-C4 alkyl), -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or -(Ci-C4alkyl)-heteroaryl, wherein at least one H of -(C1-C4 alkyl) may be substituted with -X or -OH, at least one H of -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or -(Ci-C4 alkyl)-heteroaryl may be substituted with -X, -OH, -CF3or -CF2H;RDand REare each independently -H, -(C1-C4 alkyl), -aryl or -(Ci-C4alkyl)-aryl, wherein, at least one H of -(Ci-C4 alkyl) may be substituted with -X or -OH, at least one H of - aryl or -(C1-C4 alkyl)-aryl may be substituted with -X, -OH, -CF3or -CF2H;RFis -H, -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(C1-C4 alkyl)-O-(Ci-C4alkyl), -C(=O)-(Ci-C4alkyl), -C(=O)-O-(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O-(Ci-C4alkyl), -(C1-C4 alkyl)- NRDRE, -S(=O)2-(Ci-C4alkyl), -aryl, -(Ci-C4alkyl)-aryl, -(C2-C4alkenyl)-aryl, - heteroaryl, -(C1-C4 alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -(C2-C6heterocycloalkyl) or -(C1-C4 alkyl)-C(=O)-(C2-C6heterocycloalkyl), wherein:at least one H of -(Ci-C6alkyl), -(C1-C4 alkyl)-OH, -(Ci-C4alkyl)-O-(Ci-C4 alkyl), - C(=O)-(Ci-C4alkyl), -C(=O)-O-(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O-(Ci-C4Docket No. PAT059983-PCT-SEC01 alkyl), -(Ci-C4alkyl)-NRDREor -S(=O)2-(Ci-C4alkyl) may be substituted with - X, andat least one H of -aryl, -(Ci-C4alkyl)-aryl, -(C2-C4alkenyl)-aryl, -heteroaryl, -(C C4alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -C2-C6heterocycloalkyl or-(Cr C4alkyl)-C(=0)-(C2-C6heterocycloalkyl) may be substituted with -X, -OH, -CF3or -CF2H;RGis -H or -(Ci-C4alkyl);Q is -O- or a bond;> is a single bond or double bond, provided that,>is a double bond, Yi is =CH-;a to e are each independently an integer of 0, 1 , 2, 3 or 4, provided that, a and b may not be simultaneously 0, and c and d may not be simultaneously 0; andX is each independently F, Cl, Br or I,wherein the compound of Formula (I) is administered at a dose of about 100 to about 600 mg per day or at the equivalent dose for a pharmaceutically acceptable salt thereof.

[0371] Embodiment 48: A method of reducing atrial fibrillation (AF) burden in a patient in need thereof, the method comprising administering to the patient a compound of Formula (I)or a pharmaceutically acceptable salt thereof,wherein:Li, L2or L3are each independently a bond or -(Ci-C2alkylene)-;Ri is -CX2H or -CX3;-OH, -O(Ci-C4alkyl), -NRDRE, -(Ci-C4alkyl), -CF3, -CF2H, -CN, -aryl, -heteroaryl, -(Ci- C4alkyl)-aryl or -(Ci-C4alkyl)-heteroaryl, wherein at least one H of the -aryl, -Docket No. PAT059983-PCT-SEC01 heteroaryl, -(C1-C4 alkyl)-aryl or -(Ci-C4alkyl)-heteroaryl may be substituted with -X, - OH, -CF3or -CF2H;R3is -H, -(C1-C4 alkyl), -(C C4alkyl)-O-(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O-(Ci-C4alkyl), -(C3-C7cycloalkyl), -(C2-C6cycloheteroalkyl), -aryl, -heteroaryl, -adamantyl,at least one H of -(C1-C4 alkyl) may be substituted with -X or -OH,at least one H of -aryl or -heteroaryl each independently may be substituted with -X, - OH, -O(Ci-C4alkyl), -OCF3, -O-aryl, -NRDRE, -(C1-C4 alkyl), -CF3, -CF2H, -C(=O)- (C1-C4 alkyl), -C(=O)-O(Ci-C4alkyl), -C(=O)-NRDRE, -S(=O)2-(Ci-C4alkyl), aryl,least one H of may be substituted with -X, -(C1-C4 alkyl), - NRDRE, -CF3or-CF2H, andat least one H of -(C3-C7cycloalkyl), -(C2-C6cycloheteroalkyl), adamantyl,may be each independently substituted with - X, -OH or -(Ci-C4alkyl);Y1, Y2and Y4are each independently -CH2-, -NRF-, -O-, -C(=O)- or -S(=O)2-;Y3is -CH- or -N-;Z1 to Z4are each independently N or CRZ, wherein at least three of Z1 to Z4may not be simultaneously N, and Rzis -H, -X or -O(Ci-C4alkyl);Z5 and Ze are each independently -CH2- or-O-;Z7and Z8are each independently =CH- or =N-;Zg is -NRG- or-S-;RAand RBare each independently -H, -(C1-C4 alkyl), -(C1-C4 alkyl)-OH, -(C1-C4 alkyl)- NRDRE, -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl, -(C1-C4 aryl)-heteroaryl, -(C3-C7 / A , ,¥4,Y3Q-<- cycloalkyl), -(C2-C6heterocycloalkyl) or1 &3 , wherein:Docket No. PAT059983-PCT-SEC01 at least one H of the -(C1-C4 alkyl), -(C1-C4 alkyl)-OH or -(Ci-C4alkyl)-NRDREmay be substituted with -X,at least one H of the -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl, -(C1-C4 alkyl)-heteroaryl, - (C3-C7cycloalkyl) or-(C2-C6heterocycloalkyl) may be substituted with -X, -OH, - O(Ci-C4alkyl), -(C1-C4 alkyl), -CF3, -CF2H or-CN, andJZXi.aat least oneH of may be substituted with n-X, -OH, -O(Cr C4alkyl), -(C1-C4 alkyl), -CF3, -CF2H, -CN, -(C2-C6heterocycloalkyl), -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or -heteroaryl-(Ci-C4alkyl);Rcis -(C1-C4 alkyl), -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or -(Ci-C4alkyl)-heteroaryl, wherein at least one H of -(C1-C4 alkyl) may be substituted with -X or -OH, at least one H of -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or -(Ci-C4alkyl)-heteroaryl may be substituted with -X, -OH, -CF3or -CF2H;RDand REare each independently -H, -(C1-C4 alkyl), -aryl or -(Ci-C4 alkyl)-aryl, wherein, at least one H of -(Ci-C4alkyl) may be substituted with -X or -OH, at least one H of - aryl or -(C1-C4 alkyl)-aryl may be substituted with -X, -OH, -CF3or -CF2H;RFis -H, -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(C1-C4 alkyl)-O-(Ci-C4alkyl), -C(=O)-(Ci-C4alkyl), -C(=O)-O-(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O-(Ci-C4alkyl), -(C1-C4 alkyl)- NRDRE, -S(=O)2-(Ci-C4alkyl), -aryl, -(Ci-C4alkyl)-aryl, -(C2-C4alkenyl)-aryl, - heteroaryl, -(C1-C4 alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -(C2-C6heterocycloalkyl) or -(C1-C4 alkyl)-C(=O)-(C2-C6 heterocycloalkyl), wherein:at least one H of -(Ci-C6alkyl), -(C1-C4 alkyl)-OH, -(Ci-C4alkyl)-O-(Ci-C4 alkyl), - C(=O)-(Ci-C4alkyl), -C(=O)-O-(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O-(Ci-C4alkyl), -(Ci-C4alkyl)-NRDREor -S(=O)2-(Ci-C4alkyl) may be substituted with - X, andat least one H of -aryl, -(Ci-C4alkyl)-aryl, -(C2-C4alkenyl)-aryl, -heteroaryl, -(C C4alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -C2-C6heterocycloalkyl or-(Cr C4alkyl)-C(=0)-(C2-C6heterocycloalkyl) may be substituted with -X, -OH, -CF3or -CF2H;RGis -H or -(C1-C4 alkyl);Q is -O- or a bond;>1is a single bond or double bond, provided that, > is a double bond, Y1 is =CH-;a to e are each independently an integer of 0, 1 , 2, 3 or 4, provided that, a and b may not be simultaneously 0, and c and d may not be simultaneously 0; andDocket No. PAT059983-PCT-SEC01 X is each independently F, Cl, Br or I,wherein the compound of Formula (I) is administered at a dose of about 100 to about 600 mg per day or at the equivalent dose for a pharmaceutically acceptable salt thereof.

[0372] Embodiment 49: A method of reducing a risk of recurrent atrial fibrillation (AF) episode in a patient in need thereof, the method comprising administering to the patient a compound of Formula (I)or a pharmaceutically acceptable salt thereof,wherein:Li, L2or L3are each independently a bond or -(C1-C2 alkylene)-;Ri is -CX2H or -CX3;R2is -NRARB, -ORC,-OH, -O(Ci-C4alkyl), -NRDRE, -(Ci-C4alkyl), -CF3, -CF2H, -CN, -aryl, -heteroaryl, -(Ci- C4alkyl)-aryl or -(Ci-C4alkyl)-heteroaryl, wherein at least one H of the -aryl, - heteroaryl, -(Ci-C4alkyl)-aryl or -(Ci-C4alkyl)-heteroaryl may be substituted with -X, - OH, -CF3or -CF2H;R3is -H, -(Ci-C4alkyl), -(C C4alkyl)-O-(Ci-C4alkyl), -(Ci-C4alkyl)-C(=O)-O-(Ci-C4alkyl), -(C3-C7cycloalkyl), -(C2-C6cycloheteroalkyl), -aryl, -heteroaryl, -adamantyl,at least one H of -(Ci-C4alkyl) may be substituted with -X or -OH,at least one H of -aryl or -heteroaryl each independently may be substituted with -X, - OH, -O(Ci-C4alkyl), -OCF3, -O-aryl, -NRDRE, -(Ci-C4alkyl), -CF3, -CF2H, -C(=O)- (Ci-C4alkyl), -C(=O)-O(Ci-C4alkyl), -C(=O)-NRDRE, -S(=O)2-(Ci-C4alkyl), aryl,Docket No. PAT059983-PCT-SEC01, wherein atleast one H of < may be substituted with -X, -(Ci-C4alkyl), - NRDRE, -CF3or-CF2H, andat least one H of -(C3-C7cycloalkyl), -(C2-C6cycloheteroalkyl), adamantyl,may be each independently substituted with - X, -OH or -(Ci-C4alkyl);Yi, Y2and Y4are each independently -CH2-, -NRF-, -O-, -C(=O)- or -S(=O)2-;Y3is -CH- or -N-;Zi to Z4are each independently N or CRZ, wherein at least three of Zi to Z4may not be simultaneously N, and Rzis -H, -X or -O(Ci-C4alkyl);Z5and Z6are each independently -CH2- or-O-;Z7and Z8are each independently =CH- or =N-;Zg is -NRG- or-S-;RAand RBare each independently -H, -(Ci-C4alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)- NRDRE, -aryl, -(Ci-C4alkyl)-aryl, -heteroaryl, -(Ci-C4aryl)-heteroaryl, -(C3-C7 / A <^4 / G HjeQ-l- cycloalkyl), -(C2-C6heterocycloalkyl) or '15, wherein:at least one H of the -(Ci-C4alkyl), -(Ci-C4alkyl)-OH or -(Ci-C4alkyl)-NRDREmay be substituted with -X,at least one H of the -aryl, -(Ci-C4alkyl)-aryl, -heteroaryl, -(Ci-C4alkyl)-heteroaryl, - (C3-C7cycloalkyl) or-(C2-C6heterocycloalkyl) may be substituted with -X, -OH, - O(Ci-C4alkyl), -(C C4alkyl), -CF3, -CF2H or-CN, andat least oneH of ? may be substituted with n-X, -OH, -O(Cr C4alkyl), -(Ci-C4alkyl), -CF3, -CF2H, -CN, -(C2-C6heterocycloalkyl), -aryl, -(Ci-C4alkyl)-aryl, -heteroaryl or -heteroaryl-(Ci-C4alkyl);Docket No. PAT059983-PCT-SEC01 Rcis -(C1-C4 alkyl), -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or -(Ci-C4alkyl)-heteroaryl, wherein at least one H of -(C1-C4 alkyl) may be substituted with -X or -OH, at least one H of -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or -(Ci-C4alkyl)-heteroaryl may be substituted with -X, -OH, -CF3or -CF2H;RDand REare each independently -H, -(C1-C4 alkyl), -aryl or -(Ci-C4alkyl)-aryl, wherein, at least one H of -(Ci-C4alkyl) may be substituted with -X or -OH, at least one H of - aryl or -(C1-C4 alkyl)-aryl may be substituted with -X, -OH, -CF3or -CF2H; RFis -H, -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(C1-C4 alkyl)-O-(Ci-C4alkyl), -C(=O)-(Ci-C4alkyl), -C(=O)-O-(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O-(Ci-C4alkyl), -(C1-C4 alkyl)- NRDRE, -S(=O)2-(Ci-C4alkyl), -aryl, -(Ci-C4alkyl)-aryl, -(C2-C4alkenyl)-aryl, - heteroaryl, -(C1-C4 alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -(C2-C6 heterocycloalkyl) or -(C1-C4 alkyl)-C(=O)-(C2-C6heterocycloalkyl), wherein:at least one H of -(Ci-C6alkyl), -(C1-C4 alkyl)-OH, -(Ci-C4alkyl)-O-(Ci-C4 alkyl), - C(=O)-(Ci-C4alkyl), -C(=O)-O-(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O-(Ci-C4alkyl), -(Ci-C4alkyl)-NRDREor -S(=O)2-(Ci-C4alkyl) may be substituted with - X, andat least one H of -aryl, -(Ci-C4alkyl)-aryl, -(C2-C4alkenyl)-aryl, -heteroaryl, -(C C4alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -C2-C6heterocycloalkyl or-(Cr C4alkyl)-C(=0)-(C2-C6heterocycloalkyl) may be substituted with -X, -OH, -CF3or -CF2H;RGis -H or -(C1-C4 alkyl);Q is -O- or a bond;> is a single bond or double bond, provided that, > is a double bond, Y1 is =CH-;a to e are each independently an integer of 0, 1 , 2, 3 or 4, provided that, a and b may not be simultaneously 0, and c and d may not be simultaneously 0; andX is each independently F, Cl, Br or I,wherein the compound of Formula (I) is administered at a dose of about 100 to about 600 mg per day or at the equivalent dose for a pharmaceutically acceptable salt thereof.

[0373] Embodiment 50: A method of preventing atrial fibrillation (AF) in a patient in need thereof, the method comprising administering to the patient a compound of Formula (I)Docket No. PAT059983-PCT-SEC01 or a pharmaceutically acceptable salt thereof,wherein:Li, L2or L3are each independently a bond or -(Ci-C2alkylene)-;Ri is -CX2H or -CX3;R2is -NRARB, -ORC, , wherein at least<one H of may be substituted with -X, -OH, -O(Ci-C4alkyl), -NRDRE, -(C1-C4 alkyl), -CF3, -CF2H, -CN, -aryl, -heteroaryl, -(C1- C4alkyl)-aryl or -(Ci-C4alkyl)-heteroaryl, wherein at least one H of the -aryl, - heteroaryl, -(C1-C4 alkyl)-aryl or -(Ci-C4alkyl)-heteroaryl may be substituted with -X, - OH, -CF3or -CF2H;R3is -H, -(C1-C4 alkyl), -(C1-C4 alkyl)-O-(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O-(Ci-C4alkyl), -(C3-C7cycloalkyl), -(C2-C6cycloheteroalkyl), -aryl, -heteroaryl, -adamantyl, Z7- / / zszgor ^9 , wherein:at least one H of -(C1-C4 alkyl) may be substituted with -X or -OH,at least one H of -aryl or -heteroaryl each independently may be substituted with -X, - OH, -O(Ci-C4alkyl), -OCF3, -O-aryl, -NRDRE, -(C1-C4 alkyl), -CF3, -CF2H, -C(=O)- (C1-C4 alkyl), -C(=O)-O(Ci-C4alkyl), -C(=O)-NRDRE, -S(=O)2-(Ci-C4alkyl), aryl, z Zg Y< .,?5K « h b-f heteroaryl, or s , wherein at aleast one H of may be substituted with -X, -(C1-C4 alkyl), - NRDRE, -CF3or-CF2H, andDocket No. PAT059983-PCT-SEC01 at least one H of -(C3-C7cycloalkyl), -(C2-C6cycloheteroalkyl), adamantyl,ij \ jor may be each independently substituted with - X, -OH or -(Ci-C4alkyl);Yi, Y2and Y4are each independently -CH2-, -NRF-, -O-, -C(=O)- or -S(=O)2-;Y3is -CH- or -N-;Zi to Z4are each independently N or CRZ, wherein at least three of Zi to Z4may not be simultaneously N, and Rzis -H, -X or -O(Ci-C4alkyl);Z5and Z6are each independently -CH2- or-O-;Z7and Z8are each independently =CH- or =N-;Zg is -NRG- or-S-;RAand RBare each independently -H, -(Ci-C4alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)- NRDRE, -aryl, -(Ci-C4alkyl)-aryl, -heteroaryl, -(Ci-C4aryl)-heteroaryl, -(C3-C7cycloalkyl), -(C2-C6heterocycloalkyl) or , wherein:at least one H of the -(Ci-C4alkyl), -(Ci-C4alkyl)-OH or -(Ci-C4alkyl)-NRDREmay be substituted with -X,at least one H of the -aryl, -(Ci-C4alkyl)-aryl, -heteroaryl, -(Ci-C4alkyl)-heteroaryl, - (C3-C7cycloalkyl) or-(C2-C6heterocycloalkyl) may be substituted with -X, -OH, - O(Ci-C4alkyl), -(Ci-C4alkyl), -CF3, -CF2H or-CN, andmay be substituted with n-X, -OH, -O(Cr C4alkyl), -(Ci-C4alkyl), -CF3, -CF2H, -CN, -(C2-C6heterocycloalkyl), -aryl, -(Ci-C4alkyl)-aryl, -heteroaryl or -heteroaryl-(Ci-C4alkyl);Rcis -(Ci-C4alkyl), -aryl, -(Ci-C4alkyl)-aryl, -heteroaryl or -(Ci-C4alkyl)-heteroaryl, wherein at least one H of -(Ci-C4alkyl) may be substituted with -X or -OH, at least one H of -aryl, -(Ci-C4alkyl)-aryl, -heteroaryl or -(Ci-C4alkyl)-heteroaryl may be substituted with -X, -OH, -CF3or -CF2H;RDand REare each independently -H, -(Ci-C4alkyl), -aryl or -(Ci-C4alkyl)-aryl, wherein, at least one H of -(Ci-C4alkyl) may be substituted with -X or -OH, at least one H of - aryl or -(Ci-C4alkyl)-aryl may be substituted with -X, -OH, -CF3or -CF2H;Docket No. PAT059983-PCT-SEC01 RFis -H, -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(C1-C4 alkyl)-O-(Ci-C4alkyl), -C(=O)-(Ci-C4alkyl), -C(=O)-O-(Ci-C4alkyl), -(Ci-C4alkyl)-C(=O)-O-(Ci-C4alkyl), -(Ci-C4alkyl)- NRDRE, -S(=O)2-(C C4alkyl), -aryl, -(Ci-C4alkyl)-aryl, -(C2-C4alkenyl)-aryl, - heteroaryl, -(Ci-C4alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -(C2-C6heterocycloalkyl) or -(Ci-C4alkyl)-C(=O)-(C2-C6heterocycloalkyl), wherein:at least one H of -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)-O-(Ci-C4alkyl), - C(=O)-(Ci-C4alkyl), -C(=O)-O-(Ci-C4alkyl), -(C C4alkyl)-C(=O)-O-(Ci-C4alkyl), -(Ci-C4alkyl)-NRDREor -S(=O)2-(Ci-C4alkyl) may be substituted with - X, andat least one H of -aryl, -(Ci-C4alkyl)-aryl, -(C2-C4alkenyl)-aryl, -heteroaryl, -(C C4alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -C2-Ce heterocycloalkyl or-(Ci- C4alkyl)-C(=0)-(C2-C6heterocycloalkyl) may be substituted with -X, -OH, -CF3or -CF2H;RGis -H or -(Ci-C4alkyl);Q is -O- or a bond;tss ss HSfl mss m m■™™“ iSa single bond or double bond, provided that, jS adouble bond, Yi is =CH-;a to e are each independently an integer of 0, 1 , 2, 3 or 4, provided that, a and b may not be simultaneously 0, and c and d may not be simultaneously 0; andX is each independently F, Cl, Br or I,wherein the compound of Formula (I) is administered at a dose of about 100 to about 600 mg per day or at the equivalent dose for a pharmaceutically acceptable salt thereof.

[0374] Embodiment 51 : A method of increasing circulating acetylated alpha tubulin (AAT) in a patient in need thereof, the method comprising administering to the patient a compound of Formula (I),. •'^'1.•■■> 'A / / / * / / \\ / / . z y _ y — N ^2 ^>3b (I), or a pharmaceutically acceptable salt thereof,wherein:Li, L2or L3are each independently a bond or -(Ci-C2alkylene)-;Ri is -CX2H or -CX3;Docket No. PAT059983-PCT-SEC01R2is -NRARB, -ORC, wherein at leastr smay be substituted with -X, -OH, -O(Ci-C4alkyl), -NRDRE, -(C1-C4 alkyl), -CF3, -CF2H, -CN, -aryl, -heteroaryl, -(Ci- C4alkyl)-aryl or -(Ci-C4alkyl)-heteroaryl, wherein at least one H of the -aryl, - heteroaryl, -(Ci-C4alkyl)-aryl or -(Ci-C4alkyl)-heteroaryl may be substituted with -X, - OH, -CF3or -CF2H;R3is -H, -(Ci-C4alkyl), -(C C4alkyl)-O-(Ci-C4alkyl), -(Ci-C4alkyl)-C(=O)-O-(Ci-C4alkyl), -(C3-C7cycloalkyl), -(C2-C6cycloheteroalkyl), -aryl, -heteroaryl, -adamantyl,, wherein:at least one H of -(Ci-C4alky ) may be substituted with -X o -OH,at least one H of -aryl or -het< jroaryl each independently ms be substituted with -X, - OH, -O(Ci-C4alkyl), -OCF "3, -O-aryl, -NRDRE, -(Ci-C4alk / I), -CF3, -CF2H, -C(=O)- (Ci-C4alkyl), -C(=O)-O(C i-C4alkyl), -C(=O)-NRDRE, -S(:O)2-(CI-C4alkyl), aryl,heteroaryl,zs ? , wherein at S.aQ-$- least oneH ofbs may be substituted-X, -(Ci-C4alkyl), - NRDRE, -CF3or-CF2H, anat least one H of -(C3-C7cycloalkyl), -(C2-C6cycloheteroalkyl), adamantyl,< / \!N i 7Y I H :\ -i Uor may be each independently substituted with - X, -OH or -(Ci-C4alkyl);Yi, Y2and Y4are each independently -CH2-, -NRF-, -O-, -C(=O)- or -S(=O)2-;Y3is -CH- or -N-;Docket No. PAT059983-PCT-SEC01 Zi to Z4are each independently N or CRZ, wherein at least three of Zi to Z4may not be simultaneously N, and Rzis -H, -X or -O(Ci-C4alkyl);Z5and Z6are each independently -CH2- or-O-;Z7and Z8are each independently =CH- or =N-;Zg is -NRG- or-S-;RAand RBare each independently -H, -(Ci-C4alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)- NRDRE, -aryl, -(Ci-C4alkyl)-aryl, -heteroaryl, -(Ci-C4aryl)-heteroaryl, -(C3-C7^4 / Y3r~\Jecycloalkyl), -(C2-C6heterocycloalkyl)or '05 , wherein:at least one H of the -(Ci-C4alkyl), -(Ci-C4alkyl)-OH or -(Ci-C4alkyl)-NRDREmay be substituted with -X,at least one H of the -aryl, -(Ci-C4alkyl)-aryl, -heteroaryl, -(Ci-C4alkyl)-heteroaryl, - (C3-C7 cycloalkyl) or-(C2-C6heterocycloalkyl) may be substituted with -X, -OH, - O(Ci-C4alkyl), -(Ci-C4alkyl), -CF3, -CF2H or-CN, and / Na4 . [~\LV / Q-4- at least oneH of may be substituted with n-X, -OH, -O(Cr C4alkyl), -(Ci-C4alkyl), -CF3, -CF2H, -CN, -(C2-C6heterocycloalkyl), -aryl, -(Ci-C4alkyl)-aryl, -heteroaryl or -heteroaryl-(Ci-C4alkyl);Rcis -(Ci-C4alkyl), -aryl, -(Ci-C4alkyl)-aryl, -heteroaryl or -(Ci-C4alkyl)-heteroaryl, wherein at least one H of -(Ci-C4alkyl) may be substituted with -X or -OH, at least one H of -aryl, -(Ci-C4alkyl)-aryl, -heteroaryl or -(Ci-C4alkyl)-heteroaryl may be substituted with -X, -OH, -CF3 or -CF2H;RDand REare each independently -H, -(Ci-C4alkyl), -aryl or -(Ci-C4alkyl)-aryl, wherein, at least one H of -(Ci-C4alkyl) may be substituted with -X or -OH, at least one H of - aryl or -(Ci-C4alkyl)-aryl may be substituted with -X, -OH, -CF3 or -CF2H;RFis -H, -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)-O-(Ci-C4alkyl), -C(=O)-(Ci-C4alkyl), -C(=O)-O-(Ci-C4alkyl), -(Ci-C4alkyl)-C(=O)-O-(Ci-C4alkyl), -(Ci-C4alkyl)- NRDRE, -S(=O)2-(Ci-C4alkyl), -aryl, -(Ci-C4alkyl)-aryl, -(C2-C4alkenyl)-aryl, - heteroaryl, -(Ci-C4alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -(C2-C6heterocycloalkyl) or -(Ci-C4alkyl)-C(=O)-(C2-C6heterocycloalkyl), wherein:at least one H of -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)-O-(Ci-C4alkyl), - C(=O)-(Ci-C4alkyl), -C(=O)-O-(Ci-C4alkyl), -(C C4alkyl)-C(=O)-O-(Ci-C4Docket No. PAT059983-PCT-SEC01 alkyl), -(Ci-C4alkyl)-NRDREor -S(=O)2-(Ci-C4alkyl) may be substituted with - X, andat least one H of -aryl, -(Ci-C4alkyl)-aryl, -(C2-C4alkenyl)-aryl, -heteroaryl, -(C C4alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -C2-C6heterocycloalkyl or-(Cr C4alkyl)-C(=0)-(C2-C6heterocycloalkyl) may be substituted with -X, -OH, -CF3or -CF2H;RGis -H or -(Ci-C4alkyl);Q is -O- or a bond;is a single bond or double bond, provided that, is a double bond, Yi is =CH-;a to e are each independently an integer of 0, 1 , 2, 3 or 4, provided that, a and b may not be simultaneously 0, and c and d may not be simultaneously 0; andX is each independently F, Cl, Br or I,wherein the compound of Formula (I) is administered at a dose of about 100 to about 600 mg per day or at the equivalent dose for a pharmaceutically acceptable salt thereof.

[0375] Embodiment 52: The method according to any one of Embodiments 47 to 51 , wherein, in the compound of Formula (I):Li, L2or L3are each independently a bond or -(Ci-C2alkylene)-;Ri is -CX2H or -CX3;R2is -NRARB, -ORC, , wherein at least oneof H of is or may be substituted with -X, - OH, -NRDRE, -(Ci-C4alkyl);R3is -(Ci-C4alkyl), -(C3-C7cycloalkyl), -aryl, -heteroaryl, -adamantyl,orAZgy , wherein:at least one H of -aryl or -heteroaryl may be each independently substituted with -X, -O(Ci-C4alkyl), -OCF3, -O-aryl, -NRDRE, -(Ci-C4alkyl), -CF3, -S(=O)2-(Ci-Docket No. PAT059983-PCT-SEC01may be substituted with -NRDREor -(C1-C4 alkyl); andat least oneH of maybe each independently substituted with -(C1-C4 alkyl);Y1, Y2and Y4are each independently -CH2-, -NRF-, -O-, -C(=O)- or -S(=O)2-;Y3is -CH- or -N-;Z1 to Z4is each independently N or CRZ, wherein at least three of Z1 to Z4may not be simultaneously N, and Rzis -H, -X or -O(Ci-C4alkyl);Z5 and Ze are each independently -CH2- or-O-;Z7and Z8are each independently =CH- or =N-;Zg is -NRG- or-S-;RAand RBare each independently -H, -(C1-C4 alkyl), -(Ci-C4alkyl)-OH, -(C1-C4 alkyl)-; V ; _ M < NRDRE, -aryl, -(C1-C4 alkyl)-aryl, -(C3-C7 cycloalkyl)or 's7 , whereinat least oneH of ' =• may be substituted with -X, -(C1-C4 alkyl), -CF3, -(C2-C6heterocycloalkyl), -(C1-C4 alkyl)-aryl, -heteroaryl or heteroaryl-(Ci-C4alkyl); Rcis -(C1-C4 alkyl) or -aryl;RDand REare each independently -H, -(C1-C4 alkyl) or -(Ci-C4alkyl)-aryl;RFis -H, -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(C1-C4 alkyl)-O-(Ci-C4alkyl), -C(=O)-(Ci- C4alkyl), -C(=O)-O(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O(Ci-C4alkyl), -(Ci-C4alkyl)- NRDRE, -S(=O)2-(Ci-C4alkyl), -aryl, -(Ci-C4alkyl)-aryl, -(C2-C4alkenyl)-aryl, - heteroaryl, -(C1-C4 alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -(C2-C6heterocycloalkyl) or -(C1-C4 alkyl)-C(=O)-(C2-C6heterocycloalkyl), wherein at least one H of -(Ci-C4alkyl) or-C(=0)-0(Ci-C4alkyl) may be substituted with -X, and at least one H of -aryl may be substituted with -X};Docket No. PAT059983-PCT-SEC01 RGis -(C1-C4 alkyl);Q is -O- or a bond;""""" is a single bond or a double bond, provided that """""is a double bond, Y1 is - CH-;a to e are each independently an integer of 0, 1 , 2, 3 or 4, provided that a and b may not be simultaneously 0, and c and d may not be simultaneously 0; andX is each independently F, Cl, Br or I.

[0376] Embodiment 53: The method according to any one of Embodiments 47 to 52, wherein the compound of Formula (I) has the structure of Formula (la):or a pharmaceutically acceptable salt thereof,wherein:Ra is -aryl, wherein, at least one H of -aryl may be each independently substituted with - X;Y1 is -O- or -S(=O)2-;Z1 is N or CRZ, wherein, Rzis -X;a and b are each independently an integer of 0, 1 , 2, 3 or 4, wherein, a and b may not be simultaneously 0; andX is each independently F, Cl, Br or I.

[0377] Embodiment 54: The method according to Embodiment 53, wherein, in the compound of Formula (la):R3is -phenyl, wherein at least one H of -phenyl each independently is substituted with -F or -Cl;Y1 is -O- or -S(=O)2-; andDocket No. PAT059983-PCT-SEC01 Zi is N or CF.

[0378] Embodiment 55: The method according to any one of Embodiments 47 to 51 , wherein the compound of Formula (I) is one selected from the compounds in Table A.

[0379] Embodiment 56: The method according to any one of Embodiments 47 to 51 , wherein the compound of Formula (I) is selected from the group consisting of:

[0380] Embodiment 57: The method according to any one of Embodiments 48 to 56, wherein the AF is paroxysmal atrial fibrillation, persistent atrial fibrillation, long-term persistent atrial fibrillation, valvularatrial fibrillation, non-valvularatrial fibrillation, or non-permanent atrial fibrillation.

[0381] Embodiment 58: The method according to any one of Embodiments 47 to 57, wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof, is administered orally.

[0382] Embodiment 59: The method according to any one of Embodiments 47 to 58, wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof is administered twice daily.

[0383] Embodiment 60: The method according to any one of Embodiments 47 to 59, wherein the compound of Formula (I) is administered at a dose of about 50 mg to about 300 mg, about 50 mg to about 200 mg, about 100 mg to 300 mg, about 50 mg to about 100 mg, about 100 mg to about 200 mg, or about 200 mg to about 300 mg, or at equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID).

[0384] Embodiment 61 : The method according to any one of Embodiments 47 to 60, wherein the compound of Formula (I) is administered at a dose of about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, or about 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID).Docket No. PAT059983-PCT-SEC01

[0385] Embodiment 62: The method according to any one of Embodiments 47 to 61 , wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof, is administered at a dose of 50 mg, or 100 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID).

[0386] Embodiment 63: The method according to any one of Embodiments 47 to 62, wherein the compound of Formula (I) or the pharmaceutically acceptable salt thereof is administered for at least 6 weeks, at least 12 weeks, at least 18 weeks, at least 24 weeks, at least 30 weeks, or at least 36 weeks.

[0387] Embodiment 64: The method according to any one of Embodiments 47 to 63, wherein the patient is a human patient.

[0388] Embodiment 65: The method according to any one of Embodiments 1 to 64, whereinthe compound is or a pharmaceutically acceptable salt thereof.

[0389] Embodiment 66: The method according to any one of Embodiments 1 to 64, wherein the compound is, or a pharmaceutically acceptable salt thereof.

[0390] Embodiment 67: The method according to any one of Embodiments 1 to 64, wherein the compound is, or a pharmaceutically acceptable salt thereof.

[0391] Embodiment 68: The method according to any one of Embodiments 1 to 64, wherein the compound is<> , or a pharmaceutically acceptable salt thereof.

[0392] Embodiment 69: The method according to any one of Embodiments 1 to 64, wherein the compound isDocket No. PAT059983-PCT-SEC01f ■'XN "'''■'0N-H'*> , or a pharmaceutically acceptable salt thereof.

[0393] Embodiment 70: The method according to any one of Embodiments 1 to 64, wherein the compound isr '«■ 4 il A v o6 , or a pharmaceutically acceptable salt thereof.

[0394] Embodiment 71 : A pharmaceutical composition comprising an HDAC6 inhibitor and a pharmaceutically acceptable excipient, for use in the treating atrial fibrillation (AF) in a patient in need thereof, wherein the HDAC6 inhibitor comprises a compound of Formula (I)or a pharmaceutically acceptable salt thereof,where...

Claims

Docket No. PAT059983-US-PRI02WHAT IS CLAIMED IS:

1. A method of treating atrial fibrillation (AF) in a patient in need thereof, the method comprising administering to the patient a compound of Formula (I)or a pharmaceutically acceptable salt thereof,wherein:Li, L2or L3are each independently a bond or-(Ci-C2alkylene)-;Ri is -CX2H or -CX3;O(Ci-C4alkyl), -NRDRE, -(C1-C4 alkyl), -CF3, -CF2H, -CN, -aryl, -heteroaryl, -(Ci-C4alkyl)- aryl or-(Ci-C4alkyl)-heteroaryl, wherein at least one H of the -aryl, -heteroaryl, -(Ci-C4alkyl)-aryl or-(Ci-C4alkyl)-heteroaryl may be substituted with -X, -OH, -CF3or-CF2H; R3is -H, -(Ci-C4alkyl), -(Ci-C4alkyl)-O-(Ci-C4alkyl), -(Ci-C4alkyl)-C(=O)-O-(Ci-C4alkyl), - (C3-C7cycloalkyl), -(C2-C6cycloheteroalkyl), -aryl, -heteroaryl, -adamantyl,at least one H of -(Ci-C4alkyl) may be substituted with -X or -OH,at least one H of -aryl or -heteroaryl each independently may be substituted with -X, - OH, -O(Ci-C4alkyl), -OCF3, -O-aryl, -NRDRE, -(Ci-C4alkyl), -CF3, -CF2H, -C(=O)-(Ci- C4alkyl), -C(=O)-O(Ci-C4alkyl), -C(=O)-NRDRE, -S(=O)2-(Ci-C4alkyl), aryl,Docket No. PAT059983-US-PRI02f h ^-8 heteroaryl,Q-?- oneH of 7 may be substituted with -X, -(C1-C4 alkyl), -NRDRE, - CF3or-CF2H, andat least one H of -(C3-C7 cycloalkyl), -(C2-C6cycloheteroalkyl), adamantyl,^6 ormay be each independently substituted with -X, - OH or -(C1-C4 alkyl);Y1, Y2and Y4are each independently -CH2-, -NRF-, -O-, -C(=O)- or-S(=0)2-;Y3is -CH- or-N-;Z1 to Z4are each independently N or CRZ, wherein at least three of Z1 to Z4may not be simultaneously N, and Rzis -H, -X or -O(Ci-C4alkyl);Z5and Z6are each independently -CH2- or-O-;Z7and Z8are each independently =CH- or =N-;Z9is -NRG- or -S-;RAand RBare each independently -H, -(C1-C4 alkyl), -(C1-C4 alkyl)-OH, -(C1-C4 alkyl)- NRDRE, -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl, -(C1-C4 aryl)-heteroaryl, -(C3-C7 cycloalkyl),-(C2-C6heterocycloalkyl) or ■s , wherein:at least one H of the -(C1-C4 alkyl), -(C1-C4 alkyl)-OH or-(Ci-C4alkyl)-NRDREmay be substituted with -X,at least one H of the -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl, -(C1-C4 alkyl)-heteroaryl, -(C3- C7cycloalkyl) or-(C2-C6heterocycloalkyl) may be substituted with -X, -OH, -O(Ci-C4alkyl), -(C1-C4 alkyl), -CF3,-CF2H or -ON, andDocket No. PAT059983-US-PRI02Y4 ZY3H~~\XLQ’4’at least oneH of1 &S may be substituted with n-X, -OH, -O(Ci-C4alkyl), -(C1-C4 alkyl), -CF3, -CF2H, -CN, -(C2-C6heterocycloalkyl), -aryl, -(C1-C4 alkydaryl, -heteroaryl or-heteroaryl-(Ci-C4alkyl);Rcis -(C1-C4 alkyl), -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or-(Ci-C4alkyl)-heteroaryl, wherein at least one H of -(Ci-C4alkyl) may be substituted with -X or -OH, at least one H of -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or-(Ci-C4alkyl)-heteroaryl may be substituted with -X, - OH, -CF3or-CF2H;RDand REare each independently -H, -(C1-C4 alkyl), -aryl or-(Ci-C4alkyl)-aryl, wherein, at least one H of -(C1-C4 alkyl) may be substituted with -X or -OH, at least one H of -aryl or -(C1-C4 alkyl)-aryl may be substituted with -X, -OH, -CF3or-CF2H;RFis -H, -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)-O-(Ci-C4alkyl), -C(=O)-(Ci-C4alkyl), -C(=O)-O-(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O-(Ci-C4alkyl), -(Ci-C4alkyl)-NRDRE, - S(=O)2-(Ci-C4alkyl), -aryl, -(C1-C4 alkyl)-aryl, -(C2-C4alkenyl)-aryl, -heteroaryl, -(C1-C4 alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -(C2-C6heterocycloalkyl) or-(Ci-C4alkyl)- C(=O)-(C2-C6heterocycloalkyl), wherein:at least one H of -(C1-C4 alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)-O-(Ci-C4alkyl), - C(=O)-(Ci-C4alkyl), -C(=O)-O(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O(Ci-C4alkyl), -(Ci-C4alkyl)-NRDREor -S(=O)2-(Ci-C4alkyl) may be substituted with - X, andat least one H of -aryl, -(Ci-C4alkyl)-aryl, -(C2-C4alkenyl)-aryl, -heteroaryl, -(C1- C4alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -C2-C6heterocycloalkyl or- (Ci-C4alkyl)-C(=0)-(C2-C6heterocycloalkyl) may be substituted with -X, -OH, -CF3or-CF2H;RGis -H or -(C1-C4 alkyl);Q is -O- or a bond;"""""""""uis a single bond or double bond, provided that, """""""""""""""" is a double bond, Y1 is =CH-;a to e are each independently an integer of 0, 1, 2, 3 or 4, provided that, a and b may not be simultaneously 0, and c and d may not be simultaneously 0; andX is each independently F, Cl, Br or I,Docket No. PAT059983-US-PRI02 wherein the compound of Formula (I) is administered at a dose of about 100 to about 600 mg per day or at the equivalent dose for a pharmaceutically acceptable salt thereof.The method according to claim 1 , wherein, in the compound of Formula (I):Li, L2or L3are each independently a bond or -(Ci-C2alkylene)-;Ri is -CX2H or -CX3;R2is -NRARB, -ORC, , wherein at least one ofH of may be substituted with -X, -OH, - NRDRE, -(C1-C4 alkyl);R3is -(C1-C4 alkyl), -(C3-C7cycloalkyl), -aryl, -heteroaryl, -adamantyl,wherein:at least one H of -aryl or -heteroaryl may be each independently substituted with -X, -O(Ci-C4alkyl), -OCF3, -O-aryl, -NRDRE, -(C1-C4 alkyl), -CF3, -S(=O)2-(Ci-C4alkyl),wherein at least one H of be substituted with -NRDREor -(C1-C4 alkyl); andDocket No. PAT059983-US-PRI02zs-^7C z7.^at least oneH of ^6 or maybe each independently substituted with -(Ci-C4alkyl);Yi, Y2and Y4are each independently -CH2-, -NRF-, -0-, -C(=0)- or-S(=0)2-;Y3is -CH- or-N-;Zi to Z4is each independently N or CRZ, wherein at least three of Zi to Z4may not be simultaneously N, and Rzis -H, -X or -O(Ci-C4alkyl);Z5and Z6are each independently -CH2- or-O-;Z7and Z8are each independently =CH- or =N-;Z9is -NRG- or -S-;RAand RBare each independently -H, -(Ci-C4alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)-NRDRE,■ V-- W.-aryl, -(Ci-C4alkyl)-aryl, -(C3-C7 cycloalkyl)or&wherein at least oneQ--<-H of may be substituted with -X, -(Ci-C4alkyl), -CF3, -(C2-C6heterocycloalkyl), -(Ci-C4alkyl)-aryl, -heteroaryl or heteroaryl-(Ci-C4alkyl);Rcis -(Ci-C4alkyl) or -aryl;RDand REare each independently -H, -(Ci-C4alkyl) or -(Ci-C4alkyl)-aryl;RFis -H, -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)-O-(Ci-C4alkyl), -C(=O)-(Ci-C4alkyl), - C(=O)-O(Ci-C4alkyl), -(Ci-C4alkyl)-C(=O)-O(Ci-C4alkyl), -(Ci-C4alkyl)-NRDRE, -S(=O)2- (Ci-C4alkyl), -aryl, -(Ci-C4alkyl)-aryl, -(C2-C4alkenyl)-aryl, -heteroaryl, -(Ci-C4alkyl)- heteroaryl, -C(=O)-(C3-C7cycloalkyl), -(C2-C6heterocycloalkyl) or -(Ci-C4alkyl)-C(=O)- (C2-C6heterocycloalkyl), wherein at least one H of -(Ci-C4alkyl) or -C(=O)-O(Ci-C4alkyl) may be substituted with -X, and at least one H of -aryl may be substituted with -X};RGis -(Ci-C4alkyl);Q is -O- or a bond;is a single bond or a double bond, provided thatis a double bond, Y1 is - CH-;a to e are each independently an integer of 0, 1, 2, 3 or 4, provided that a and b may not be simultaneously 0, and c and d may not be simultaneously 0; andDocket No. PAT059983-US-PRI02 X is each independently F, Cl, Br or I.

3. The method according to claim 1 or 2, wherein the compound of Formula I has the structure of Formula (la):or a pharmaceutically acceptable salt thereof,wherein:Rais -aryl, wherein, at least one H of -aryl may be each independently substituted with -X; Yi is -0- or-S(=0)2-;Zi is N orCRz, wherein, Rzis -X;a and b are each independently an integer of 0, 1, 2, 3 or 4, wherein, a and b may not be simultaneously 0; andX is each independently F, Cl, Br or I.

4. The method according to claim 3, wherein, in the compound of Formula (la):R2isR3is -phenyl, wherein at least one H of -phenyl each independently is substituted with -F or -Cl;Yi is -O- or -S(=O)2-; andZi is N or CF.

5. The method according to claim 1, wherein the compound of Formula (I) is one selected from the compounds in Table A.Docket No. PAT059983-US-PRI02 6. The method according to claim 1 , wherein the compound of Formula (I) is selected from the group consisting of:

7. The method according to any one of claims 1 to 6, wherein the AF is paroxysmal atrial fibrillation, persistent atrial fibrillation, long-term persistent atrial fibrillation, valvular atrial fibrillation, non-valvular atrial fibrillation, or non-permanent atrial fibrillation.

8. The method according to any one of claims 1 to 7, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered orally.

9. The method according to any one of claims 1 to 8, wherein the compound of Formula (I) or a pharmaceutically acceptable salt thereof, is administered in a form of tablet or capsule.

10. The method according to any one of claims 1 to 9, wherein the compound of Formula (I) or a pharmaceutically acceptable salt thereof, is administered twice daily (BID).

11. The method according to any one of claims 1 to 10, wherein the compound of Formula (I) is administered at a dose of about 50 mg to about 300 mg, about 50 mg to about 200 mg, about 100 mg to 300 mg, about 50 mg to about 100 mg, about 100 mg to about 200 mg, or about 200 mg to about 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID).Docket No. PAT059983-US-PRI0212. The method according to any one of claims 1 to 11 , wherein the compound of Formula (I) is administered at a dose of about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, or about 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID).

13. The method according to any one of claims 1 to 12, wherein the compound of Formula (I) is administered at a dose of 50 mg, or 100 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID).

14. The method according to any one of claims 1 to 13, wherein the compound of Formula (I) or the pharmaceutically acceptable salt thereof is administered for at least 6 weeks, at least 12 weeks, at least 18 weeks, at least 24 weeks, at least 30 weeks, or at least 36 weeks.

15. The method according to any one of claims 1 to 14, wherein the patient is a human patient.

16. The method according to any one of claims 1 to 15, wherein the patient is male or female 18 years old or older.

17. The method according to any one of claims 1 to 16, wherein the patient has a history of at least two AF episodes, or at least two episodes of atrial fibrillation and / or atrial flutter where at least one episode is atrial fibrillation.

18. The method according to claim 17, wherein at least one of the AF episodes occur within the last 12 months prior to the treatment and documented by 12-lead ECG, Holter, or any other ECG recording method, as confirmed by patient’s medical record.

19. The method according to any one of claims 1 to 18, wherein the patient has one or more of the following conditions:i. atrial fibrillation burden (AFB) of 1% or higher on a local ambulatory Holter, mobile cardiac telemetry, ECG patch monitor, or other ambulatory electrocardiographic monitor within the last 12 months prior to the treatmentii. CHA2DS2-VASc score of 2 or higher in males, 3 or higher in femalesiii. Stable heart failure or with New York Heart Association class I or II symptoms iv. NT-proBNP level of 300 pg / mL or higher on a local lab test within the last 12 monthsDocket No. PAT059983-US-PRI02 prior to the treatment.

20. The method according to any one of claims 1 to 19, wherein the patient is on guideline- directed stroke prevention treatment, as confirmed by the patient’s medical record.

21. The method according to any one of claims 1 to 20, wherein the patient has a body mass index (BMI) is about or greater than 18.

22. The method according to any one of claims 1 to 21 , wherein the patient has sinus rhythm documented by 12-lead ECG before administering the compound of Formula (I) or the pharmaceutically acceptable salt thereof.

23. The method according to any one of claims 1 to 22, wherein if the patient has persistent AF, the patient is cardioverted before administering the compound of Formula (I) or the pharmaceutically acceptable salt thereof.

24. The method according to any one of claims 1 to 23, wherein the patient does not have one or more of the following conditions:(i) Permanent AF;(ii) Ongoing reversible cause of AF selected from hyperthyroidism, myocarditis, alcohol use, sepsis- or infection-related AF, surgery-related AF, and pulmonary embolism;(iii) Ongoing use of antiarrhythmic therapy;(iv) History of an AF ablation procedure (for example, within the last 6 months) without a recurrence of AF at least 2 or more months after the ablation;(v) Implanted pacemaker, defibrillator, or cardiac monitor;(vi) Infiltrative or hypertrophic cardiomyopathy;(vii) Current decompensated heart failure or hospitalization for heart failure within 3 months prior to the treatment;(viii) Left ventricular ejection fraction of 40% or less documented within the last 12 months prior to the treatment, or during the treatment period, wherein if multiple LVEF measurements are recorded within the last 12 months, the most recent LVEF measurement should be used;(ix) Severe valvular disease or planned valvular intervention during study;Docket No. PAT059983-US-PRI02 (x) Stroke within the last 6 months, or other neurologic or psychiatric conditions likely to affect study compliance;(xi) Cardiac surgery within the last 6 months;(xii) Unstable angina, myocardial infarction, coronary angioplasty within the last 6 months; and(xiii) Known allergic reactions to adhesives or hydrogels.

25. The method according to any one of claims 1 to 24, wherein the patient does not have known history of or current clinically significant ventricular arrhythmias, personal history of an inherited arrhythmia syndrome, long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, idiopathic ventricular fibrillation, or arrhythmogenic cardiomyopathy.

26. The method according to any one of claims 1 to 25, wherein the patient does not have:(i) history of or current significant ECG abnormalities that indicate a high safety risk in the study,(ii) HR < 50 bpm or HR < 45 bpm if on a beta blocker or calcium channel blocker, or (iii) QTcF > 450 msec (males) or QTcF > 460 msec (females).

27. The method according to any one of claims 1 to 26, wherein the patient does not have a history of drug abuse or unhealthy alcohol use within 12 months prior to the treatment.

28. The method according to any one of claims 1 to 27, wherein the patient is not (a) pregnant, (b) a nursing or lactating woman, or (c) a woman having child-bearing potential unless the patient is using effective methods of contraception during the treatment.

29. The method according to any one of claims 1 to 28, wherein the patient does not have Liver disease or liver injury indicated by abnormal liver function tests.

30. The method according to any one of claims 1 to 29, wherein the patient does not have a history or presence of impaired renal function.Docket No. PAT059983-US-PRI02 31. The method according to any one of claims 1 to 30, wherein, just prior to administering, the patient has not used other drugs or therapies within 5 half-lives of the other drugs or therapies on the day of administering, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer.

32. The method according to any one of claims 1 to 31 , wherein the patient has not been treated with any apalutamide or III anti-arrhythmic drug.

33. The method according to any one of claims 1 to 32, wherein the patient has not been treated with amiodarone.

34. The method according to any one of claims 1 to 33, wherein, prior to administering, the patient has not been in ongoing treatment with a drug that is a CYP3A4 inhibitor.

35. The method according to any one of claims 1 to 34, wherein prior to administering, the patient has not been in ongoing treatment with a drug that is a CYP3A4 inducer.

36. The method according to any one of claims 1 to 35, wherein the patient has not been treated with one or more selected from boceprevir, ceritinib, clarithromycin, cobicistat, conivaptan, danoprevir / ritonavir, elvitegravir / ritonavir, grapefruit or grapefruit juice, idelalisib, indinavir, indinavir, ritonavir, itraconazole, josamycin, ketoconazole, lopinavir / ritonavir, mibefradil, mifepristone, nefazodone, nelfinavir, ombitasvir / paritaprevir / dasabuvir / ritonavir (Viekira Pak), posaconazole, ribociclib, ritonavir, saquinavir, saquinavir / ritonavir, telaprevir, telithromycin, tipranavir / ritonavir, troleandomycin, tucatinib, voriconazole, aprepitant, amprenavir, atazanavir, atazanavir / ritonavir, casopitant, cimetidine, ciprofloxacin, crizotinib, darunavir, darunavir / ritonavir, diltiazem, dronedarone, duvelisib, erythromycin, faldaprevir, fedratinib, fluconazole, imatinib, isavuconazole, istradefylline, lefamulin, letermovir, Magnolia vine (Schisandra sphenanthera), netupitant, nilotinib, ravuconazole, tofisopam, verapamil, voxelotor, apalutamide, avasimibe, carbamazepine, enzalutamide, ivosidenib, lumacaftor, mitotane, phenytoin, rifampicin, rifapentine, and St. John’s wort (Hypericum perforatum).

37. The method according to any one of claims 1 to 36, wherein the patient has not been treated with a drug known to prolong the QT interval.Docket No. PAT059983-US-PRI0238. The method according to any one of claims 1 to 37, wherein the patient does not have significant illness which has not resolved within two weeks prior to administering the compound of Formula (I) or the pharmaceutically acceptable salt thereof.

39. The method according to any one of claims 1 to 38, wherein the method further comprises assessing the treatment by measuring AF burden, time to recurrent AF, presence or absence of AF recurrence, ventricular arrhythmias, orQTc duration using an ECG Patch, a 12-lead ECG, a mobile handheld ECG, ora photoplethysmography (PPG) wearable device.

40. The method according to any one of claims 1 to 39, wherein the method further comprises assessing the treatment by measuring a level of a biomarker from a blood sample obtained from the patient.

41. The method according to claim 40, wherein the biomarker is peripheral acetylated alpha tubulin (AAT) and a fold change of the peripheral AAT is measured based on a baseline AAT level measured prior to the administering the compound of Formula (I) or the pharmaceutically acceptable salt thereof .

42. The method according to claim 40 or 41 , wherein the biomarker is NT-proBNP and / or cardiac troponin and a serum level of the NT-proBNP and / or cardiac troponin is measured.

43. The method according to any one of claims 40 to 42, wherein the biomarker is FGF23 and / or BMP10 and a serum level of the FGF23 and / or BMP10 is measured.

44. The method according to any one of claims 1 to 43, wherein the method of treating AF results in increases in the peripheral AAT in the patient by about 1.1 to 15.0 fold compared to a baseline AAT level measured prior to the administering the compound of Formula (I) or the pharmaceutically acceptable salt thereof.

45. The method according to any one of claims 1 to 44, wherein AF burden in the patient measured by the ECG patch is reduced by at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 35%, at least about 40%, or by at least aboutDocket No. PAT059983-US-PRI02 45 % after administering the compound of Formula (I) or the pharmaceutically acceptable salt thereof.

46. The method according to any one of claims 1 to 45, wherein AF recurrence in the patient is reduced by at least about 10%, at least about 15%, at least about 20%, by at least about 25%, or by at least about 30% after administering the compound of Formula (I), or the pharmaceutically acceptable salt thereof wherein the AF recurrence is measured by a time (d) from the date of the treatment to the time of a first recurrent AF episode.

47. A method of inhibiting or reducing histone deacetylase 6 (HDAC6) activity in a patient in need thereof, the method comprising administering to the patient a compound of Formula (I),or a pharmaceutically acceptable salt thereof,wherein:Li, L2or L3are each independently a bond or-(Ci-C2alkylene)-;Ri is -CX2H or -CX3;O(Ci-C4alkyl), -NRDRE, -(C1-C4 alkyl), -CF3, -CF2H, -CN, -aryl, -heteroaryl, -(Ci-C4alkyl)- aryl or-(Ci-C4alkyl)-heteroaryl, wherein at least one H of the -aryl, -heteroaryl, -(Ci-C4alkyl)-aryl or-(Ci-C4alkyl)-heteroaryl may be substituted with -X, -OH, -CF3or-CF2H;Docket No. PAT059983-US-PRI02 R3is -H, -(C1-C4 alkyl), -(C1-C4 alkyl)-O-(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O-(Ci-C4alkyl), - (C3-C7 cycloalkyl), -(C2-C6cycloheteroalkyl), -aryl, -heteroaryl, -adamantyl,wherein:at least one H of -(C1-C4 alkyl) may be substituted with -X or -OH,at least one H of -aryl or -heteroaryl each independently may be substituted with -X, - OH, -O(Ci-C4alkyl), -OCF3, -O-aryl, -NRDRE, -(C1-C4 alkyl), -CF3, -CF2H, -C(=O)-(Ci- C4alkyl), -C(=O)-O(Ci-C4alkyl), -C(=O)-NRDRE, -S(=O)2-(Ci-C4alkyl), aryl,z Xf1 / I II7f / i ’ Pheteroaryl,\ Z k > ) or >!Z ’*> w- , wherein at least M\Z Q-|- oneH of may be substituted with -X, -(C1-C4 alkyl), -NRDRE, - CF3or-CF2H, andat least one H of -(C3-C7 cycloalkyl), -(C2-C6cycloheteroalkyl), adamantyl,OH or -(C1-C4 alkyl);Y1, Y2and Y4are each independently -CH2-, -NRF-, -O-, -C(=O)- or-S(=0)2-;Y3is -CH- or-N-;Z1 to Z4are each independently N or CRZ, wherein at least three of Z1 to Z4may not be simultaneously N, and Rzis -H, -X or -O(Ci-C4alkyl);Z5and Z6are each independently -CH2- or-O-;Z7and Z8are each independently =CH- or =N-;Z9is -NRG- or -S-;Docket No. PAT059983-US-PRI02 RAand RBare each independently -H, -(C1-C4 alkyl), -(C1-C4 alkyl)-OH, -(C1-C4 alkyl)- NRDRE, -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl, -(C1-C4 aryl)-heteroaryl, -(C3-C7 cycloalkyl),3 r\]eQ-?- -(C2-C6heterocycloalkyl) or 5 , wherein:at least one H of the -(C1-C4 alkyl), -(C1-C4 alkyl)-OH or-(Ci-C4alkyl)-NRDREmay be substituted with -X,at least one H of the -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl, -(C1-C4 alkyl)-heteroaryl, -(C3- C7cycloalkyl) or-(C2-C6heterocycloalkyl) may be substituted with -X, -OH, -O(Ci-C4alkyl), -(C1-C4 alkyl), -CF3,-CF2H or-CN, and\ x '' Sat least oneH ofbS may be substituted with n-X, -OH, -O(Ci-C4alkyl), -(C1-C4 alkyl), -CF3, -CF2H, -ON, -(C2-C6heterocycloalkyl), -aryl, -(C1-C4 alkydaryl, -heteroaryl or-heteroaryl-(Ci-C4alkyl);Rcis -(C1-C4 alkyl), -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or-(Ci-C4alkyl)-heteroaryl, wherein at least one H of -(Ci-C4alkyl) may be substituted with -X or -OH, at least one H of -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or-(Ci-C4alkyl)-heteroaryl may be substituted with -X, - OH, -CF3or-CF2H;RDand REare each independently -H, -(C1-C4 alkyl), -aryl or-(Ci-C4alkyl)-aryl, wherein, at least one H of -(C1-C4 alkyl) may be substituted with -X or -OH, at least one H of -aryl or -(C1-C4 alkyl)-aryl may be substituted with -X, -OH, -CF3or-CF2H;RFis -H, -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)-O-(Ci-C4alkyl), -C(=O)-(Ci-C4alkyl), -C(=O)-O-(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O-(Ci-C4alkyl), -(Ci-C4alkyl)-NRDRE, - S(=O)2-(Ci-C4alkyl), -aryl, -(C1-C4 alkyl)-aryl, -(C2-C4alkenyl)-aryl, -heteroaryl, -(C1-C4 alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -(C2-C6heterocycloalkyl) or-(Ci-C4alkyl)- C(=O)-(C2-C6heterocycloalkyl), wherein:at least one H of -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)-O-(Ci-C4 alkyl), - C(=O)-(Ci-C4alkyl), -C(=O)-O-(Ci-C4alkyl), -(Ci-C4alkyl)-C(=O)-O-(Ci-C4alkyl), - (Ci-C4alkyl)-NRDREor -S(=O)2-(Ci-C4alkyl) may be substituted with -X, and at least one H of -aryl, -(C1-C4 alkyl)-aryl, -(C2-C4alkenyl)-aryl, -heteroaryl, -(C1-C4 alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -C2-C6heterocycloalkyl or-(Ci-Docket No. PAT059983-US-PRI02 C4alkyl)-C(=0)-(C2-C6heterocycloalkyl) may be substituted with -X, -OH, -CF3or- CF2H;RGis -H or -(C1-C4 alkyl);Q is -O- or a bond;is a single bond or double bond, provided that, is a double bond, Y1 is =CH-;a to e are each independently an integer of 0, 1, 2, 3 or 4, provided that, a and b may not be simultaneously 0, and c and d may not be simultaneously 0; andX is each independently F, Cl, Br or I,wherein the compound of Formula (I) is administered at a dose of about 100 to about 600 mg per day or at the equivalent dose for a pharmaceutically acceptable salt thereof.

48. A method of reducing atrial fibrillation (AF) burden in a patient in need thereof, the method comprising administering to the patient a compound of Formula (I)or a pharmaceutically acceptable salt thereof,wherein:Li, L2or L3 are each independently a bond or-(Ci-C2alkylene)-;R1 is -CX2H or -CX3;O(Ci-C4alkyl), -NRDRE, -(C1-C4 alkyl), -CF3, -CF2H, -CN, -aryl, -heteroaryl, -(C1-C4 alkyl)- aryl or-(Ci-C4alkyl)-heteroaryl, wherein at least one H of the -aryl, -heteroaryl, -(C1-C4 alkyl)-aryl or-(Ci-C4alkyl)-heteroaryl may be substituted with -X, -OH, -CF3or-CF2H;Docket No. PAT059983-US-PRI02 R3is -H, -(C1-C4 alkyl), -(C1-C4 alkyl)-O-(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O-(Ci-C4alkyl), - (C3-C7 cycloalkyl), -(C2-C6cycloheteroalkyl), -aryl, -heteroaryl, -adamantyl,wherein:at least one H of -(C1-C4 alkyl) may be substituted with -X or -OH,at least one H of -aryl or -heteroaryl each independently may be substituted with -X, - OH, -O(Ci-C4alkyl), -OCF3, -O-aryl, -NRDRE, -(C1-C4 alkyl), -CF3, -CF2H, -C(=O)-(Ci- C4alkyl), -C(=O)-O(Ci-C4alkyl), -C(=O)-NRDRE, -S(=O)2-(Ci-C4alkyl), aryl,z Xf1 / I II7f / i ’ Pheteroaryl,\ Z k > ) or >!Z ’*> w- , wherein at least M\Z Q-|- oneH of may be substituted with -X, -(C1-C4 alkyl), -NRDRE, - CF3or-CF2H, andat least one H of -(C3-C7 cycloalkyl), -(C2-C6cycloheteroalkyl), adamantyl,OH or -(C1-C4 alkyl);Y1, Y2and Y4are each independently -CH2-, -NRF-, -O-, -C(=O)- or-S(=0)2-;Y3is -CH- or-N-;Z1 to Z4are each independently N or CRZ, wherein at least three of Z1 to Z4may not be simultaneously N, and Rzis -H, -X or -O(Ci-C4alkyl);Z5and Z6are each independently -CH2- or-O-;Z7and Z8are each independently =CH- or =N-;Z9is -NRG- or -S-;Docket No. PAT059983-US-PRI02 RAand RBare each independently -H, -(C1-C4 alkyl), -(C1-C4 alkyl)-OH, -(C1-C4 alkyl)- NRDRE, -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl, -(C1-C4 aryl)-heteroaryl, -(C3-C7 cycloalkyl),3 r\]eQ-?- -(C2-C6heterocycloalkyl) or 5 , wherein:at least one H of the -(C1-C4 alkyl), -(C1-C4 alkyl)-OH or-(Ci-C4alkyl)-NRDREmay be substituted with -X,at least one H of the -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl, -(C1-C4 alkyl)-heteroaryl, -(C3- C7cycloalkyl) or-(C2-C6heterocycloalkyl) may be substituted with -X, -OH, -O(Ci-C4alkyl), -(C1-C4 alkyl), -CF3,-CF2H or-CN, and\ x '' Sat least oneH ofbS may be substituted with n-X, -OH, -O(Ci-C4alkyl), -(C1-C4 alkyl), -CF3, -CF2H, -ON, -(C2-C6heterocycloalkyl), -aryl, -(C1-C4 alkydaryl, -heteroaryl or-heteroaryl-(Ci-C4alkyl);Rcis -(C1-C4 alkyl), -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or-(Ci-C4alkyl)-heteroaryl, wherein at least one H of -(Ci-C4alkyl) may be substituted with -X or -OH, at least one H of -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or-(Ci-C4alkyl)-heteroaryl may be substituted with -X, - OH, -CF3or-CF2H;RDand REare each independently -H, -(C1-C4 alkyl), -aryl or-(Ci-C4alkyl)-aryl, wherein, at least one H of -(C1-C4 alkyl) may be substituted with -X or -OH, at least one H of -aryl or -(C1-C4 alkyl)-aryl may be substituted with -X, -OH, -CF3or-CF2H;RFis -H, -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)-O-(Ci-C4alkyl), -C(=O)-(Ci-C4alkyl), -C(=O)-O-(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O-(Ci-C4alkyl), -(Ci-C4alkyl)-NRDRE, - S(=O)2-(Ci-C4alkyl), -aryl, -(C1-C4 alkyl)-aryl, -(C2-C4alkenyl)-aryl, -heteroaryl, -(C1-C4 alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -(C2-C6heterocycloalkyl) or-(Ci-C4alkyl)- C(=O)-(C2-C6heterocycloalkyl), wherein:at least one H of -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)-O-(Ci-C4 alkyl), - C(=O)-(Ci-C4alkyl), -C(=O)-O-(Ci-C4alkyl), -(Ci-C4alkyl)-C(=O)-O-(Ci-C4alkyl), - (Ci-C4alkyl)-NRDREor -S(=O)2-(Ci-C4alkyl) may be substituted with -X, and at least one H of -aryl, -(C1-C4 alkyl)-aryl, -(C2-C4alkenyl)-aryl, -heteroaryl, -(C1-C4 alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -C2-C6heterocycloalkyl or-(Ci-Docket No. PAT059983-US-PRI02 C4alkyl)-C(=0)-(C2-C6heterocycloalkyl) may be substituted with -X, -OH, -CF3or- CF2H;RGis -H or -(C1-C4 alkyl);Q is -O- or a bond;is a single bond or double bond, provided that, is a double bond, Y1 is =CH-;a to e are each independently an integer of 0, 1, 2, 3 or 4, provided that, a and b may not be simultaneously 0, and c and d may not be simultaneously 0; andX is each independently F, Cl, Br or I,wherein the compound of Formula (I) is administered at a dose of about 100 to about 600 mg per day or at the equivalent dose for a pharmaceutically acceptable salt thereof.

49. A method of reducing a risk of recurrent atrial fibrillation (AF) episode in a patient in need thereof, the method comprising administering to the patient a compound of Formula (I) Rg - Lg Z^— 2^ / N - Ln * - (\ \\ / / \ \ / ; / / sX. / / '> ' o - 7 — 7 HO (I), or a pharmaceutically acceptable salt thereof,wherein:Li, L2or L3 are each independently a bond or-(Ci-C2alkylene)-;R1 is -CX2H or -CX3;O(Ci-C4alkyl), -NRDRE, -(C1-C4 alkyl), -CF3, -CF2H, -CN, -aryl, -heteroaryl, -(C1-C4 alkyl)- aryl or-(Ci-C4alkyl)-heteroaryl, wherein at least one H of the -aryl, -heteroaryl, -(C1-C4 alkyl)-aryl or-(Ci-C4alkyl)-heteroaryl may be substituted with -X, -OH, -CF3or-CF2H;Docket No. PAT059983-US-PRI02 R3is -H, -(C1-C4 alkyl), -(C1-C4 alkyl)-O-(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O-(Ci-C4alkyl), - (C3-C7 cycloalkyl), -(C2-C6cycloheteroalkyl), -aryl, -heteroaryl, -adamantyl,wherein:at least one H of -(C1-C4 alkyl) may be substituted with -X or -OH,at least one H of -aryl or -heteroaryl each independently may be substituted with -X, - OH, -O(Ci-C4alkyl), -OCF3, -O-aryl, -NRDRE, -(C1-C4 alkyl), -CF3, -CF2H, -C(=O)-(Ci- C4alkyl), -C(=O)-O(Ci-C4alkyl), -C(=O)-NRDRE, -S(=O)2-(Ci-C4alkyl), aryl,z Xf1 / I II7f / i ’ Pheteroaryl,\ Z k > ) or >!Z ’*> w- , wherein at least M\Z Q-|- oneH of may be substituted with -X, -(C1-C4 alkyl), -NRDRE, - CF3or-CF2H, andat least one H of -(C3-C7 cycloalkyl), -(C2-C6cycloheteroalkyl), adamantyl,OH or -(C1-C4 alkyl);Y1, Y2and Y4are each independently -CH2-, -NRF-, -O-, -C(=O)- or-S(=0)2-;Y3is -CH- or-N-;Z1 to Z4are each independently N or CRZ, wherein at least three of Z1 to Z4may not be simultaneously N, and Rzis -H, -X or -O(Ci-C4alkyl);Z5and Z6are each independently -CH2- or-O-;Z7and Z8are each independently =CH- or =N-;Z9is -NRG- or -S-;Docket No. PAT059983-US-PRI02 RAand RBare each independently -H, -(C1-C4 alkyl), -(C1-C4 alkyl)-OH, -(C1-C4 alkyl)- NRDRE, -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl, -(C1-C4 aryl)-heteroaryl, -(C3-C7 cycloalkyl),3 r\]eQ-?- -(C2-C6heterocycloalkyl) or 5 , wherein:at least one H of the -(C1-C4 alkyl), -(C1-C4 alkyl)-OH or-(Ci-C4alkyl)-NRDREmay be substituted with -X,at least one H of the -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl, -(C1-C4 alkyl)-heteroaryl, -(C3- C7cycloalkyl) or-(C2-C6heterocycloalkyl) may be substituted with -X, -OH, -O(Ci-C4alkyl), -(C1-C4 alkyl), -CF3,-CF2H or-CN, and\ x '' Sat least oneH ofbS may be substituted with n-X, -OH, -O(Ci-C4alkyl), -(C1-C4 alkyl), -CF3, -CF2H, -ON, -(C2-C6heterocycloalkyl), -aryl, -(C1-C4 alkydaryl, -heteroaryl or-heteroaryl-(Ci-C4alkyl);Rcis -(C1-C4 alkyl), -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or-(Ci-C4alkyl)-heteroaryl, wherein at least one H of -(Ci-C4alkyl) may be substituted with -X or -OH, at least one H of -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or-(Ci-C4alkyl)-heteroaryl may be substituted with -X, - OH, -CF3or-CF2H;RDand REare each independently -H, -(C1-C4 alkyl), -aryl or-(Ci-C4alkyl)-aryl, wherein, at least one H of -(C1-C4 alkyl) may be substituted with -X or -OH, at least one H of -aryl or -(C1-C4 alkyl)-aryl may be substituted with -X, -OH, -CF3or-CF2H;RFis -H, -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)-O-(Ci-C4alkyl), -C(=O)-(Ci-C4alkyl), -C(=O)-O-(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O-(Ci-C4alkyl), -(Ci-C4alkyl)-NRDRE, - S(=O)2-(Ci-C4alkyl), -aryl, -(C1-C4 alkyl)-aryl, -(C2-C4alkenyl)-aryl, -heteroaryl, -(C1-C4 alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -(C2-C6heterocycloalkyl) or-(Ci-C4alkyl)- C(=O)-(C2-C6heterocycloalkyl), wherein:at least one H of -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)-O-(Ci-C4 alkyl), - C(=O)-(Ci-C4alkyl), -C(=O)-O-(Ci-C4alkyl), -(Ci-C4alkyl)-C(=O)-O-(Ci-C4alkyl), - (Ci-C4alkyl)-NRDREor -S(=O)2-(Ci-C4alkyl) may be substituted with -X, and at least one H of -aryl, -(C1-C4 alkyl)-aryl, -(C2-C4alkenyl)-aryl, -heteroaryl, -(C1-C4 alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -C2-C6heterocycloalkyl or-(Ci-Docket No. PAT059983-US-PRI02 C4alkyl)-C(=0)-(C2-C6heterocycloalkyl) may be substituted with -X, -OH, -CF3or- CF2H;RGis -H or -(C1-C4 alkyl);Q is -O- or a bond;is a single bond or double bond, provided that, is a double bond, Y1 is =CH-;a to e are each independently an integer of 0, 1, 2, 3 or 4, provided that, a and b may not be simultaneously 0, and c and d may not be simultaneously 0; andX is each independently F, Cl, Br or I,wherein the compound of Formula (I) is administered at a dose of about 100 to about 600 mg per day or at the equivalent dose for a pharmaceutically acceptable salt thereof.

50. A method of preventing atrial fibrillation (AF) in a patient in need thereof, the method comprising administering to the patient a compound of Formula (I)or a pharmaceutically acceptable salt thereof,wherein:Li, L2or L3 are each independently a bond or-(Ci-C2alkylene)-;R1 is -CX2H or -CX3;O(Ci-C4alkyl), -NRDRE, -(C1-C4 alkyl), -CF3, -CF2H, -CN, -aryl, -heteroaryl, -(C1-C4 alkyl)- aryl or-(Ci-C4alkyl)-heteroaryl, wherein at least one H of the -aryl, -heteroaryl, -(C1-C4 alkyl)-aryl or-(Ci-C4alkyl)-heteroaryl may be substituted with -X, -OH, -CF3or-CF2H;Docket No. PAT059983-US-PRI02 R3is -H, -(C1-C4 alkyl), -(C1-C4 alkyl)-O-(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O-(Ci-C4alkyl), - (C3-C7 cycloalkyl), -(C2-C6cycloheteroalkyl), -aryl, -heteroaryl, -adamantyl,wherein:at least one H of -(C1-C4 alkyl) may be substituted with -X or -OH,at least one H of -aryl or -heteroaryl each independently may be substituted with -X, - OH, -O(Ci-C4alkyl), -OCF3, -O-aryl, -NRDRE, -(C1-C4 alkyl), -CF3, -CF2H, -C(=O)-(Ci- C4alkyl), -C(=O)-O(Ci-C4alkyl), -C(=O)-NRDRE, -S(=O)2-(Ci-C4alkyl), aryl,z Xf1 / I II7f / i ’ Pheteroaryl,\ Z k > ) or >!Z ’*> w- , wherein at least M\Z Q-|- oneH of may be substituted with -X, -(C1-C4 alkyl), -NRDRE, - CF3or-CF2H, andat least one H of -(C3-C7 cycloalkyl), -(C2-C6cycloheteroalkyl), adamantyl,OH or -(C1-C4 alkyl);Y1, Y2and Y4are each independently -CH2-, -NRF-, -O-, -C(=O)- or-S(=0)2-;Y3is -CH- or-N-;Z1 to Z4are each independently N or CRZ, wherein at least three of Z1 to Z4may not be simultaneously N, and Rzis -H, -X or -O(Ci-C4alkyl);Z5and Z6are each independently -CH2- or-O-;Z7and Z8are each independently =CH- or =N-;Z9is -NRG- or -S-;Docket No. PAT059983-US-PRI02 RAand RBare each independently -H, -(C1-C4 alkyl), -(C1-C4 alkyl)-OH, -(C1-C4 alkyl)- NRDRE, -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl, -(C1-C4 aryl)-heteroaryl, -(C3-C7 cycloalkyl),3 r\]eQ-?- -(C2-C6heterocycloalkyl) or 5 , wherein:at least one H of the -(C1-C4 alkyl), -(C1-C4 alkyl)-OH or-(Ci-C4alkyl)-NRDREmay be substituted with -X,at least one H of the -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl, -(C1-C4 alkyl)-heteroaryl, -(C3- C7cycloalkyl) or-(C2-C6heterocycloalkyl) may be substituted with -X, -OH, -O(Ci-C4alkyl), -(C1-C4 alkyl), -CF3,-CF2H or-CN, and\ x '' Sat least oneH ofbS may be substituted with n-X, -OH, -O(Ci-C4alkyl), -(C1-C4 alkyl), -CF3, -CF2H, -ON, -(C2-C6heterocycloalkyl), -aryl, -(C1-C4 alkydaryl, -heteroaryl or-heteroaryl-(Ci-C4alkyl);Rcis -(C1-C4 alkyl), -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or-(Ci-C4alkyl)-heteroaryl, wherein at least one H of -(Ci-C4alkyl) may be substituted with -X or -OH, at least one H of -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or-(Ci-C4alkyl)-heteroaryl may be substituted with -X, - OH, -CF3or-CF2H;RDand REare each independently -H, -(C1-C4 alkyl), -aryl or-(Ci-C4alkyl)-aryl, wherein, at least one H of -(C1-C4 alkyl) may be substituted with -X or -OH, at least one H of -aryl or -(C1-C4 alkyl)-aryl may be substituted with -X, -OH, -CF3or-CF2H;RFis -H, -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)-O-(Ci-C4alkyl), -C(=O)-(Ci-C4alkyl), -C(=O)-O-(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O-(Ci-C4alkyl), -(Ci-C4alkyl)-NRDRE, - S(=O)2-(Ci-C4alkyl), -aryl, -(C1-C4 alkyl)-aryl, -(C2-C4alkenyl)-aryl, -heteroaryl, -(C1-C4 alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -(C2-C6heterocycloalkyl) or-(Ci-C4alkyl)- C(=O)-(C2-C6heterocycloalkyl), wherein:at least one H of -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)-O-(Ci-C4 alkyl), - C(=O)-(Ci-C4alkyl), -C(=O)-O-(Ci-C4alkyl), -(Ci-C4alkyl)-C(=O)-O-(Ci-C4alkyl), - (Ci-C4alkyl)-NRDREor -S(=O)2-(Ci-C4alkyl) may be substituted with -X, and at least one H of -aryl, -(C1-C4 alkyl)-aryl, -(C2-C4alkenyl)-aryl, -heteroaryl, -(C1-C4 alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -C2-C6heterocycloalkyl or-(Ci-Docket No. PAT059983-US-PRI02 C4alkyl)-C(=0)-(C2-C6heterocycloalkyl) may be substituted with -X, -OH, -CF3or- CF2H;RGis -H or -(C1-C4 alkyl);Q is -O- or a bond;is a single bond or double bond, provided that, is a double bond, Y1 is =CH-;a to e are each independently an integer of 0, 1, 2, 3 or 4, provided that, a and b may not be simultaneously 0, and c and d may not be simultaneously 0; andX is each independently F, Cl, Br or I,wherein the compound of Formula (I) is administered at a dose of about 100 to about 600 mg per day or at the equivalent dose for a pharmaceutically acceptable salt thereof.

51. The method according to claims 1 through 46, and 48 through 50, wherein the patient in need thereof has atrial flutter or is diagnosed with atrial flutter.

52. The method according to claims 1 through 46, and 48 through 51 , wherein the method further comprises reducing atrial flutter in the patient in need thereof.

53. A method of increasing circulating acetylated alpha tubulin (AAT) in a patient in need thereof, the method comprising administering to the patient a compound of Formula (I),or a pharmaceutically acceptable salt thereof,wherein:Li, L2or L3are each independently a bond or-(Ci-C2alkylene)-;R1 is -CX2H or -CX3;Docket No. PAT059983-US-PRI02O(Ci-C4alkyl), -NRDRE, -(C1-C4 alkyl), -CF3, -CF2H, -CN, -aryl, -heteroaryl, -(Ci-C4alkyl)- aryl or-(Ci-C4alkyl)-heteroaryl, wherein at least one H of the -aryl, -heteroaryl, -(Ci-C4alkyl)-aryl or-(Ci-C4alkyl)-heteroaryl may be substituted with -X, -OH, -CF3or-CF2H; R3is -H, -(Ci-C4alkyl), -(Ci-C4alkyl)-O-(Ci-C4alkyl), -(Ci-C4alkyl)-C(=O)-O-(Ci-C4alkyl), - (C3-C7cycloalkyl), -(C2-C6cycloheteroalkyl), -aryl, -heteroaryl, -adamantyl,wherein:at least one H of -(Ci-C4alkyl) may be substituted with -X or -OH,at least one H of -aryl or -heteroaryl each independently may be substituted with -X, - OH, -O(Ci-C4alkyl), -OCF3, -O-aryl, -NRDRE, -(Ci-C4alkyl), -CF3, -CF2H, -C(=O)-(Ci- C4alkyl), -C(=O)-O(Ci-C4alkyl), -C(=O)-NRDRE, -S(=O)2-(Ci-C4alkyl), aryl,heteroaryl, wherein at leastone H of may be substituted with -X, -(Ci-C4alkyl), -NRDRE, - CF3or-CF2H, andat least one H of -(C3-C7 cycloalkyl), -(C2-C6cycloheteroalkyl), adamantyl,( Jl or 4 ^9 ii may be each independently substituted with -X, - OH or -(Ci-C4alkyl);Yi, Y2and Y4are each independently -CH2-, -NRF-, -O-, -C(=O)- or-S(=0)2-;Docket No. PAT059983-US-PRI02 Y3is -CH- or-N-;Zi to Z4are each independently N or CRZ, wherein at least three of Zi to Z4may not be simultaneously N, and Rzis -H, -X or -O(Ci-C4alkyl);Z5and Z6are each independently -CH2- or-O-;Z7and Z8are each independently =CH- or =N-;Z9is -NRG- or -S-;RAand RBare each independently -H, -(Ci-C4alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)- NRDRE, -aryl, -(Ci-C4alkyl)-aryl, -heteroaryl, -(Ci-C4aryl)-heteroaryl, -(C3-C7 cycloalkyl), / / KN.®...¥3 r~\jgY / f Q-|- -(C2-C6heterocycloalkyl)orBS . wherein:at least one H of the -(Ci-C4alkyl), -(Ci-C4alkyl)-OH or-(Ci-C4alkyl)-NRDREmay be substituted with -X,at least one H of the -aryl, -(Ci-C4alkyl)-aryl, -heteroaryl, -(Ci-C4alkyl)-heteroaryl, -(C3- C7cycloalkyl) or-(C2-C6heterocycloalkyl) may be substituted with -X, -OH, -O(Ci-C4alkyl), -(Ci-C4alkyl), -CF3,-CF2H or-CN, andZY3 r\Je / Q-S- at least oneH of1 b? may be substituted with n-X, -OH, -O(Ci-C4alkyl), -(Ci-C4alkyl), -CF3, -CF2H, -ON, -(C2-C6heterocycloalkyl), -aryl, -(Ci-C4alkydaryl, -heteroaryl or-heteroaryl-(Ci-C4alkyl);Rcis -(Ci-C4alkyl), -aryl, -(Ci-C4alkyl)-aryl, -heteroaryl or-(Ci-C4alkyl)-heteroaryl, wherein at least one H of -(Ci-C4alkyl) may be substituted with -X or -OH, at least one H of -aryl, -(Ci-C4alkyl)-aryl, -heteroaryl or-(Ci-C4alkyl)-heteroaryl may be substituted with -X, - OH, -CF3or-CF2H;RDand REare each independently -H, -(Ci-C4alkyl), -aryl or-(Ci-C4alkyl)-aryl, wherein, at least one H of -(Ci-C4alkyl) may be substituted with -X or -OH, at least one H of -aryl or -(Ci-C4alkyl)-aryl may be substituted with -X, -OH, -CF3or-CF2H;RFis -H, -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)-O-(Ci-C4alkyl), -C(=O)-(Ci-C4alkyl), -C(=O)-O-(Ci-C4alkyl), -(Ci-C4alkyl)-C(=O)-O-(Ci-C4alkyl), -(Ci-C4alkyl)-NRDRE, - S(=O)2-(Ci-C4alkyl), -aryl, -(Ci-C4alkyl)-aryl, -(C2-C4alkenyl)-aryl, -heteroaryl, -(Ci-C4alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -(C2-C6heterocycloalkyl) or-(Ci-C4alkyl)- C(=O)-(C2-C6heterocycloalkyl), wherein:Docket No. PAT059983-US-PRI02 at least one H of -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)-O-(Ci-C4alkyl), - C(=O)-(Ci-C4alkyl), -C(=O)-O-(Ci-C4alkyl), -(Ci-C4alkyl)-C(=O)-O-(Ci-C4alkyl), - (Ci-C4alkyl)-NRDREor -S(=O)2-(Ci-C4alkyl) may be substituted with -X, and at least one H of -aryl, -(Ci-C4alkyl)-aryl, -(C2-C4alkenyl)-aryl, -heteroaryl, -(Ci-C4alkyl)-heteroaryl, -C(=O)-(C3-C7cycloalkyl), -C2-C6heterocycloalkyl or-(Ci- C4alkyl)-C(=0)-(C2-C6heterocycloalkyl) may be substituted with -X, -OH, -CF3or- CF2H;RGis -H or -(Ci-C4alkyl);Q is -O- or a bond;“°°°°°°^ is a single bond or double bond, provided that, is a double bond, Yi is =CH-;a to e are each independently an integer of 0, 1, 2, 3 or 4, provided that, a and b may not be simultaneously 0, and c and d may not be simultaneously 0; andX is each independently F, Cl, Br or I,wherein the compound of Formula (I) is administered at a dose of about 100 to about 600 mg per day or at the equivalent dose for a pharmaceutically acceptable salt thereof.

54. The method according to any one of claims 47 to 53, wherein, in the compound of Formula (I):Li, L2or L3are each independently a bond or -(Ci-C2alkylene)-;Ri is -CX2H or -CX3;R2is -NRARB, -ORC, wherein at least one ofNRDRE, -(Ci-C4alkyl);Docket No. PAT059983-US-PRI02Rs is -(C1-C4 alkyl), -(C3-C7 cycloalkyl), -aryl, -heteroaryl, -adamantyl,wherein:at least one H of -aryl or -heteroaryl may be each independently substituted with -X, -O(Ci-C4alkyl), -OCF3, -O-aryl, -NRDRE, -(C1-C4 alkyl), -CF3, -S(=O)2-(Ci-C4alkyl),(V: wherein at least one H of ‘ may be substituted with -NRDREor -(C1-C4 alkyl); andat least oneH of maybe each independently substituted with -(C1-C4 alkyl);Y1, Y2and Y4are each independently -CH2-, -NRF-, -O-, -C(=O)- or-S(=0)2-;Y3is -CH- or-N-;Z1 to Z4is each independently N or CRZ, wherein at least three of Z1 to Z4may not be simultaneously N, and Rzis -H, -X or -O(Ci-C4alkyl);Z5and Z6are each independently -CH2- or-O-;Z7and Z8are each independently =CH- or =N-;Z9is -NRG- or -S-;RAand RBare each independently -H, -(C1-C4 alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)-NRDRE,-aryl, -(Ci-C4alkyl)-aryl, -(C3-C7 cycloalkyl)or 1 , wherein at least oneDocket No. PAT059983-US-PRI02H of:may be substituted with -X, -(C1-C4 alkyl), -CF3, -(C2-C6heterocycloalkyl), -(C1-C4 alkyl)-aryl, -heteroaryl or heteroaryl-(Ci-C4alkyl);Rcis -(C1-C4 alkyl) or -aryl;RDand REare each independently -H, -(C1-C4 alkyl) or -(C1-C4 alkyl)-aryl;RFis -H, -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)-O-(Ci-C4alkyl), -C(=O)-(Ci-C4alkyl), - C(=O)-O(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O(Ci-C4alkyl), -(Ci-C4alkyl)-NRDRE, -S(=O)2- (C1-C4 alkyl), -aryl, -(C1-C4 alkyl)-aryl, -(C2-C4alkenyl)-aryl, -heteroaryl, -(Ci-C4alkyl)- heteroaryl, -C(=O)-(C3-C7cycloalkyl), -(C2-C6heterocycloalkyl) or -(Ci-C4alkyl)-C(=O)- (C2-C6heterocycloalkyl), wherein at least one H of -(Ci-C4alkyl) or -C(=O)-O(Ci-C4alkyl) may be substituted with -X, and at least one H of -aryl may be substituted with -X};RGis -(C1-C4 alkyl);Q is -O- or a bond;is a single bond or a double bond, provided thatadouble bond, Y1 is - CH-;a to e are each independently an integer of 0, 1, 2, 3 or 4, provided that a and b may not be simultaneously 0, and c and d may not be simultaneously 0; andX is each independently F, Cl, Br or I.

55. The method according to any one of claims 47 to 54, wherein the compound of Formula (I) has the structure of Formula (la):or a pharmaceutically acceptable salt thereof,wherein:R2is * ' b ;R3is -aryl, wherein, at least one H of -aryl may be each independently substituted with -X;Docket No. PAT059983-US-PRI02 Yi is -0- or-S(=0)2-;Zi is N orCRz, wherein, Rzis -X;a and b are each independently an integer of 0, 1, 2, 3 or 4, wherein, a and b may not be simultaneously 0; andX is each independently F, Cl, Br or I.

56. The method according to claim 55, wherein, in the compound of Formula (la):YR2isR3is -phenyl, wherein at least one H of -phenyl each independently is substituted with -F or -Cl;Yi is -O- or -S(=O)2-; andZi is N or CF.

57. The method according to any one of claims 47 to 53, wherein the compound of Formula (I) is one selected from the compounds in Table A.

58. The method according to any one of claims 47 to 53, wherein the compound of Formula (I) is selected from the group consisting of:Docket No. PAT059983-US-PRI02 59. The method according to any one of claims 48 to 58, wherein the AF is paroxysmal atrial fibrillation, persistent atrial fibrillation, long-term persistent atrial fibrillation, valvular atrial fibrillation, non-valvular atrial fibrillation, or non-permanent atrial fibrillation.

60. The method according to any one of claims 47 to 59, wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof, is administered orally.

61. The method according to any one of claims 47 to 60, wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof is administered twice daily.

62. The method according to any one of claims 47 to 61 , wherein the compound of Formula (I) is administered at a dose of about 50 mg to about 300 mg, about 50 mg to about 200 mg, about 100 mg to 300 mg, about 50 mg to about 100 mg, about 100 mg to about 200 mg, or about 200 mg to about 300 mg, or at equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID).

63. The method according to any one of claims 47 to 62, wherein the compound of Formula (I) is administered at a dose of about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, or about 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID).

64. The method according to any one of claims 47 to 62, wherein the compound of Formula (I), or the pharmaceutically acceptable salt thereof, is administered at a dose of 50 mg, or 100 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID).

65. The method according to any one of claims 47 to 64, wherein the compound of Formula (I) or the pharmaceutically acceptable salt thereof is administered for at least 6 weeks, at least 12 weeks, at least 18 weeks, at least 24 weeks, at least 30 weeks, or at least 36 weeks.

66. The method according to any one of claims 47 to 65, wherein the patient is a human patient.Docket No. PAT059983-US-PRI02 67. The method according to any one of claims 1 to 66, wherein the compound isor a pharmaceutically acceptable salt thereof.

68. The method according to any one of claims 1 to 66, wherein the compound is, or a pharmaceutically acceptable salt thereof.

69. The method according to any one of claims 1 to 66, wherein the compound isO , or a pharmaceutically acceptable salt thereof.

70. The method according to any one of claims 1 to 66, wherein the compound isor a pharmaceutically acceptable salt thereof.

71. The method according to any one of claims 1 to 66, wherein the compound is° , or a pharmaceutically acceptable salt thereof.

72. The method according to any one of claims 1 to 66, wherein the compound isDocket No. PAT059983-US-PRI02or a pharmaceutically acceptable salt thereof.

73. A pharmaceutical composition comprising an HDAC6 inhibitor and a pharmaceutically acceptable excipient, for use in the treating atrial fibrillation (AF) in a patient in need thereof, wherein the HDAC6 inhibitor comprises a compound of Formula (I)or a pharmaceutically acceptable salt thereof,wherein:Li, l_2 or L3 are each independently a bond or-(Ci-C2alkylene)-;Ri is -CX2H or -CX3;R2is -NRARB, -ORC, , wherein at least one Hof may be substituted with -X, -OH, - O(Ci-C4alkyl), -NRDRE, -(C1-C4 alkyl), -CF3, -CF2H, -CN, -aryl, -heteroaryl, -(Ci-C4alkyl)- aryl or-(Ci-C4alkyl)-heteroaryl, wherein at least one H of the -aryl, -heteroaryl, -(Ci-C4alkyl)-aryl or-(Ci-C4alkyl)-heteroaryl may be substituted with -X, -OH, -CF3or-CF2H; R3is -H, -(Ci-C4alkyl), -(Ci-C4alkyl)-O-(Ci-C4alkyl), -(Ci-C4alkyl)-C(=O)-O-(Ci-C4alkyl), - (C3-C7cycloalkyl), -(C2-C6cycloheteroalkyl), -aryl, -heteroaryl, -adamantyl,Z5- *-8or s , wherein:at least one H of -(Ci-C4alkyl) may be substituted with -X or -OH,Docket No. PAT059983-US-PRI02 at least one H of -aryl or -heteroaryl each independently may be substituted with -X, - OH, -O(Ci-C4alkyl), -OCF3, -O-aryl, -NRDRE, -(Ci-C4alkyl), -CF3, -CF2H, -C(=O)-(Ci- C4alkyl), -C(=O)-O(Ci-C4alkyl), -C(=O)-NRDRE, -S(=O)2-(Ci-C4alkyl), aryl,heteroaryl, wherein at leastone H ofb5 may be substituted with -X, -(Ci-C4alkyl), -NRDRE, - CF3or-CF2H, andat least one H of -(C3-C7cycloalkyl), -(C2-C6cycloheteroalkyl), adamantyl,OH or -(Ci-C4alkyl);Yi, Y2and Y4are each independently -CH2-, -NRF-, -O-, -C(=O)- or-S(=0)2-;Y3is -CH- or-N-;Zi to Z4are each independently N or CRZ, wherein at least three of Zi to Z4may not be simultaneously N, and Rzis -H, -X or -O(Ci-C4alkyl);Z5and Z6are each independently -CH2- or-O-;Z7and Z8are each independently =CH- or =N-;Z9is -NRG- or -S-;RAand RBare each independently -H, -(Ci-C4alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)- NRDRE, -aryl, -(Ci-C4alkyl)-aryl, -heteroaryl, -(Ci-C4aryl)-heteroaryl, -(C3-C7cycloalkyl),-(C2-C6heterocycloalkyl) orat least one H of the -(Ci-C4alkyl), -(Ci-C4alkyl)-OH or-(Ci-C4alkyl)-NRDREmay be substituted with -X,at least one H of the -aryl, -(Ci-C4alkyl)-aryl, -heteroaryl, -(Ci-C4alkyl)-heteroaryl, -(C3- C7cycloalkyl) or-(C2-C6heterocycloalkyl) may be substituted with -X, -OH, -O(Ci-C4alkyl), -(Ci-C4alkyl), -CF3,-CF2H or -ON, andDocket No. PAT059983-US-PRI02Y4 ZY3H~~\XLQ’4’at least oneH of1 &S may be substituted with n-X, -OH, -O(Ci-C4alkyl), -(C1-C4 alkyl), -CF3, -CF2H, -CN, -(C2-C6heterocycloalkyl), -aryl, -(C1-C4 alkydaryl, -heteroaryl or-heteroaryl-(Ci-C4alkyl);Rcis -(C1-C4 alkyl), -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or-(Ci-C4alkyl)-heteroaryl, wherein at least one H of -(Ci-C4alkyl) may be substituted with -X or -OH, at least one H of -aryl, -(C1-C4 alkyl)-aryl, -heteroaryl or-(Ci-C4alkyl)-heteroaryl may be substituted with -X, - OH, -CF3or-CF2H;RDand REare each independently -H, -(C1-C4 alkyl), -aryl or-(Ci-C4alkyl)-aryl, wherein, at least one H of -(C1-C4 alkyl) may be substituted with -X or -OH, at least one H of -aryl or -(C1-C4 alkyl)-aryl may be substituted with -X, -OH, -CF3or-CF2H;RFis -H, -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)-O-(Ci-C4alkyl), -C(=O)-(Ci-C4alkyl), -C(=O)-O-(Ci-C4alkyl), -(C1-C4 alkyl)-C(=O)-O-(Ci-C4alkyl), -(Ci-C4alkyl)-NRDRE, - S(=O)2-(Ci-C4alkyl), -aryl, -(C1-C4 alkyl)-aryl, -(C2-C4alkenyl)-aryl, -heteroaryl, -(C1-C4 alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -(C2-C6heterocycloalkyl) or-(Ci-C4alkyl)- C(=O)-(C2-C6heterocycloalkyl), wherein:at least one H of -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)-O-(Ci-C4alkyl), - C(=O)-(Ci-C4alkyl), -C(=O)-O-(Ci-C4alkyl), -(Ci-C4alkyl)-C(=O)-O-(Ci-C4alkyl), - (Ci-C4alkyl)-NRDREor -S(=O)2-(Ci-C4alkyl) may be substituted with -X, and at least one H of -aryl, -(C1-C4 alkyl)-aryl, -(C2-C4alkenyl)-aryl, -heteroaryl, -(C1-C4 alkyl)-heteroaryl, -C(=O)-(C3-C7 cycloalkyl), -C2-C6heterocycloalkyl or-(Ci- C4alkyl)-C(=0)-(C2-C6heterocycloalkyl) may be substituted with -X, -OH, -CF3or- CF2H;RGis -H or -(C1-C4 alkyl);Q is -O- or a bond;“ “ “ is a single bond or double bond, provided that,—is a double bond, Y1 is =CH-;a to e are each independently an integer of 0, 1, 2, 3 or 4, provided that, a and b may not be simultaneously 0, and c and d may not be simultaneously 0; andX is each independently F, Cl, Br or I,wherein the compound of Formula (I) is administered at a dose of about 100 to about 600 mg per day or at the equivalent dose for a pharmaceutically acceptable salt thereof.Docket No. PAT059983-US-PRI0274. The pharmaceutical composition for use according to claim 73, wherein, in the compound of Formula (I):Li, l_2 or L3 are each independently a bond or -(C1-C2 alkylene)-;Ri is -CX2H or -CX3;NRDRE, -(C1-C4 alkyl);R3is -(C1-C4 alkyl), -(C3-C7cycloalkyl), -aryl, -heteroaryl, -adamantyl,wherein:at least one H of -aryl or -heteroaryl may be each independently substituted with -X, -O(Ci-C4alkyl), -OCF3, -O-aryl, -NRDRE, -(C1-C4 alkyl), -CF3, -S(=O)2-(Ci-C4alkyl),A— --aryl, -heteroaryl,wherein at least one H of < may be substituted with -NRDREor -(C1-C4 alkyl); andmaybe each independently substituted with -(C1-C4 alkyl);Docket No. PAT059983-US-PRI02 Yi, Y2and Y4are each independently -CH2-, -NRF-, -0-, -C(=0)- or-S(=0)2-;Y3is -CH- or-N-;Zi to Z4is each independently N or CRZ, wherein at least three of Zi to Z4may not be simultaneously N, and Rzis -H, -X or -O(Ci-C4alkyl);Z5and Z6are each independently -CH2- or-O-;Z7and Z8are each independently =CH- or =N-;Z9is -NRG- or -S-;RAand RBare each independently -H, -(Ci-C4alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)-NRDRE, / / ZkV V I -.M / Y3 T\ '«\Z Q -5 - -aryl, -(Ci-C4alkyl)-aryl, -(C3-C7 cycloalkyl) or! b != , wherein at least one^4 . {"’sj e'V,,ZH of ? may be substituted with -X, -(Ci-C4alkyl), -CF3, -(C2-C6heterocycloalkyl), -(Ci-C4alkyl)-aryl, -heteroaryl or heteroaryl-(Ci-C4alkyl);Rcis -(Ci-C4alkyl) or -aryl;RDand REare each independently -H, -(Ci-C4alkyl) or -(Ci-C4alkyl)-aryl;RFis -H, -(Ci-C6alkyl), -(Ci-C4alkyl)-OH, -(Ci-C4alkyl)-O-(Ci-C4alkyl), -C(=O)-(Ci-C4alkyl), - C(=O)-O(Ci-C4alkyl), -(Ci-C4alkyl)-C(=O)-O(Ci-C4alkyl), -(Ci-C4alkyl)-NRDRE, -S(=O)2- (Ci-C4alkyl), -aryl, -(Ci-C4alkyl)-aryl, -(C2-C4alkenyl)-aryl, -heteroaryl, -(Ci-C4alkyl)- heteroaryl, -C(=O)-(C3-C7cycloalkyl), -(C2-C6heterocycloalkyl) or -(Ci-C4alkyl)-C(=O)- (C2-C6heterocycloalkyl), wherein at least one H of -(Ci-C4alkyl) or -C(=O)-O(Ci-C4alkyl) may be substituted with -X, and at least one H of -aryl may be substituted with -X};RGis -(Ci-C4alkyl);Q is -O- or a bond;IK Ki iM W » W «> is a single bond or a double bond, provided that > is a double bond, Y1 is - CH-;a to e are each independently an integer of 0, 1, 2, 3 or 4, provided that a and b may not be simultaneously 0, and c and d may not be simultaneously 0; andX is each independently F, Cl, Br or I.

75. The pharmaceutical composition for use according to claim 73 or 74, wherein the compound of Formula (I) has the structure of Formula (la):Docket No. PAT059983-US-PRI02or a pharmaceutically acceptable salt thereof,wherein:Rais -aryl, wherein, at least one H of -aryl may be each independently substituted with -X; Yi is -0- or-S(=0)2-;Zi is N orCRz, wherein, Rzis -X;a and b are each independently an integer of 0, 1, 2, 3 or 4, wherein, a and b may not be simultaneously 0; andX is each independently F, Cl, Br or I.

76. The pharmaceutical composition for use according to claim 75, wherein, in the compound of Formula (la):R3is -phenyl, wherein at least one H of -phenyl each independently is substituted with -F or -Cl;Yi is -O- or -S(=O)2-; andZi is N or CF.

77. The pharmaceutical composition for use according to any one of claims 73 to 76, wherein the compound of Formula (I) is one selected from the compounds in Table A.

78. The pharmaceutical composition for use according to any one of claims 73 to 77, wherein the compound of Formula (I) is selected from the group consisting of:Docket No. PAT059983-US-PRI0279. The pharmaceutical composition for use according to any one of claims 73 to 78, wherein the AF is paroxysmal atrial fibrillation, persistent atrial fibrillation, long-term persistent atrial fibrillation, valvular atrial fibrillation, non-valvular atrial fibrillation, or non-permanent atrial fibrillation.

80. The pharmaceutical composition for use according to any one of claims 73 to 79, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is administered orally.

81. The pharmaceutical composition for use according to any one of claims 73 to 80, wherein the compound of Formula (I) or a pharmaceutically acceptable salt thereof is administered twice daily.

82. The pharmaceutical composition for use according to any one of claims 73 to 81 , wherein the compound of Formula (I) is administered at a dose of about 50 mg to about 300 mg, about 50 mg to about 200 mg, about 100 mg to 300 mg, about 50 mg to about 100 mg, about 100 mg to about 200 mg, or about 200 mg to about 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID).Docket No. PAT059983-US-PRI02 83. The pharmaceutical composition for use according to any one of claims 73 to 82, wherein the compound of Formula (I) is administered at a dose of about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, or about 300 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID).

84. The pharmaceutical composition for use according to any one of claims 73 to 83, wherein the compound of Formula (I) is administered at a dose of 50 mg, or 100 mg, or at the equivalent dose for the pharmaceutically acceptable salt thereof, and each dose is administered twice daily (BID).

85. The pharmaceutical composition for use according to any one of claims 73 to 84, wherein the compound of Formula (I) or the pharmaceutically acceptable salt thereof is administered for at least 6 weeks, at least 12 weeks, at least 18 weeks, at least 24 weeks, at least 30 weeks, or at least 36 weeks.

86. The pharmaceutical composition for use according to any one of claims 73 to 85, wherein Cl ... 1f N x 'O 'rj othe compound is o , or a pharmaceutically acceptable salt thereof.

87. The pharmaceutical composition for use according to any one of claims 73 to 85, wherein the compound is, or a pharmaceutically acceptable salt thereof.

88. The pharmaceutical composition for use according to any one of claims 73 to 85, wherein the compound isDocket No. PAT059983-US-PRI02<■’ , or a pharmaceutically acceptable salt thereof.

89. The pharmaceutical composition for use according to any one of claims 73 to 85, wherein the compound is, or a pharmaceutically acceptable salt thereof.

90. The pharmaceutical composition for use according to any one of claims 73 to 85, wherein the compound is, or a pharmaceutically acceptable salt thereof.

91. The pharmaceutical composition for use according to any one of claims 73 to 85, wherein the compound isFo , or a pharmaceutically acceptable salt thereof.